| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Abbott Laboratories$93.93
-0.47 (-0.5%)
A 85Pipeline Score MedTech · Commercial
Market Cap
151.49 B
EPS
3.61
P/E Ratio
24.23 $
Value Trade
911.42 M
SEC Financials
Q1 2026Dilution Risk
Revenue
11.16 B
R&D Expenses
767.00 M
Operating CF
1.31 B
Total Assets
110.43 B
Total Liabilities
110.43 B
Equity
52.06 B
D/E Ratio
12,345
1.77 %
Week
-5.63 %
1 Month
-22.09 %
3 Month
-29.89 %
6 Month
-26.07 %
5 Year
52,988.69 %
All Time
Cash Data
Cash Position
7.29 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
6.91 M
52 Week Range
81.97 - 139.06
% held by Insiders
0.68 %
% held by Institutions
82.57 %
Enterprise Value
178.88 B
Total Shares
1.74 B
Short %
1.35 %
Float Shares
1.73 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Abbott Laboratories
1448Total events
2Upcoming
569Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 2
Event history 1446
Jun 8, 2026
▲Oral PresentationPresentation
New research on Healthy Food Rx program presented at ADA 86th Scientific Sessions
type 2 diabetessource ↗
Jun 6, 2026
●NDA SubmissionRegulatory Filing
FDA regulatory submission for Libre Duo and Libre Duo 10 Day
diabetessource ↗
Jun 1, 2026
◆Oral PresentationPresentation
Pipeline Innovation abstract presentation at ASCO 2026
Pipeline Innovationsource ↗
Jun 1, 2026
◆Oral PresentationCancerguardPresentation
Cancerguard MCED test abstract presentation at ASCO 2026
Multi-Cancer Early Detectionsource ↗
Jun 1, 2026
◆Oral PresentationOncodetectPresentation
Oncodetect MRD test abstract presentation at ASCO 2026
Molecular Residual Diseasesource ↗
Jun 1, 2026
◆Oral PresentationPresentation
Oncotype DX Breast Recurrence Score test abstract presentation at ASCO 2026
Breast Cancersource ↗
Jun 1, 2026
◆Poster PresentationCologuardPresentation
Cologuard test abstract presentation at ASCO 2026 (online only)
Colorectal Cancer Screeningsource ↗
May 28, 2026
▲EU ApprovalEx-US Regulatory
CE Mark secured for Libre Duo dual glucose-ketone sensing system
diabetessource ↗
May 6, 2026
▲Other Regulator MilestoneEx-US Regulatory
Anvisa approval for Epic Max surgical valve
aortic valve stenosis or aortic valve insufficiencysource ↗
May 2026
▲Other Regulator MilestoneEx-US Regulatory
CE Mark for Libre Duo and Libre Duo 10 Day
diabetessource ↗
Apr 28, 2026
▲FDA Filing AcceptedRegulatory Filing
FDA clearance for Ultreon 3.0 Software
coronary artery diseasesource ↗
Apr 28, 2026
Drug Pipeline Intelligence
A85
Pipeline Score $100.6B
Pipeline ValueValuation Signal
86
Drugs Scored0.7x
rNPV / MCap Top 98%
Large Pharma (rank 19 of 911)
Percentile RankAbbott Laboratories earns an A-grade pipeline score (85/100), with $100.6B risk-adjusted pipeline value, led by paricalcitol in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| paricalcitol Small molecule | Chronic Kidney Disease | Phase 3 | NCT00646932 | 54% | $13.3B | COMPLETED | 263 | - | - | — | - | Mar 31, 2008 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TactiFlex Duo Ablation Catheter | complex atrial fibrillation | — | 2026-04-25 | six-month data for the 188-patient FlexPulse IDE study show positive patient outcomes Read More | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field... Read More | |
TactiFlex Duo Ablation Catheter | complex atrial fibrillation | — | 2026-04-25 | six-month data for the 188-patient FlexPulse IDE study show positive patient outcomes Read More | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field... Read More | |
TactiFlex Duo Ablation Catheter | complex atrial fibrillation | — | 2026-04-25 | six-month data for the 188-patient FlexPulse IDE study show positive patient outcomes Read More | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ABT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABTAbbott hosts conference call for second-quarter earnings
Abbott will announce its second-quarter 2026 financial results on July 16, prior to market opening. Following the announcement, a live webcast of the earnings conference call will be held at 8 a.m. Central time. The call will be accessible via Abbott's Investor Relations website, with an archived version available later.
Read more →ABTNew Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents Parenthood is widely anticipated as one of life's most fulfilling journeys, yet for today's new parents – especially Gen Z – that excitement is often ...
A new survey by Similac reveals that social media pressures are impacting Gen Z parents' perceptions of parenthood. In response, the brand has launched the 'Love Without Measure' initiative, aimed at promoting authentic portrayals of parenting and combating comparison culture. This effort seeks to support new parents in embracing their unique journeys.
Read more →ABTAbbott declares 410th consecutive quarterly dividend
Abbott has announced a quarterly dividend of 63 cents per share, marking its 410th consecutive payout since 1924. This dividend will be paid on August 17, 2026, to shareholders recorded by July 15, 2026. Abbott has a strong history of increasing dividends for 54 years and is recognized in the S&P 500 Dividend Aristocrats Index.
Read more →ABTNew research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating...
Research presented at the American Diabetes Association's 86th Scientific Sessions indicates that Abbott's Healthy Food Rx program significantly improves health outcomes for adults with type 2 diabetes when paired with community health worker support. The study involved 284 participants who received healthy food boxes alongside coaching over six months. Key findings highlight advancements in diet, physical activity, and overall health, suggesting the effectiveness of combining healthy food access with robust personal support systems. These insights reinforce the value of community-centered approaches in managing chronic diseases.
Read more →ABTNew Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected ...
Abbott recently presented new findings at the American Diabetes Association's Scientific Sessions, highlighting the rising issue of diabetic ketoacidosis (DKA) among diabetes patients. The data indicates a significant increase in DKA-related hospitalizations across various age groups, emphasizing the need for better awareness and detection strategies. Abbott’s dual glucose-ketone monitoring technology aims to address these challenges by allowing for earlier detection of rising ketone levels. This technology is currently pending FDA clearance and could help reduce preventable hospitalizations for DKA.
Read more →ABTAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesDeutschland - EnglishDeutschland - Deutsch
Abbott has received CE Mark approval for its innovative Libre Duo system, the first dual glucose and ketone sensing technology for diabetes management. This system allows continuous monitoring of glucose and ketone levels every minute, enhancing patient safety by providing real-time data. The launch of Libre Duo is set for select European markets later this year.
Read more →ABTACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Abbott has been reaffirmed by the American Cancer Society as a leader in noninvasive colorectal cancer screening with its Cologuard and Cologuard Plus tests. These tests are recommended for adults aged 45 and older at average risk for colorectal cancer, emphasizing early detection and treatment. Abbott is also preparing to launch a blood-based test pending FDA approval, enhancing its screening portfolio.
Read more →ABTAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology...
Abbott has received CE Mark approval for its innovative dual glucose-ketone sensing technology, known as Libre Duo. This groundbreaking system allows continuous monitoring of both glucose and ketone levels, aiding in diabetes management and the prevention of diabetic ketoacidosis. The Libre Duo will be launched in select European countries later this year, marking a significant advancement in diabetes care.
Read more →ABTAbbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology...
Abbott (NYSE: ABT) is set to present 11 abstracts at the American Society of Clinical Oncology (ASCO) 2026, showcasing new evidence across cancer diagnostics. This includes advancements in tests such as the Cancerguard® Multi-Cancer Early Detection Test and the Oncodetect® Molecular Residual Disease Test. The presentations reflect Abbott's continuous efforts and innovations in the cancer care continuum, signifying their commitment to improving patient outcomes through advanced diagnostics.
Read more →ABTAbbott recebe aprovação da Anvisa para a válvula biológica Epic™ Max para tratar pacientes com estenose ou insuficiência da válvula aórtica
Abbott has received regulatory approval from Anvisa for its Epic Max biological valve, intended for treating aortic valve insufficiency and stenosis. This new valve is part of Abbott's Epic surgical valve platform, known for its safety and clinical results. The Epic Max aims to enhance blood flow and offers future treatment options for patients. Its production in Brazil underscores Abbott's investment in local healthcare solutions.
Read more →ABTAbbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
Abbott has received FDA clearance and CE Mark for its Ultreon 3.0 AI-powered imaging platform. This next-generation technology combines optical coherence tomography with AI to enhance coronary imaging during minimally invasive procedures. The platform aims to improve clinical decision-making and patient outcomes by providing real-time insights and detailed imaging of arterial blockages.
Read more →ABTAbbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field...
Abbott has presented new late-breaking clinical data at the Heart Rhythm Society 2026, showcasing its innovations in treating heart rhythm disorders. The findings include positive six-month outcomes from the FlexPulse IDE study for the TactiFlex Duo Ablation Catheter, as well as promising results from trials for the Volt PFA System and investigational CSP technologies. These results highlight Abbott's commitment to improving patient care with advanced therapies for complex atrial fibrillation and conducting pacing solutions. Overall, Abbott's portfolio appears to be evolving effectively in addressing various arrhythmias.
Read more →ABTIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -------------------------------------------------------x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATI
Abbott Laboratories is involved in a proposed settlement for consolidated derivative litigation concerning breaches of fiduciary duty and violations of federal securities laws. The settlement aims to resolve claims against certain directors and officers while maintaining governance reforms that enhance Abbott's internal oversight. A settlement hearing is set for June 4, 2026, where the court will assess the fairness of the proposed settlement and related attorney fees. The defendants continue to deny any wrongdoing but support the settlement to avoid further litigation costs and disruptions.
Read more →ABTNew data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
Abbott presented new data at the AACR Annual Meeting 2026 highlighting advancements in its Cancerguard® multi-cancer early detection test. The data showcases a multi-biomarker approach that enhances early-stage cancer detection. Additionally, the DETECT-A study, which demonstrated long-term outcomes for patients, received recognition for its significant contributions to the field.
Read more →ABT▼ -6%on this newsshared move
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
Abbott reported its first-quarter 2026 results, highlighting a successful acquisition of Exact Sciences, which is expected to enhance growth. The company anticipates a full-year sales growth of 6.5% to 7.5% and adjusted earnings per share between $5.38 and $5.58. Despite some challenges in the Nutrition segment, overall performance aligns with expectations.
Read more →ABTNew survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
A new survey by Abbott reveals that while 74% of U.S. adults believe chronic diseases are preventable, only 25% feel confident in managing their health. The survey indicates that confusion, information overload, and costs hinder health actions. Abbott emphasizes the importance of simple, consistent healthy habits and has partnered with Sesame Workshop to promote healthy routines for families.
Read more →ABTAbbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Abbott has announced the integration of its Precision Oncology portfolio with Flatiron's OncoEMR platform, allowing oncology providers to order tests and receive results directly within their clinical workflow. This integration aims to streamline processes and improve patient care by providing access to a range of tests, including Oncotype DX and OncoExTra, across a network of over 1,600 cancer care centers. The initiative is designed to facilitate faster treatment decisions and reduce administrative burdens for clinicians.
Read more →ABTAbbott hosts conference call for first-quarter earnings
Abbott will release its first-quarter 2026 financial results on April 16, 2026, before the market opens. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central time. Investors can access the call through Abbott's Investor Relations website, with an archived version available later.
Read more →ABTJohn Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
Abbott has launched a campaign featuring John Stamos and Jodie Sweetin to promote colorectal cancer screening through the Cologuard test. The campaign, titled 'The (Second) Talk,' aims to encourage adults aged 45 and older to engage in conversations about screening, emphasizing its importance in preventing and detecting cancer early. The Cologuard test is a noninvasive option that can be done at home, making it more accessible for individuals.
Read more →ABTAbbott completes acquisition of Exact Sciences
Abbott has successfully acquired Exact Sciences, positioning itself as a leader in cancer screening and diagnostics. This acquisition allows Abbott to enhance its offerings in early cancer detection and personalized treatment, catering to a growing market. The completion of the deal marks a significant milestone for Abbott, expanding its capabilities in a vital healthcare segment.
Read more →ABTAbbott completes acquisition of Exact Sciences Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give p
Abbott has completed its acquisition of Exact Sciences, thereby enhancing its position in the rapidly growing cancer screening and diagnostics sectors. This acquisition allows Abbott to expand its reach and improve access to vital diagnostic tools for early cancer detection and personalized treatments. The integration marks Exact Sciences as a wholly owned subsidiary of Abbott, which underscores Abbott's commitment to transforming cancer care. However, the company faces challenges in integrating operations and achieving projected benefits from the transaction.
Read more →ABTAbbott acquisition of Exact Sciences set to close on March 23, 2026
Abbott announced the expected closure of its acquisition of Exact Sciences on March 23, 2026, following necessary regulatory approvals. This acquisition aims to enhance Abbott's capabilities in cancer screening and diagnostics, potentially adding $3 billion in sales by 2026. However, it may also dilute earnings per share and involves integration risks.
Read more →ABTLandmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementUSA - EnglishDeutschland - DeutschDeutschland - English
Abbott's FreeDM2 trial demonstrated that FreeStyle Libre CGM technology significantly improves glucose management in Type 2 diabetes patients on basal insulin. The study showed a notable reduction in HbA1c and increased time spent in a healthy glucose range. Findings were presented at the ATTD conference, highlighting the importance of real-time glucose insights for better self-management.
Read more →ABTStudie zeigt: FreeStyle Libre Technologie verhilft Menschen mit Typ-2-Diabetes und Basalinsulin zu einem besseren GlukosemanagementDeutschland - DeutschDeutschland - EnglishUSA - English
Abbott's FreeDM2 study demonstrates that the FreeStyle Libre continuous glucose monitoring (CGM) system significantly improves glucose management in individuals with type 2 diabetes on basal insulin. Participants using the CGM achieved better HbA1c levels and spent more time within the target glucose range compared to those using traditional fingerstick methods. The findings highlight the potential for CGM to enhance diabetes care and support for patients.
Read more →ABTAbbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual...
Abbott has partnered with Real Madrid to launch the 'Abbott Dream Team', a nationwide initiative aimed at youth health and soccer skill development. The program includes selection events where participants will receive training from Real Madrid coaches and health education from Abbott experts. Successful candidates will get an all-expenses-paid trip to Madrid for advanced training and health workshops. This initiative builds on the previous year's success and is focused on inspiring young athletes to embrace healthy lifestyles through sports.
Read more →ABTAbbott declares 409th consecutive quarterly dividend
Abbott has announced its 409th consecutive quarterly dividend of 63 cents per share, payable on May 15, 2026. This achievement highlights Abbott's commitment to returning value to shareholders, with a history of increasing dividends for 54 years. The company is recognized as a member of the S&P 500 Dividend Aristocrats Index.
Read more →ABTLate-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
Abbott announced positive clinical data at the AF Symposium, showcasing the safety and efficacy of its Volt Pulsed Field Ablation System and TactiFlex Duo Ablation Catheter for treating atrial fibrillation. The Volt system achieved an 84.2% success rate in preventing rhythm recurrence, while TactiFlex Duo reported an 81% success rate. Both devices have received FDA and CE Mark approvals, indicating their readiness for market use.
Read more →ABT▼ -10%on this news
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Abbott reported strong financial results for Q4 2025, with double-digit earnings growth and a productive product pipeline. Despite a decline in Nutrition and Diagnostics sales, the company anticipates growth in 2026, projecting organic sales growth of 6.5% to 7.5%. Abbott also declared its 408th consecutive quarterly dividend, reflecting its commitment to shareholders.
Read more →ABTAbbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Abbott has received CE Mark approval for its TactiFlex Duo Ablation Catheter, designed for treating atrial fibrillation (AFib). This catheter utilizes both radiofrequency and pulsed field ablation technologies to provide personalized treatment options. The approval follows successful commercial cases and is supported by data from the FOCALFLEX clinical trial, demonstrating its effectiveness in managing AFib. This marks a significant advancement in Abbott's electrophysiology portfolio.
Read more →ABTAbbott hosts conference call for fourth-quarter earnings
Abbott will announce its fourth-quarter 2025 financial results on January 22, 2026. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time. This event will be accessible through Abbott's Investor Relations website, with an archived edition available later in the day.
Read more →ABTAbbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Abbott has launched the Libre Assist feature within its Libre app, aimed at aiding individuals with diabetes in making informed food choices. This innovative tool uses generative AI to predict glucose impacts of meals before consumption and offers personalized guidance. The feature is accessible without extra fees or prescriptions, enhancing the user experience for diabetes management.
Read more →ABTAbbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott has received FDA approval for its Volt Pulsed Field Ablation System, aimed at treating atrial fibrillation (AFib). The approval follows promising results from the VOLT-AF IDE study, which highlighted the system's safety and effectiveness. The Volt PFA System is designed to enhance patient outcomes and streamline the ablation process, offering a minimally invasive option for patients with AFib.
Read more →ABTAbbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery...
Abbott has received FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, designed to treat patent ductus arteriosus (PDA) in premature infants. This development simplifies the implantation process, requiring only one catheter instead of multiple, and enhances precision during procedures. The system aims to reduce risks and improve long-term outcomes for these infants. Abbott continues to innovate in pediatric heart therapies, confirming its commitment to addressing the needs of vulnerable patients.
Read more →ABTAbbott increases quarterly dividend for 54th consecutive year
Abbott has announced a 6.8% increase in its quarterly dividend to 63 cents per share, marking the 54th consecutive year of dividend growth. This increase reflects a more than 70% rise in dividend payouts since 2020. The dividend is set to be paid on February 13, 2026, to shareholders of record by January 15, 2026.
Read more →ABTBY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting
Abbott Laboratories has adopted new by-laws as restated and amended effective December 12, 2025. The document outlines the structure and requirements for the corporation's board meetings, nominations of directors, and the transactions of business during annual shareholder meetings. Key provisions detail the timing and manner of shareholder notifications for nominations and discussions at these meetings. The updated by-laws are intended to ensure transparency and order in corporate governance.
Read more →ABTAbbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
Abbott has launched its Lingo continuous glucose monitor for Android users, enhancing access to real-time glucose data for millions. This device aids individuals in understanding how various factors affect their glucose levels, promoting healthier lifestyle choices. The app's features, including Lingo Count, help users track glucose spikes and improve metabolic health. Abbott's research indicates that protein supplementation can further support lower glucose levels.
Read more →ABTUniversity of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
The University of Wisconsin triumphed in the Abbott and Big Ten's 'We Give Blood' competition, achieving a 319% increase in blood donations compared to the previous year. The initiative resulted in 15,476 donations, potentially saving 46,428 lives. Abbott will award the university $1 million to promote health initiatives. The campaign highlighted the importance of blood donations, especially among younger donors.
Read more →ABTMuscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Abbott has launched two new shakes in the Ensure Max Protein line aimed at supporting muscle health, particularly for adults over 40. The Ensure Max Protein 42g and Ensure Max Protein 2 in 1 Muscle Support are designed to meet the nutritional needs of active and older adults. The products will be exclusively available at Walmart until March 2026, with plans for broader distribution thereafter.
Read more →ABTAbbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Abbott has announced its acquisition of Exact Sciences for approximately $21 billion, aiming to enhance its capabilities in cancer diagnostics. The deal will allow Abbott to leverage Exact Sciences' innovative products and expertise to improve cancer detection and management. The transaction is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals.
Read more →ABTAbbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments Acquisition adds a new growth vertical to Abbott's already high single-digit
Abbott has announced its acquisition of Exact Sciences for $21 billion, enabling access to the $60 billion U.S. cancer screening and diagnostics market. This move is expected to enhance Abbott's growth trajectory and reinforce its leadership in cancer care. Exact Sciences, known for products like Cologuard and Oncotype DX, will become a subsidiary of Abbott, with its offerings significantly impacting cancer detection and treatment options. The transaction is projected to close in the second quarter of 2026, subject to regulatory approvals.
Read more →ABTAbbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"
Abbott's HeartMates program will be featured in the Hallmark movie 'The More the Merrier,' premiering on November 28. The film showcases real stories from heart patients and includes Damar Hamlin as an ambassador. It aims to inspire and connect those affected by heart health challenges, emphasizing community support.
Read more →ABTAbbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
Abbott reported its third-quarter 2025 financial results, showcasing solid performance driven by strong sales in Adult Nutrition and Medical Devices. The company reaffirmed its full-year guidance for organic sales growth, despite a decline in COVID-19 testing-related sales. Abbott's commitment to delivering long-term value is evident as it continues to expand its product pipeline.
Read more →ABTLa vidéo "Diabète & Préjugés » développée par Abbott révèle que les idées reçues peuvent avoir un impact sur la prise en charge des personnes vivant avec un diabète.
Abbott has launched a campaign titled #DiabeteEtPrejuges to address the stigma surrounding diabetes. The initiative highlights how societal judgments can negatively affect the mental health and care access of over 4.3 million people living with diabetes in France. The campaign aims to foster understanding and inclusivity, supported by healthcare professionals and patient organizations.
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings
Abbott will announce its third-quarter 2025 financial results on October 15, prior to market opening. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central Time. Abbott emphasizes its role as a global healthcare leader with a wide range of products and services.
Read more →ABTAbbott Declares 407th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecutive...
Abbott (NYSE: ABT) has announced its 407th consecutive quarterly dividend of 59 cents per share, which underscores the company's longstanding commitment to returning value to shareholders. This dividend will be payable on November 17, 2025, to shareholders recorded by October 15, 2025. Abbott has a notable track record of increasing its dividend payout for 53 consecutive years and is recognized as a member of the S&P 500 Dividend Aristocrats Index, highlighting its stable financial performance over the decades.
Read more →ABTAbbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and...
Abbott's Navitor TAVI system has received CE Mark approval for expanded use to treat symptomatic, severe aortic stenosis in patients at low and intermediate risk for open-heart surgery. This new indication builds upon its previous approval for high-risk patients and is supported by positive results from the VANTAGE study. The expanded use allows for a significant increase in the number of patients who can benefit from this innovative, minimally invasive treatment option.
Read more →ABTAbbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access...
Abbott has received regulatory approval for the first denosumab biosimilar in Thailand, which will make advanced treatments for osteoporosis and cancer-related bone loss more accessible and affordable. This initiative is part of Abbott's strategy to expand its biosimilar portfolio in the Asia Pacific region, following similar launches in Malaysia and India. The approval is expected to significantly benefit the estimated 3 million individuals in Thailand affected by these conditions.
Read more →ABTAbbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood...
Abbott and the Big Ten Conference have launched Year 2 of the 'We Give Blood' drive, encouraging blood donations among students, alumni, and fans. The competition aims to address the U.S. blood shortage and will run from August 27 to December 5, rewarding the university with the most donations with $1 million. The drive seeks to inspire new blood donors, as participation has declined among younger generations. In its inaugural year, the University of Nebraska-Lincoln led with nearly 4,000 donors, saving thousands of lives.
Read more →ABT▼ -8.5%on this news
Abbott Reports Second-Quarter 2025 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025....
Abbott (NYSE: ABT) announced its financial results for Q2 2025, highlighting high single-digit organic sales growth and double-digit EPS growth. The sales results were driven by significant improvements across different segments, especially Medical Devices, which saw a reported increase of 13.4%. However, some segments, including Diagnostics, faced declines due to reduced demand for COVID-19 tests and other market pressures. Abbott's management conveyed confidence in sustaining this momentum into 2026 as they advance key programs in their product pipeline.
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens. The announcement will be...
Abbott (NYSE: ABT) is scheduled to release its financial results for the second quarter of 2025 on July 17, before the market opens. Following the announcement, there will be a live webcast of the earnings conference call at 8 a.m. Central time, available through Abbott's Investor Relations website. This event underscores Abbott's commitment to keeping investors informed about its performance and operations.
Read more →ABTNew Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE: ABT) Healthy Food Rx...
Recent research presented at the American Diabetes Association's 85th Scientific Sessions highlighted Abbott's Healthy Food Rx program, which promotes a 'food is medicine' approach for individuals living with diabetes. Conducted as a randomized controlled trial, this study involved 364 participants in a low-income community, showing significant improvements in diet quality and health. The program provides home-delivered healthy food boxes along with nutrition education, emphasizing the importance of nutrition in managing diabetes and chronic diseases.
Read more →ABTAbbott Declares 406th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive...
Abbott Labs has declared a quarterly dividend of 59 cents per share, marking its 406th consecutive payout since 1924. The dividend will be payable on August 15, 2025, to shareholders recorded by July 15, 2025. Abbott has a long-standing history of increasing its dividends for 53 years and is part of the S&P 500 Dividend Aristocrats Index. The company's diverse portfolio includes diagnostics, medical devices, and nutritional products, positioning it as a leader in the healthcare industry.
Read more →ABTAbbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve...
Abbott has received FDA approval for its Tendyne transcatheter mitral valve replacement system, designed for patients with severe mitral valve disease. This innovative therapy presents an alternative option for high-risk patients who cannot undergo traditional open-heart surgery due to health complications. The device aims to mitigate symptoms associated with mitral regurgitation and stenosis, providing a less invasive treatment method. Abbott's leadership in the use of advanced heart devices positions Tendyne as a significant addition to its existing structural heart portfolio.
Read more →ABTAbbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring...
Abbott's recent REFLECT studies have revealed that their FreeStyle Libre continuous glucose monitoring (CGM) technology significantly reduces hospitalization rates for heart complications in diabetes patients. Findings indicate an impressive 80% reduction in heart-related hospitalizations for Type 1 diabetes patients without a prior history of cardiovascular disease. The studies suggest that this innovative technology not only aids diabetes management but also enhances heart health, potentially lowering healthcare costs. These results underline the critical impact of CGMs in improving health outcomes for individuals living with diabetes.
Read more →ABTAbbott and Real Madrid Kick Off Search to Empower Young Soccer Talent Abbott (NYSE: ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across...
Abbott has launched the 'Abbott Dream Team' initiative, aimed at identifying talented young soccer players across the United States. The program provides these athletes a chance to train with Real Madrid coaches in Madrid and learn about sports nutrition and health. Tryouts for the team will be held in five major cities, allowing up to 250 athletes per location to participate. This initiative is part of Abbott's broader campaign to promote health and nutrition education through sports, impacting communities positively.
Read more →ABTMotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races Abbott (NYSE: ABT), the global healthcare company, and MotoAmerica, the premier motorcycle road racing series in North America, announced today that...
Abbott and MotoAmerica have partnered to implement the i-STAT TBI blood test, making MotoAmerica the first sports organization globally to use this technology for on-site concussion evaluations at races. This innovative test delivers results in 15 minutes, enabling quick medical assessments of riders who may have sustained a mild traumatic brain injury (mTBI). The availability of this rapid testing during the 2025 season is set to enhance the safety protocols in motorcycle racing, providing essential information to medical staff at the event. The initiative highlights the increasing importance of objective assessment tools in sports medicine.
Read more →ABTAbbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a...
Abbott has announced a groundbreaking collaboration with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring systems into Epic's electronic health record systems. This initiative allows healthcare providers to access critical glucose data directly within their workflow, improving patient management and care efficiency. The integration is expected to benefit over 575,000 healthcare providers and streamline the management of diabetes for millions of patients in the U.S. Abbott aims to extend this integration model to their other medical devices in the future.
Read more →ABTAbbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System...
Abbott announced successful late-breaking data from its AVEIR Conduction System Pacing (CSP) acute clinical feasibility study at the Heart Rhythm Society's annual meeting. This study showcases the first human assessment of a leadless pacemaker, which allows for pacing in the left bundle branch area of the heart. The positive outcomes indicate that the AVEIR CSP may offer a novel and more physiologic approach to cardiac pacing. Abbott is also working on two unique conduction system pacing technologies that could enhance treatment options for patients with heart rhythm disorders.
Read more →ABTNew Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving...
Abbott has released new data from its Volt CE Mark Study, highlighting the long-term benefits of its Volt PFA System for patients with atrial fibrillation (AFib). The study showed strong safety and efficacy over a 12-month period, revealing that the system requires fewer therapy applications than competitors. This study included 150 patients and assessed two groups: those with paroxysmal AFib and persistent AFib. Experts praised the results, suggesting the Volt PFA System will positively impact patient care.
Read more →ABTAbbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025....
Abbott reported its first-quarter 2025 financial results, demonstrating strong sales growth across several segments, notably in medical devices and nutrition. Total company sales increased by 4.0% on a reported basis, with an organic growth of 6.9%. The company reaffirmed its full-year guidance, projecting an organic sales growth of 7.5% to 8.5%. However, the diagnostics segment faced a decline in sales primarily due to reduced demand for COVID-19 testing. Abbott also declared a quarterly dividend, marking its 405th consecutive payment to shareholders.
Read more →ABTNew Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair...
Abbott has announced promising results from its TRILUMINATE Pivotal trial, demonstrating that the TriClip transcatheter edge-to-edge repair system substantially improves tricuspid regurgitation (TR) after two years. The device was shown to significantly reduce heart failure hospitalizations and enhance quality of life for patients who are not candidates for traditional surgery. Highlights from the data include sustained benefits in the severity of TR and improvements in overall health outcomes. The findings were shared at the American College of Cardiology's Annual Scientific Session and have been published in Circulation.
Read more →ABTAbbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed...
Abbott announced the receipt of a CE Mark for its Volt PFA System, a new treatment for patients with atrial fibrillation. This development allows for the commercialization of the system in Europe, following successful clinical study results demonstrating high efficacy in ablation procedures. The Volt PFA System features a single-catheter approach that streamlines the treatment process. Abbott plans to expand the use of this technology across European markets throughout 2025.
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens. The announcement will be...
Abbott will announce its first-quarter financial results for 2025 on April 16 before market opening. Following the announcement, a live webcast of the conference call will occur at 8 a.m. Central time, with an archived edition available later. Abbott is recognized as a global healthcare leader, providing a broad range of healthcare technologies and solutions to a global audience.
Read more →ABTAbbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its...
Abbott has received FDA approval for an investigational device exemption for its Coronary Intravascular Lithotripsy (IVL) System, aimed at treating severe calcification in coronary arteries prior to stenting. The TECTONIC trial will involve up to 335 participants across 47 U.S. sites, seeking to optimize stent placement in patients with coronary artery disease (CAD). This approval positions Abbott to further its leadership in cardiac interventions by potentially enhancing treatment efficacy for CAD patients through the use of innovative IVL technology. The system utilizes high-energy sound pressure waves to fracture calcium blockages, potentially improving clinical outcomes.
Read more →ABTAbbott Declares 405th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 405th consecutive...
Abbott (NYSE: ABT) has declared a quarterly common dividend of 59 cents per share, marking the 405th consecutive dividend since 1924. The cash dividend is set to be paid on May 15, 2025, to shareholders of record by April 15, 2025. Abbott has a long history of increasing its dividend payouts for 53 consecutive years and is recognized as a member of the S&P 500 Dividend Aristocrats Index, which includes companies with a strong track record of dividend growth.
Read more →ABTAbbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care 'One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have diabetes.' New survey...
Abbott has launched the 'Above the Bias' initiative, including a film that addresses misconceptions affecting diabetes care. Survey data indicates that stigma and stereotypes significantly impact the health management of people living with diabetes. The initiative seeks to cultivate a deeper understanding of the challenges faced by individuals with diabetes and highlights the importance of both technological and communal support. Abbott continues to innovate in diabetes care with its FreeStyle Libre continuous glucose monitoring system.
Read more →ABTAbbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024....
Abbott (NYSE: ABT) reported strong fourth-quarter and full-year financial results for 2024, marking the highest sales growth and earnings per share for the year in Q4. The company achieved their guidance for 2024 and anticipates robust growth in 2025. Sales in the Medical Devices segment notably increased, while the Diagnostics segment faced challenges due to declining sales of COVID-19 testing. Overall, Abbott demonstrated resilience in several key areas despite some challenges in specific divisions.
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. The announcement will be...
Abbott (NYSE: ABT) is set to announce its financial results for the fourth quarter of 2024 on January 22, 2025, before market opening. Following the announcement, investors can participate in a live webcast of the earnings call at 8:30 a.m. Central Time. Abbott continues to be recognized for its extensive portfolio of healthcare products and services.
Read more →ABTAbbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left...
Abbott has announced the successful completion of the world's first leadless pacing procedures targeting the left bundle branch area of the heart using its investigational AVEIR Conduction System Pacing (CSP). This landmark achievement, conducted as part of a feasibility study, showcases a new treatment option for patients with slower-than-normal heart rhythms. The AVEIR CSP system aims to enhance cardiac pacing by mimicking the heart's natural beats while eliminating traditional leads. FDA has granted Breakthrough Device Designation for this innovative technology, reflecting its potential to improve cardiac care.
Read more →ABTAbbott Increases Quarterly Dividend for 53rd Consecutive Year Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an...
Abbott (NYSE: ABT) announced a 7.3% increase in its quarterly common dividend, now set at 59 cents per share. This increase marks the 53rd consecutive year of dividend growth and the 404th consecutive quarterly dividend paid since 1924. The cash dividend will be payable on February 14, 2025, to shareholders of record by January 15, 2025. Abbott continues to be recognized as an S&P 500 Dividend Aristocrat for its long-standing commitment to increasing dividends annually.
Read more →ABTUniversity of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college...
Abbott and the Big Ten Conference launched the "We Give Blood Drive" competition this college season, encouraging nearly 20,000 students and fans to donate blood. This initiative succeeded in saving approximately 60,000 lives during a critical nationwide blood shortage. The University of Nebraska-Lincoln won the competition and received a $1 million grant from Abbott, which will be used to enhance health initiatives within the community. The program aims to foster a culture of blood donation among younger demographics, addressing a significant decline in donors aged 19 to 24.
Read more →ABTAbbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI)...
Abbott has announced the successful completion of the first patient procedures using its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating severe aortic stenosis. This new device is designed to enhance treatment options through the use of artificial intelligence, potentially transforming patient management in interventional cardiology. The system aims to provide a customizable solution for patients with unique anatomical challenges, complementing Abbott's existing Navitor™ TAVI system. The initial procedures were performed in Uzbekistan, indicating Abbott's progress and commitment to addressing a critical healthcare need.
Read more →ABTAbbott inaugura una planta de fabricación global de última generación en Kilkenny, Irlanda Abbott (NYSE: ABT) ha inaugurado hoy oficialmente su planta de fabricación de última generación en Kilkenny (Irlanda), con una ceremonia a la que han ...
Abbott has officially opened a new state-of-the-art manufacturing plant in Kilkenny, Ireland, which will focus on the production of FreeStyle Libre 3 sensors for diabetes management. This facility is part of a larger investment of 440 million euros in Ireland, including expansions at existing sites that will create additional jobs. The new plant emphasizes sustainability, featuring renewable energy sources and rainwater collection systems. The opening highlights Abbott's commitment to supporting the global demand for diabetes care technology.
Read more →ABTAbbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland Abbott (NYSE: ABT) today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by...
Abbott has officially opened a state-of-the-art manufacturing facility in Kilkenny, Ireland, which will serve as a global center for its diabetes care business. The new facility, part of a €440 million investment, will create over 800 jobs and produce FreeStyle Libre 3 sensors. This expansion aligns with Abbott's commitment to innovative healthcare solutions for diabetes management and features sustainable practices in its operations. The announcement was celebrated by government officials, highlighting Ireland's role in advanced manufacturing.
Read more →ABTAbbott eröffnet eine hochmoderne globale Produktionsstätte in Kilkenny, Irland Abbott (NYSE: ABT) hat heute seine hochmoderne Produktionsstätte in Kilkenny, Irland, in Anwesenheit des irischen Premierministers Simon Harris und...
Abbott has officially opened a state-of-the-art manufacturing facility in Kilkenny, Ireland, aimed at enhancing its Diabetes Care division. The 30,000 square meter facility is part of a €440 million investment, which includes creating additional jobs in Donegal. This new site will produce the FreeStyle Libre 3 sensors, catering to the increasing demand for diabetes management solutions. The facility also emphasizes sustainability, featuring renewable energy sources and water conservation systems.
Read more →ABTAbbott inaugure un site de fabrication de pointe à Kilkenny, en Irlande Abbott (NYSE : ABT) marque aujourd'hui l'ouverture officielle de son site de production ultramoderne à Kilkenny, en Irlande, lors d'une cérémonie à...
Abbott has officially opened a state-of-the-art manufacturing facility in Kilkenny, Ireland, aimed at enhancing its diabetes care operations. This center of excellence will create over 800 jobs and is part of a larger €440 million investment in the country, which includes expansion projects at its Donegal site. The facility will manufacture the FreeStyle Libre 3 sensors, recognized as the smallest sensors globally, contributing to the growing demand for diabetes management solutions. Additionally, the plant incorporates sustainable practices such as solar energy and rainwater collection.
Read more →ABTAbbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure Abbott (NYSE: ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who...
Abbott has announced the initiation of a groundbreaking clinical trial, named TEAM-HF, aimed at improving outcomes for patients with advanced heart failure. The trial will enroll up to 850 patients globally and utilize Abbott's CardioMEMS HF System to measure pulmonary artery pressures. By identifying high-risk patients earlier, the study seeks to enhance the timely implementation of life-saving heart pumps, potentially improving survival rates and quality of life. Enrollment for the trial is set to begin shortly, with primary results expected at the two-year mark and follow-up extending to five years.
Read more →ABTAbbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2024. Third-quarter GAAP diluted EPS of $0.94 and adjusted ...
Abbott reported its third-quarter results for 2024, revealing a GAAP diluted EPS of $0.94. The company's diversified business model demonstrated strength, with strong sales growth in the Medical Devices segment, particularly in diabetes care and structural heart products. However, challenges remained, as certain divisions like Nutrition experienced sales declines, and demand for COVID-19 testing continued to decrease. Abbott's management remains optimistic, raising the midpoint of its full-year EPS guidance range.
Read more →ABTAbbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA)...
Abbott (NYSE: ABT) has announced significant advancements in pulsed field ablation (PFA) technology with the early completion of the VOLT-AF IDE Study and the launch of the FOCALFLEX trial. The VOLT-AF study supports the Volt PFA System, while the FOCALFLEX trial evaluates the TactiFlex Duo Ablation Catheter designed for paroxysmal atrial fibrillation. Additionally, Abbott received FDA clearance for the Advisor HD Grid X Mapping Catheter, which will improve cardiac mapping for ablation procedures. These developments represent notable steps forward in the treatment of abnormal heart rhythms.
Read more →ABTAbbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive' To help address the greatest need for blood in a generation, Abbott, a global leader in blood testing, and the Big Ten Conference are teaming up to...
Abbott has partnered with the Big Ten Conference to launch 'The We Give Blood Drive', a nationwide blood donation competition aimed at mitigating the severe blood shortages in the U.S. The initiative, running from September 26 to December 6, encourages participation from students, alumni, and fans by leveraging school rivalries and community spirit. The school that donates the most blood during the campaign will be awarded $1 million to improve student or community health. This effort not only aims to boost immediate blood supply but also seeks to inspire lifelong blood donation habits among younger individuals.
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens. The announcement will be...
Abbott (NYSE: ABT) is set to announce its third-quarter 2024 financial results on October 16, before market opening. Following the announcement, a live conference call will be held at 8 a.m. Central time, accessible via Abbott's Investor Relations website. The company has a significant global workforce and a wide range of healthcare products, emphasizing its role as a leader in the healthcare sector.
Read more →ABTAbbott Declares 403rd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 403rd consecutive...
Abbott (NYSE: ABT) has declared a quarterly common dividend of 55 cents per share, marking its 403rd consecutive quarterly payout. This dividend is set to be distributed on November 15, 2024 to shareholders of record by October 15, 2024. Abbott has achieved a significant milestone by increasing its dividend payouts for 52 consecutive years, earning it a place in the S&P 500 Dividend Aristocrats Index, which recognizes companies with a strong history of dividend growth.
Read more →ABTAbbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a...
Abbott announced the U.S. launch of its Lingo™ continuous glucose monitoring system, designed for consumers aged 18 and older not on insulin. This innovative technology tracks glucose levels in real-time and provides personalized insights via a mobile app, enabling users to improve their metabolic health and wellness. Lingo is based on Abbott's established FreeStyle Libre® technology, which is currently used by over 6 million diabetes patients worldwide. The Lingo system aims to bridge the gap between traditional healthcare and preventive health measures by empowering users to manage their health actively.
Read more →ABTAbbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep...
Abbott has initiated a pivotal clinical trial called the TRANSCEND study to evaluate its deep brain stimulation (DBS) system for treatment-resistant depression (TRD). The FDA granted Breakthrough Device designation to accelerate the development of this innovative technology. The trial will enroll 100 patients who have failed at least four types of antidepressants, aiming to gather clinical evidence for DBS effectiveness. Early studies have indicated promising results, with significant symptom improvement for many patients.
Read more →ABTAbbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores Pure Bliss™ Organic and Pure Bliss Organic with A2 Milk infant formulas – both USDA-certified – are now part of the Pure Bliss by Similac® line that...
Abbott has announced the expansion of its Pure Bliss line of infant formulas, introducing new organic and European-made options to meet diverse parental preferences. Among the new offerings are the first and only organic liquid formula available in U.S. retail stores. The Pure Bliss by Similac line emphasizes quality sourcing and adheres to USDA certifications while being backed by Abbott's extensive experience in infant nutrition. Parents can find these products at major retailers like Amazon, Target, and Walmart, enhancing their choices for infant nutrition.
Read more →ABTAbbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM)...
Abbott has partnered with Medtronic to develop an integrated continuous glucose monitoring (CGM) system that leverages Abbott's advanced FreeStyle Libre technology. This collaboration aims to enable automatic insulin adjustments through Medtronic's insulin delivery devices, enhancing diabetes management for users. The commercial availability timeline and financial details were not disclosed, however, the partnership is a strategic move to simplify diabetes care and increase device accessibility.
Read more →ABTAbbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted EPS of $0.74 and...
Abbott (NYSE: ABT) announced its second-quarter results for 2024, highlighting a strong underlying business growth and raising its full-year guidance. The company reported a GAAP diluted EPS of $0.74 and emphasized increased sales in its Nutrition and Medical Devices segments, driven by organic growth. However, Diagnostics sales were adversely affected by a drop in COVID-19 testing-related revenue. Overall, Abbott experienced improved performance across several key areas, indicating optimism as the year progresses.
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be...
Abbott (NYSE: ABT) is set to announce its second-quarter financial results for 2024 on July 18. Following the announcement, there will be a live webcast of the conference call at 8 a.m. Central time. Abbott's extensive portfolio covers multiple healthcare areas, and the company has a strong global presence with 114,000 employees in over 160 countries.
Read more →ABTAbbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase...
Abbott has partnered with the National Association of Community Health Centers (NACHC) to enhance access to nutritious food via the Innovation Incubator initiative. This year, eight selected community health centers will receive funding and support to develop innovative solutions that address food insecurity and improve health outcomes for their populations. The initiative aims to integrate nutritional support into clinical care, recognizing the importance of diet in managing chronic conditions. Community health centers will share their successful strategies nationally, potentially impacting over 31 million patients.
Read more →ABTAbbott Declares 402nd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 402nd consecutive...
Abbott has announced its 402nd consecutive quarterly dividend of 55 cents per share, which will be paid on August 15, 2024. This demonstrates Abbott's consistent commitment to returning value to its shareholders, as the company has increased its dividends for 52 consecutive years. Abbott is also noted for its inclusion in the S&P 500 Dividend Aristocrats Index, highlighting its long-standing practice of dividend growth. The company provides a wide range of healthcare products and services to improve lives globally.
Read more →ABTAbbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) ...
Abbott has received FDA clearance for two new over-the-counter continuous glucose monitoring (CGM) systems, Lingo and Libre Rio. Lingo aims to enhance wellness for general consumers while Libre Rio is tailored for adults with Type 2 diabetes managing their condition through lifestyle changes. These systems will be available without a prescription, marking a significant step in increasing access to diabetes management tools in the U.S. The Lingo system offers personalized insights and coaching, contributing to broader health improvement. Meanwhile, Libre Rio's wide measurement range enables better management of glucose levels for diabetes patients.
Read more →ABTEl stent innovador que se disuelve de Abbott recibe la aprobación de la FDA para arterias por debajo de la rodilla. Abbott ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos ha aprobado el sistema de andamio bioabsorbible ...
Abbott has announced the FDA approval of the Esprit BTK bioabsorbable scaffold system for treating below-the-knee chronic limb-threatening ischemia (CLTI). This innovative stent is designed to keep arteries open while releasing everolimus to promote vessel healing before dissolving. Previously, no FDA-approved stents or drug-coated balloons existed for below-the-knee use, with angioplasty being the standard treatment. Clinical trial results indicated that the Esprit BTK significantly reduces disease progression and enhances medical outcomes compared to traditional methods.
Read more →ABTAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable...
Abbott has received FDA approval for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, a groundbreaking treatment for chronic limb-threatening ischemia below the knee. This new system is designed to permanently open arteries while delivering medication for vessel healing before dissolving completely. Prior to this innovation, balloon angioplasty was the only approved treatment for below-the-knee uses, often with limited success. The approval is expected to significantly enhance treatment outcomes for millions suffering from peripheral artery disease.
Read more →ABTAbbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024....
Abbott reported its first-quarter 2024 financial results, highlighting a robust start to the year with double-digit organic sales growth across several segments. The company has increased its full-year sales and earnings guidance and managed to maintain positive performance despite a significant decline in COVID-19 testing-related sales. Notably, Abbott's Medical Devices and Established Pharmaceuticals businesses showed strong gains. The company also continues its long-standing tradition of dividend increases, marking 52 consecutive years of dividends.
Read more →ABTAbbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™...
Abbott announced that the FDA has approved its TriClip device, a pioneering solution for repairing leaky tricuspid valves. This minimally invasive device aims to treat patients suffering from tricuspid regurgitation, a condition that can lead to severe health complications. The approval follows positive outcomes from the TRILUMINATE Pivotal trial, showcasing TriClip's effectiveness and safety. With this device, Abbott expands its portfolio of structural heart solutions, offering new hope to patients who previously had limited treatment options.
Read more →ABTAbbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors...
Abbott's i-STAT TBI cartridge has gained FDA clearance to conduct whole blood tests for concussion assessment at the bedside. This innovative device allows healthcare providers to obtain lab-quality results in just 15 minutes, potentially transforming the evaluation of mild traumatic brain injuries. The new test can be utilized in diverse environments, including urgent care clinics, enabling quicker triage and care. Additionally, the cartridge tests for two biomarkers, providing objective data that aids in determining if patients need further imaging or evaluation.
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens. The announcement will be...
Abbott (NYSE: ABT) will announce its financial results for the first quarter of 2024 on April 17, prior to market opening. Following the announcement, a live webcast of the earnings conference call is scheduled for 8 a.m. Central time. The call will be available on Abbott's Investor Relations website and an archived edition will be accessible later that day. Abbott is recognized for its extensive range of healthcare technologies and products.
Read more →ABTReal-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes Abbott (NYSE: ABT) today announced new data from two real-world studies1, 2 showing people with Type 2 diabetes using GLP-1 medicines and FreeStyle...
Abbott (NYSE: ABT) announced new data demonstrating that using FreeStyle Libre technology alongside GLP-1 medicines improves glycemic control in people with Type 2 diabetes. Presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes, the studies showed greater reductions in HbA1c for patients using both treatments compared to those on GLP-1 therapies alone. This complementary relationship emphasizes the role of continuous glucose monitoring in enhancing diabetes management and achieving better health outcomes.
Read more →ABTAbbott Declares 401st Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 401st consecutive...
Abbott (NYSE: ABT) has announced a quarterly common dividend of 55 cents per share, marking its 401st consecutive payment. This achievement highlights Abbott's longstanding commitment to returning value to shareholders, as the company has increased its dividends for 52 consecutive years. The upcoming dividend will be payable on May 15, 2024, to shareholders of record as of April 15, 2024. Abbott is a prominent player in healthcare, offering a range of products across diverse sectors.
Read more →ABTFDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug...
The FDA Advisory Committee has voted favorably on Abbott's TriClip system, a novel treatment for tricuspid regurgitation (TR), which historically has few alternatives. The device was evaluated for safety, effectiveness, and risk-benefit, receiving strong support with votes showing significant confidence in TriClip's capabilities. The TRILUMINATE pivotal trial demonstrated a 90% improvement in TR severity for patients treated with TriClip. Although currently investigational in the U.S., the TriClip has seen over 10,000 successful applications worldwide.
Read more →ABTNew Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again A new study published online and available in the February print edition of the journal Transfusion shows the mixed reality technology for use during ...
A new study published in the journal Transfusion highlights the effectiveness of mixed reality technology developed by Abbott and Blood Centers of America in improving the blood donation experience. The pilot study involving 282 donors showed that the technology significantly reduced anxiety levels and increased the likelihood of repeat donations. Mixed reality headsets allowed donors to engage with a digital environment while remaining aware of their surroundings, contributing to a more enjoyable donation process. This innovation aims to attract and retain younger donors in response to declining donation rates in this demographic.
Read more →ABTAbbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of...
Abbott has introduced its PROTALITY brand, aimed at supporting adults in their weight loss journeys through a new line of high-protein nutrition shakes. The shakes are designed to help maintain muscle mass while individuals pursue weight loss, an important aspect that is often compromised during dieting. The product, which will be available in Milk Chocolate and Vanilla flavors, aligns with Abbott’s commitment to science-based nutrition and is set to be sold online and in various retail stores starting from February 2024. Abbott plans to continue developing additional products within the PROTALITY brand to address specific nutritional needs for weight loss.
Read more →ABTAbbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+ Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC™ DBS system,...
Abbott has announced the launch of the Liberta RC™ DBS system, approved by the FDA. This device is the smallest rechargeable deep brain stimulation system designed for treating movement disorders. Notably, it requires the fewest recharges compared to any other FDA-approved system, needing only 10 sessions a year. Additionally, the device features remote programming capabilities, allowing patients to communicate with their doctors without needing to visit in person, thereby streamlining care for those with chronic conditions like Parkinson's disease.
Read more →ABTAbbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023....
Abbott released its financial results for the fourth quarter and full year of 2023, highlighting a 2.1% organic growth in sales. While the Nutrition segment reported an increase of 12.2%, the Diagnostics division faced a substantial decline of 22.7%, primarily due to reduced COVID-19 testing demand. Despite challenges, Abbott's leadership expressed optimism for growth in 2024 driven by a strong pipeline and product diversity. The results reflect both the continuing impacts of the pandemic's transition to an endemic state and the successful recovery within the Nutrition business.
Read more →ABTAbbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial...
Abbott has successfully conducted the first global procedures using its Volt Pulsed Field Ablation (PFA) System to treat patients with abnormal heart rhythms like atrial fibrillation (AFib). This system, part of a pre-market clinical study, seeks to provide a safer and more effective alternative to traditional cardiac ablation techniques. The Volt PFA System, which uses high-energy electrical pulses rather than heat or cold, is designed to improve patient outcomes by reducing risks associated with previous methods. Abbott anticipates expanding clinical trials across Asia Pacific and Europe, and expects to receive approval for the U.S. trial in the first half of the year.
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens. The announcement will be...
Abbott (NYSE: ABT) is set to announce its fourth-quarter 2023 financial results on January 24, 2024, before market opening. A live webcast of the earnings conference call will follow at 8 a.m. Central time, accessible via Abbott's Investor Relations website. An archived version of the call will also be available later that day, allowing investors to review the updates on Abbott's performance.
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Robert B. Ford, chairman and chief...
Abbott (NYSE: ABT) is scheduled to present at the 42nd annual J.P. Morgan Healthcare Conference on January 9, 2024. Robert B. Ford, the chairman and CEO, will speak at 11 a.m. Central time. A live webcast of the event will be available on the company's Investor Relations website, enhancing transparency and investor engagement. Abbott's participation highlights its role as a major player in the global healthcare sector with diverse offerings.
Read more →ABTAbbott Increases Quarterly Dividend for 52nd Consecutive Year Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 55 cents per share, an...
Abbott has announced an increase in its quarterly dividend to 55 cents per share, marking a 7.8% rise. This is the company's 52nd consecutive year of dividend growth and will be the 400th consecutive quarterly dividend payment. Shareholders of record by January 12, 2024, will receive this dividend on February 15, 2024. Abbott is recognized as an S&P 500 Dividend Aristocrat, indicating its long-standing commitment to returning value to shareholders.
Read more →ABTLate-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump Abbott (NYSE: ABT) announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3™ heart pump who didn't...
Abbott announced promising results from the ARIES trial, which evaluated the effectiveness of an aspirin-free medication regimen for advanced heart failure patients using the HeartMate 3 heart pump. The study revealed that patients not taking aspirin experienced significantly fewer bleeding complications and hospital visits compared to those who did. Additionally, this regimen resulted in substantial cost savings associated with fewer bleeding incidents. The findings suggest a potential paradigm shift in how physicians approach treatment for patients with the HeartMate 3 device.
Read more →ABTParticipants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes A study of Abbott's (NYSE: ABT) Healthy Food Rx, a food as medicine program that provides home-delivered medical prescriptions of healthy food to...
Abbott's Healthy Food Rx program, launched in 2021 to support individuals with diabetes in Stockton, California, has demonstrated clinically significant benefits according to a study by the Public Health Institute. Participants experienced lower A1C levels, improved self-management of diabetes, and enhanced diet quality after one year of receiving healthy food prescriptions. The program, part of a broader initiative, aims to expand its reach to an additional 1,000 individuals by the year's end, emphasizing the importance of community collaboration in health improvement.
Read more →ABTAbbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution,...
Abbott has received FDA approval for its Alinity m HR HPV assay, a molecular screening solution designed for the detection of high-risk HPV infections. This test is recommended for use in routine cervical cancer screening and can provide detailed information on various cancer-causing HPV genotypes. The assay is intended to streamline HPV testing, enabling better patient care and follow-up strategies. The Alinity m system is Abbott's advanced PCR platform, supporting rapid and high-volume testing for HPV and other infectious diseases.
Read more →ABTAbbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology Abbott and Shepherd aim to raise awareness of the rising rates of diabetes diagnoses and how access to continuous glucose monitoring (CGM) systems...
Abbott has launched the 'Countdown at a Crossroads' initiative to coincide with National Diabetes Awareness Month, aiming to raise awareness about diabetes and the underutilization of continuous glucose monitoring (CGM) systems like FreeStyle Libre. This campaign features an installation in New York City highlighting personal stories of individuals impacted by diabetes, including Sherri Shepherd, who advocates for the technology's accessibility. With over half a billion adults worldwide diagnosed with diabetes, Abbott emphasizes that only 1% currently use CGM technology, underscoring the need for increased awareness and availability.
Read more →ABTAbbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program Abbott (NYSE: ABT), a global leader in heart health, announced today the Abbott HeartMates program, a new initiative that will kick off with...
Abbott has announced the launch of the HeartMates program, a new initiative aimed at building a supportive community for those affected by heart conditions. Damar Hamlin, a professional football player and advocate for heart health, will serve as the program's first ambassador. The HeartMates program is designed to facilitate emotional support and connection among participants, including patients, caregivers, and healthcare professionals. The inaugural team will be formed in early 2024, concentrating on inspiring others with shared experiences in heart health recovery.
Read more →ABTNinety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem New survey by Morning Consult on behalf of Abbott shows student loans are having a profound and far-reaching impact on young adults and their...
Abbott has launched a blueprint for its Freedom 2 Save program to help employers support employees dealing with student loan debt, based on a recent survey showing 91% of young adults with loans report financial stress affecting their wellness. The findings underscore the widespread impact of student loans, with Abbott encouraged other companies to adopt similar initiatives. The upcoming SECURE 2.0 Act will facilitate employer contributions to employee retirement accounts linked to loan repayments beginning January 2024. Abbott's innovative program has garnered recognition and aims to provide significant benefits for employees potentially achieving larger retirement savings.
Read more →ABTLate-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears...
Abbott has announced promising data from the LIFE-BTK trial, which evaluated the effectiveness of the Esprit BTK Everolimus Eluting Resorbable Scaffold System in patients with chronic limb-threatening ischemia (CLTI). The trial successfully met its primary endpoints, showing that Esprit BTK is superior to balloon angioplasty in reducing disease progression and improving patient outcomes. With no current approved alternatives for below-the-knee drug-eluting stents, this treatment could significantly benefit millions affected by peripheral artery disease. Abbott plans to submit the findings for review by the FDA.
Read more →ABTLate-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating...
Abbott (NYSE: ABT) presented late-breaking data on its minimally invasive heart devices at the 35th Transcatheter Cardiovascular Therapeutics symposium. The findings from the TRILUMINATE pivotal trial demonstrate the TriClip's safety and effectiveness in treating severe tricuspid regurgitation. Additionally, results from the MitraClip EXPAND G4 study highlight its benefits in a diverse patient population with mitral regurgitation. Abbott's innovative devices are positioned as new standards of care for structural heart disease, potentially revolutionizing treatments previously reliant on surgical interventions.
Read more →ABTAbbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023. Third-quarter GAAP diluted EPS of $0.82 and adjusted ...
Abbott announced its financial results for the third quarter of 2023, reporting total sales of $10.143 billion. The company raised the midpoint of its full-year EPS guidance, signaling confidence in its strategies. Strong performances were noted in the Nutrition and Medical Devices segments, with international sales especially robust. CEO Robert B. Ford highlighted that investments made during the pandemic are driving growth across Abbott's portfolio as the company positions itself for future success.
Read more →ABTAbbott lança seu cateter de ablação TactiFlex para tratamento de ritmo cardíaco anormal A Abbott anuncia o lançamento do seu cateter de ablação TactiFlex™, Sensor Enabled™, o primeiro cateter de ablação do mundo com uma ponta flexível e...
Abbott has launched the TactiFlex™ catheter, a new tool for treating atrial fibrillation. This catheter features a flexible tip and contact force technology, promising improved safety and reduced procedure time compared to previous models. With global atrial fibrillation cases on the rise, the TactiFlex catheter aims to meet the growing demand for innovative solutions. The catheter has already demonstrated a high success rate of over 99% in treating patients with this condition.
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens. The announcement will be...
Abbott will announce its third-quarter 2023 financial results on October 18, before the market opens. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central Time. The call will be accessible via Abbott's Investor Relations website, with an archived version available later the same day. Abbott continues to operate as a significant player in the global healthcare sector, with a wide range of technologies and products.
Read more →ABTAbbott Completes Acquisition of Bigfoot Biomedical Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems...
Abbott (NYSE: ABT) has completed its acquisition of Bigfoot Biomedical, a company specializing in smart insulin management systems for diabetes care. This acquisition aims to enhance Abbott's offerings in diabetes management, complementing its existing FreeStyle Libre portfolio. With Bigfoot now a wholly owned subsidiary, Abbott expects to advance its development of connected diabetes care solutions. However, the company faces challenges in integrating Bigfoot's operations and achieving anticipated synergies.
Read more →ABTAbbott Declares 399th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 399th consecutive...
Abbott (NYSE: ABT) has declared a quarterly common dividend of 51 cents per share, marking its 399th consecutive dividend since 1924. This continued commitment reflects the company's financial stability and success in increasing dividend payouts for 51 years. The cash dividend will be payable on November 15, 2023, to shareholders of record by October 13, 2023. Abbott is recognized as a member of the S&P 500 Dividend Aristocrats Index, which signifies a strong track record in dividend growth.
Read more →ABTAbbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets Abbott (NYSE: ABT) announced today an agreement with Spain-based global biotech leader mAbxience Holdings S.L. to commercialize several biosimilars...
Abbott has announced a partnership with mAbxience to commercialize several biosimilars in emerging markets, focusing on oncology, women's health, and respiratory diseases. This agreement, which builds on a previous collaboration, aims to improve access to affordable treatments in Latin America, Southeast Asia, the Middle East, and Africa. The first biosimilars are expected to launch in 2025, pending clinical development and registration. Abbott's extensive footprint in these regions will facilitate the distribution of these biosimilars, addressing healthcare accessibility challenges in underserved populations.
Read more →ABTAbbott and WeightWatchers Connected App Experience is Now Available for People Living with Diabetes Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help...
Abbott and WW International, known as WeightWatchers, have launched a connected app designed to assist individuals with Type 2 diabetes in managing their glucose levels through nutrition and activity tracking. This innovative tool integrates glucose data from Abbott's FreeStyle Libre 2 system within the WeightWatchers app, enabling users to follow the WW Diabetes-Tailored Plan. The collaboration aims to empower individuals to make informed health choices and improve their overall well-being. Clinical studies indicate that the WW plan can lead to significant reductions in hemoglobin A1c levels and diabetes-related distress.
Read more →ABTAbbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn...
Abbott is set to acquire Bigfoot Biomedical, specializing in smart insulin management systems for diabetes care. This agreement aims to enhance the development of personalized and connected solutions using Bigfoot's FDA-cleared technology. The acquisition combines Abbott's expertise in continuous glucose monitoring with Bigfoot's insulin dosing support systems. This collaboration could broaden the reach of advanced diabetes management tools, although it is contingent upon closing conditions and may encounter operational challenges during integration.
Read more →ABTAbbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023....
Abbott reported its financial results for the second quarter ending June 30, 2023, indicating strong growth within its underlying base business. Despite overall sales declining by 11.4% year-over-year, sectors like Pediatric Nutrition and Medical Devices showed significant improvement, which helped boost Abbott's outlook for future growth. The company attributes part of this growth to their productive pipeline and the recovery of market share in certain sectors. However, the result was tempered by substantial drops in COVID-19 testing revenue, impacting the Diagnostics sector.
Read more →ABTAbbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers,...
Abbott has received FDA approval for the AVEIR dual chamber leadless pacemaker system, the first of its kind. This innovative technology allows for synchronized pacing between two devices implanted in the heart, catering to the majority of patients who require dual chamber pacing. With a proven 98.3% implant success rate, the AVEIR system represents a significant advancement in treatment options for individuals with abnormal heart rhythms. Its design prioritizes a minimally invasive approach, minimizing potential complications and improving recovery times.
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2023 financial results on Thursday, July 20, before the market opens. The announcement will be...
Abbott Laboratories is set to announce its financial results for the second quarter of 2023 on July 20, before the market opens. This announcement will be followed by a live earnings conference call at 8:30 a.m. Central time, which will also be accessible via Abbott's Investor Relations website. The company is recognized as a leading global healthcare provider with a wide range of products and technologies across various sectors.
Read more →ABTAbbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹ Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2...
Abbott announced that the French health authority has approved the expanded reimbursement of its FreeStyle Libre 2 system for all adults with diabetes who use basal insulin. Previously, coverage was limited to individuals requiring intensive insulin therapy. This change enables an additional 3 million patients in France to access continuous glucose monitoring, with demonstrated benefits including significant reductions in hospitalizations for diabetic complications. The Real World Evidence study supported this decision by highlighting the positive outcomes experienced by users of FreeStyle Libre technology.
Read more →ABTAbbott Declares 398th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 398th consecutive...
Abbott's board of directors has declared a quarterly common dividend of 51 cents per share, marking the company's 398th consecutive dividend payment. This milestone reflects Abbott's strong financial position and ongoing commitment to shareholder returns. The dividend is payable on August 15, 2023, to shareholders on record as of July 14, 2023. Abbott is recognized as a leader in the healthcare sector, continuously increasing its dividends for 51 years, and is part of the S&P 500 Dividend Aristocrats Index.
Read more →ABTAbbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign - Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to...
Abbott, in partnership with Real Madrid and the Real Madrid Foundation, has launched the 'Beat Malnutrition' campaign aimed at reducing childhood malnutrition globally. The initiative includes providing malnutrition screening tools and funding for programs in social sports schools. It is part of a broader effort to increase awareness and education about malnutrition, especially among parents in the U.S., where confidence in identifying malnutrition is low. The campaign will also feature fitness events and awareness activities to engage communities in promoting better nutrition.
Read more →ABTEuropean Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF System ...
New data from the MONITOR-HF trial indicates that Abbott's CardioMEMS HF System significantly improves the quality of life for heart failure patients. The trial showed a 44% reduction in heart failure-related hospitalizations, highlighting the effectiveness of remote monitoring. This system allows for daily transmission of health data, enabling proactive management of heart conditions. The findings were presented at the European Society of Cardiology's annual meeting and published in The Lancet.
Read more →ABTAbbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a...
Abbott announced positive late-breaking results from its AVEIR dual-chamber leadless pacemaker study, demonstrating that the device met safety and performance endpoints. The findings were shared at the Heart Rhythm Society's annual meeting and have been submitted to the FDA for approval. This first-of-its-kind pacemaker aims to offer improved treatment options for patients with slower heart rhythms by eliminating the need for traditional leads. The study highlights the potential of leadless technology in advancing cardiac care.
Read more →ABTAbbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Sensor...
Abbott has received FDA approval for its TactiFlex™ Ablation Catheter, designed for treating atrial fibrillation, the most common abnormal heart rhythm. This catheter features a flexible tip and advanced contact force technology, promising improved safety and reduced procedure times compared to older models. The TactiFlex catheter has shown excellent efficacy, achieving over 99% acute procedural success in clinical trials. It is also approved for use in multiple countries beyond the U.S., reflecting its global significance.
Read more →ABTAbbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance,...
Abbott has announced that its Assert-IQ insertable cardiac monitor has received FDA clearance. This device allows for long-term, real-time monitoring of patients with irregular heart rhythms, addressing challenges in diagnosing conditions like arrhythmias. With options for battery life of three or six years, it provides increased flexibility for physicians. The device also uses advanced algorithms to detect hard-to-spot irregularities, enhancing patient management and care.
Read more →ABTAbbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic...
Abbott has received FDA approval for its spinal cord stimulation systems to treat chronic back pain in patients with limited surgical options. This approval is backed by the DISTINCT study, the largest randomized controlled trial for spinal cord stimulation, which demonstrated significant improvements in pain levels and daily activities. The BurstDR stimulation technology enhances discomfort management and offers a new therapeutic option for individuals who have historically struggled with back pain treatment. The announcement aims to provide relief to a significant population of chronic pain sufferers who are not candidates for surgery.
Read more →ABTAbbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and...
Abbott has announced multiple new programs aimed at enhancing diversity in its clinical trials initiative. These initiatives include partnerships with the Norton Healthcare Foundation and Barnett International, as well as the establishment of a Diversity in Research Office. The primary goal is to improve access for under-represented populations and to build sustainable clinical research models. Abbott plans to support community clinics and historical black colleges to ensure broader participation in clinical trials.
Read more →ABTAbbott Completes Acquisition of Cardiovascular Systems, Inc. Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an...
Abbott has completed its acquisition of Cardiovascular Systems, Inc. (CSI), enhancing its vascular treatment capabilities. This acquisition adds CSI's innovative atherectomy system, which is aimed at improving treatment for patients with peripheral and coronary artery disease. Following the acquisition, CSI will operate as a wholly owned subsidiary of Abbott. The deal signifies Abbott's commitment to expanding its product portfolio and improving patient care. However, Abbott acknowledges potential risks associated with the integration and realization of synergies from this transaction.
Read more →ABTAbbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life...
Abbott has announced dual FDA clearances for its CentriMag life support system, which includes a new Pre-connected Pack designed to expedite care for critically ill patients. The CentriMag system facilitates blood oxygenation, drastically improving outcomes during critical conditions, including post-surgery recovery and COVID-19 cases. These advancements aim to streamline treatment significantly, allowing physicians to deploy life-saving support more effectively in urgent situations.
Read more →ABTAbbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change Abbott is joining the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which will use data science to predict, track and control...
Abbott is partnering with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which comprises over 100 scientists specializing in public health and data science. This collaboration aims to use data science and diagnostic testing to better predict and control disease outbreaks exacerbated by climate change. Initial efforts will focus on improving disease surveillance in Africa with plans to expand globally. By leveraging data aggregation from various sources, Abbott and its partners aim to enhance pandemic preparedness and community health.
Read more →ABT▲ +7.8%on this newsshared move
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023. First-quarter GAAP diluted EPS of $0.75 and adjusted ...
Abbott reported its financial results for the first quarter of 2023, highlighting strong underlying performance with notable growth in Medical Devices, Established Pharmaceuticals, and Nutrition. Despite these positives, the company faced an overall sales decline due to the exit from the pediatric nutrition business in China and significantly lower demand for COVID-19 testing. Abbott's management emphasized the importance of organic sales growth as a more accurate reflection of core business performance. The company also announced an earnings per share guidance for the full year, projecting between $4.30 and $4.50, showcasing its optimistic outlook.
Read more →ABTAbbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day...
Abbott's FreeStyle Libre Continuous Glucose Monitoring Systems have received expanded coverage for Medicare beneficiaries, allowing a greater number of individuals with diabetes who use insulin to qualify for reimbursement. This shift is expected to benefit over two million Medicare beneficiaries. The FDA has also approved a standalone reader for the FreeStyle Libre 3 system, indicating Abbott's efforts to further enhance access to this technology. The move is viewed as a positive step towards improving diabetes management among Medicare users.
Read more →ABTFDA Clears Reader for Abbott's FreeStyle Libre® 3 System Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated...
Abbott has received FDA clearance for the reader of its FreeStyle Libre 3 integrated continuous glucose monitoring system, which features a compact glucose sensor. This new reader is designed to enhance diabetes management by providing real-time glucose readings in an easy-to-use format. Abbott aims to get the FreeStyle Libre 3 system covered by Medicare to further improve access for patients. The FreeStyle Libre portfolio has positively impacted the lives of 4.5 million individuals globally.
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023, before the market opens. The announcement will be...
Abbott has scheduled a conference call to discuss its first-quarter 2023 financial results on April 19, 2023, prior to market opening. The earnings announcement will be accompanied by a live webcast, providing investors an opportunity to engage with the company's financial updates. Abbott continues to emphasize its extensive portfolio in the healthcare sector, showcasing its commitment to transparency and investor relations. Additional information can be accessed from its Investor Relations website.
Read more →ABTAbbott recebe aprovação da ANVISA para Navitor, uma nova geração do sistema TAVI para tratar estenose aórtica A Abbott (NYSE: ABT) anuncia a recente aprovação da ANVISA (Agência Nacional de Vigilância Sanitária) para a geração mais recente do seu sistema para ...
Abbott has received approval from ANVISA for its latest TAVI system, Navitor, designed to treat patients with severe aortic stenosis. This minimally invasive option caters to high-risk surgical patients, significantly improving treatment outcomes. The Navitor system is noted for its advanced technology that reduces blood reflux, enhancing stability and precision during implantation. This approval is viewed as a major step in enhancing patient care through innovative medical solutions.
Read more →ABTDon't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of...
Abbott has launched the Concussion Awareness Now campaign in partnership with the Brain Injury Association of America, aimed at highlighting the importance of recognizing and treating concussions. The initiative features animated characters called the Melons, who portray scenarios where concussions may occur, encouraging people to seek medical assistance after head injuries. The campaign aims to dispel misconceptions about concussions, especially regarding their common causes. Additionally, celebrated actress Rebel Wilson, who experienced a concussion herself, is involved to promote the message further.
Read more →ABTA Abbott lança o autoteste Panbio HIV para oferecer mais rapidez, confiança e a discrição de um teste feito em casa Os autotestes podem ajudar a superar algumas barreiras como o estigma associado ao teste de HIV, além de ampliar o diagnóstico e o acesso aos...
Abbott has launched the Panbio HIV self-test, now available for purchase in Brazilian pharmacies. This home-testing option aims to enhance the convenience, speed, and privacy of HIV testing, helping to reduce the stigma associated with the disease. The test is capable of delivering results in 15 to 20 minutes, with high sensitivity and specificity. Abbott emphasizes the importance of this innovation in the wake of the pandemic, as it supports global goals to improve HIV diagnosis and treatment rates.
Read more →ABTAbbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic...
Abbott has received FDA clearance for its Alinity i laboratory test, the first commercially available blood test for evaluating concussions. The test, which provides results in 18 minutes, could significantly change how mild traumatic brain injuries are assessed by clinicians. With the ability to rule out the need for CT scans in cases of negative results, it promises to reduce healthcare costs and waiting times in emergency departments. This development complements Abbott's previous work in TBI testing and aims to broaden access to essential diagnostic tools for head injuries.
Read more →ABTU.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3...
Abbott announced that the FDA has cleared its FreeStyle Libre 2 and 3 sensors for integration with automated insulin delivery systems. This modification aims to facilitate better diabetes management by automatically adjusting insulin based on real-time glucose data. The devices will soon accommodate children as young as two years and pregnant women with various diabetes types. Abbott is collaborating with leading insulin pump manufacturers for rapid integration in the U.S. and plans expansions in Europe.
Read more →ABTLate-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal...
Abbott has announced five-year data from the COAPT trial for its MitraClip device, highlighting its long-term benefits for patients with mitral regurgitation. The study shows that MitraClip effectively reduces hospitalizations and improves survival for patients suffering from severe secondary heart failure. Presented at the American College of Cardiology's annual scientific session, the findings support MitraClip's role as a significant treatment option for patients historically challenging to manage. The device has been successful for nearly two decades, helping over 150,000 patients globally.
Read more →ABTNew Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation Abbott (NYSE: ABT) today announced late-breaking data for the TriClip™ transcatheter edge-to-edge repair (TEER) system, a first-of-its-kind minimally ...
Abbott has announced promising results from the TRILUMINATE Pivotal study, demonstrating that its TriClip device is superior to traditional medical therapy in treating severe tricuspid regurgitation. The late-breaking data, presented at the American College of Cardiology's annual meeting, indicates significant improvements in patients' quality of life. The TriClip offers a minimally invasive option for patients who are often ineligible for open-heart surgery, highlighting its potential to enhance care in a historically underserved area. The device has already been approved in over 50 countries and is under investigation in the U.S.
Read more →ABTLate-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in...
Abbott recently revealed promising late-breaking data on its Navitor transcatheter aortic valve implantation (TAVI) system, which has received FDA approval for treating high-risk patients with severe aortic stenosis. The findings show that Navitor offers a safe and effective option with enhanced design features, reducing blood backflow risks. Additionally, results from the Amulet IDE trial highlight the Amplatzer Amulet LAA Occluder's superior dual-seal technology, demonstrating fewer severe leaks compared to other devices. These developments were presented at the Cardiovascular Research Technologies 2023 meeting, emphasizing the ongoing innovation in minimally invasive heart technologies.
Read more →ABTAbbott Declares 397th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 397th consecutive...
Abbott (NYSE: ABT) has declared a quarterly common dividend of 51 cents per share, marking its 397th consecutive quarterly dividend since 1924. The cash dividend will be paid on May 15, 2023, to shareholders of record by April 14, 2023. Abbott has a notable track record of increasing its dividend for 51 years and is recognized as a member of the S&P 500 Dividend Aristocrats Index, which highlights its commitment to returning value to shareholders.
Read more →ABTAbbott traz para o Brasil Panbio™ COVID-19/Flu A&B Rapid Panel, um único teste rápido para que profissionais da saúde diferenciem entre três vírus respiratórios Panbio™ COVID-19/Flu A&B Rapid Panel detecta antígeno de COVID-19, Influenza A ou B em até 15 minutos, o que possibilita teste, diagnóstico e...
Abbott has launched the Panbio™ COVID-19/Flu A&B Rapid Panel test in Brazil, receiving ANVISA approval. This test allows healthcare professionals to detect COVID-19 and influenza A or B from a nasopharyngeal swab, yielding results in just 15 minutes. The rapid identification capability is crucial for accurate diagnosis and effective treatment, especially as both viruses share similar symptoms. The launch aims to enhance access to diagnostics amid a resurgence of respiratory viruses as people resume normal activities.
Read more →ABTAbbott recebe autorização da Anvisa para Ultreon™, tecnologia de imagem que usa inteligência artificial para artérias coronárias O Software Ultreon™ 1.0, primeira tecnologia de imagem do gênero, mescla a tomografia de coerência óptica com o poder da automação usando...
Abbott has received approval from Anvisa for its Ultreon™ imaging software, which utilizes optical coherence tomography (OCT) combined with artificial intelligence. This innovative platform aims to enhance visualization of coronary blood flow and blockages, aiding clinical decisions for treatment. The software has already gained FDA and CE Mark approvals, indicating its broad acceptance in the medical community. By providing automated insights, Ultreon™ plays a critical role in improving patient care in cardiology.
Read more →ABTFDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS)...
Abbott has received FDA approval for its Proclaim™ XR spinal cord stimulation system, aimed at treating painful diabetic peripheral neuropathy. This innovative therapy provides an alternative to traditional oral medications, offering significant pain relief while allowing patients to manage their treatment via Abbott's NeuroSphere Virtual Clinic app. Notably, the Proclaim XR system has a battery life of up to 10 years, enhancing convenience and adherence to therapy. The approval serves as a significant step in addressing the complications associated with diabetes, particularly the chronic pain experienced by many of its sufferers.
Read more →ABTAbbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022. Fourth-quarter sales of $10.1 billion, which were...
Abbott reported its financial results for Q4 and full-year 2022, with total sales of $10.1 billion in the fourth quarter. The company exceeded EPS guidance and highlighted a productive R&D pipeline with new launches anticipated. However, sales in various segments such as Nutrition and Diagnostics faced significant declines, particularly due to reduced demand for COVID-19 tests and past manufacturing disruptions affecting product availability. Despite these challenges, Abbott noted growth in Established Pharmaceuticals and Medical Devices, showcasing resilience in its portfolio.
Read more →ABTAbbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic ...
Abbott has received FDA approval for its next-generation transcatheter aortic valve implantation (TAVI) system, Navitor, aimed at treating patients with severe aortic stenosis at high or extreme risk for surgery. This system boasts unique advancements, including a design that minimizes backflow issues and enhances device placement accuracy. Additionally, the Navitor system is noted for its excellent hemodynamic performance. This approval represents a significant development in Abbott's efforts to provide less invasive options for patients with serious heart conditions.
Read more →ABTAbbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation Abbott (NYSE: ABT) and Blood Centers of America are unveiling an innovative new mixed reality experience for use during blood donation....
Abbott and Blood Centers of America are launching a mixed reality experience designed to enhance the blood donation process and appeal to younger donors. The immersive technology allows users to interact with a digital environment while remaining aware of their surroundings. Through a whimsical garden experience, the initiative aims to address the shortage of blood donors, particularly among individuals under 30. Currently, the pilot program is being tested at select locations across the United States.
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens. The announcement...
Abbott Laboratories will announce its fourth-quarter financial results for 2022 on January 25, 2023, prior to the market opening. Following the announcement, the company will hold a live conference call at 8 a.m. Central time, which will also be available through an archived edition later that day. This presentation is part of Abbott's commitment to financial transparency and investor engagement.
Read more →ABTAbbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany Abbott (NYSE: ABT) today announced that its FreeStyle Libre® 3 sensor is now compatible with the mylife™ Loop solution from partners, Ypsomed and...
ABBOTT PARK , Ill. , Dec. 21, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its FreeStyle Libre ® 3 sensor is now compatible with the mylife™ Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-tim
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. Robert B. Ford, chairman and chief...
ABBOTT PARK , Ill. , Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 . Robert B. Ford , chairman and chief executive officer, will present at 11 a.m. Central time . A live webcast of t
Read more →ABTAbbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system ...
ABBOTT PARK , Ill. , Dec. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently avai
Read more →ABTAbbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions Abbott (NYSE: ABT) and the Brain Injury Association of America announced today they have cofounded a coalition of nearly 20 advocacy groups, and are...
ABBOTT PARK, Ill., and WASHINGTON , Dec. 13, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) and the Brain Injury Association of America announced today they have cofounded a coalition of nearly 20 advocacy groups, and are teaming up with acclaimed actress, comedian, writer and producer
Read more →ABTAbbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an...
ABBOTT PARK , Ill. , Dec. 9, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an increase of 8.5%. This marks the company's 51 st consecutive year of dividend growth.
Read more →ABTAbbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing...
ABBOTT PARK , Ill. , Nov. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of
Read more →ABTAbbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous...
ABBOTT PARK , Ill. , Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre ® continuous glucose monitoring technology as the "Best Medical Technology" of the last 50 ye
Read more →ABT▼ -6.5%on this news
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2022. Third-quarter sales of $10.4 billion decreased 4.7...
ABBOTT PARK , Ill. , Oct. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2022 . "Our results and increased guidance in the current macroeconomic environment reflect the strength of our diversified business mod
Read more →ABTAbbott lança no Brasil novo Sistema de Mapeamento Cardíaco que melhora a forma como médicos tratam ritmos cardíacos anormais A Abbott (NYSE: ABT), empresa global de cuidados para a saúde, acaba de lançar no Brasil o Sistema de Eletrofisiologia (EF) EnSite™ X com Tecnologia...
SÃO PAULO , 18 de outubro de 2022 /PRNewswire/ -- A Abbott (NYSE: ABT ), empresa global de cuidados para a saúde, acaba de lançar no Brasil o Sistema de Eletrofisiologia (EF) EnSite™ X com Tecnologia Omnipolar (OT), uma nova plataforma de mapeamento cardíaco elaborada para auxili
Read more →ABTAbbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season As we enter cold and flu season amid continuing COVID-19 cases, Abbott (NYSE: ABT), makers of BinaxNOW™ COVID-19 Antigen Self Test, and The Home...
ABBOTT PARK , Ill. , Oct. 12, 2022 /PRNewswire/ -- As we enter cold and flu season amid continuing COVID-19 cases, Abbott (NYSE: ABT ), makers of BinaxNOW™ COVID-19 Antigen Self Test , and The Home Edit, the world's number one organizational company and a global lifestyle brand,
Read more →ABTNew Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to...
ABBOTT PARK , Ill. , Oct. 6, 2022 /PRNewswire/ -- A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's FreeStyle Libre ® 2 glucose monitoring system provided significant reductions in gl
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens. The announcement will ...
ABBOTT PARK , Ill. , Sept. 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cen
Read more →ABTLate-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies Abbott (NYSE: ABT) today announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating...
ABBOTT PARK , Ill. , Sept. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases. Data include findings that reinf
Read more →ABTAbbott Declares 395th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. This marks the 395th consecutive...
ABBOTT PARK , Ill. , Sept. 15, 2022 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 47 cents per share. This marks the 395 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable
Read more →ABTThree-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery Abbott (NYSE: ABT) today announced three-year data showing the positive impact of the Amplatzer Piccolo™ Occluder on treating babies (some weighing...
ABBOTT PARK , Ill. , Sept. 8, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced three-year data showing the positive impact of the Amplatzer Piccolo™ Occluder on treating babies (some weighing as little as two pounds) with a potentially life-threatening hole in the heart k
Read more →ABTNew Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients...
ABBOTT PARK , Ill. , Aug. 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling
Read more →ABTFDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions Abbott's new Proclaim™ Plus spinal cord stimulation (SCS) system offers the next generation of stimulation therapy, giving physicians the ability to...
ABBOTT PARK , Ill. , Aug. 23, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim™ Plus spinal cord stimulation (SCS) system featuring FlexBurst360™ therapy. The next generation of Abbott's propri
Read more →ABTNew Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from...
ABBOTT PARK , Ill. , Aug. 11, 2022 /PRNewswire/ -- A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury (TBI). Testing for these two biomarkers in the immediate afterma
Read more →ABTAbbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals Abbott (NYSE: ABT) and WW International, Inc. ( WeightWatchers or WW ) today announced a strategic partnership that will help people living with...
ABBOTT PARK , Ill. , Aug. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are
Read more →ABTAbbott lança Ensure Advance, suplemento nutricional que ajuda no restabelecimento muscular e recuperação da força A pandemia da Covid-19 elevou os índices de estilo de vida sedentário em todo o mundo1. No Brasil, mais de 60% das pessoas deixaram de fazer qualquer ...
SÃO PAULO , 2 de agosto de 2022 /PRNewswire/ -- A pandemia da Covid-19 elevou os índices de estilo de vida sedentário em todo o mundo 1 . No Brasil, mais de 60% das pessoas deixaram de fazer qualquer tipo de atividade física durante o isolamento 2 . Essa inatividade prolongada po
Read more →ABTAbbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022. Second-quarter sales of $11.3 billion increased 10.1 ...
ABBOTT PARK , Ill. , July 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2022 . "We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert B. Ford , chairman and chi
Read more →ABTAbbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance - Sales growth of 10.1 percent; organic sales growth of 14.3 percent - GAAP diluted EPS growth of 72.7 percent; adjusted diluted E
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance ABBOTT PARK, Ill., July 20, 2022 - Abbott today announced financial results for the second quarter ended June 30, 2022. "We achieved another quarter of strong growth and are raising our full-year EPS g
Read more →ABTAbbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the...
ABBOTT PARK , Ill. , July 12, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022, before the market opens. The announcement...
ABBOTT PARK , Ill. , June 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cen
Read more →ABTAbbott lança autoteste de antígeno Panbio™ no Brasil, aumentando o acesso a testes rápidos e confiáveis de COVID-19 O Autoteste de Antígeno (Panbio COVID-19 Antigen SELF-TEST) já está disponível para uso em adultos e crianças com ou sem sintomas, permitindo testes...
SÃO PAULO , 29 de junho de 2022 /PRNewswire/ -- A Abbott, empresa global de cuidados para saúde, anuncia o lançamento do Autoteste de Antígeno (Panbio COVID-19 Antigen SELF-TEST) para uso na detecção do vírus SARS-CoV-2 em adultos e crianças com ou sem sintomas. Este autoteste fo
Read more →ABTAbbott Declares 394th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. This marks the 394th consecutive...
ABBOTT PARK , Ill. , June 10, 2022 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 47 cents per share. This marks the 394 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable A
Read more →ABTLate-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative...
ABBOTT PARK , Ill. , June 5, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced late-breaking clinical data that demonstrate the FreeStyle Libre ® 3 system has an overall mean absolute relative difference (MARD) of 7.9%, 1 making it the first and only 14-day continuous gluc
Read more →ABTAbbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System Abbott (NYSE: ABT) today announced it's developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor. The...
ABBOTT PARK , Ill. , June 3, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it's developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Admin
Read more →ABTAbbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people ...
ABBOTT PARK , Ill. , May 31, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older 6 living with diabetes. "The FreeStyle Libre 3 system is
Read more →ABTAbbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing...
ABBOTT PARK , Ill. , May 24, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing Abbott to release limited quantities of its EleCare ® specialty amino acid-based
Read more →ABTNew Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings...
ABBOTT PARK , Ill. , May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transca
Read more →ABTAbbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich., infant...
ABBOTT PARK , Ill. , May 16, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich. , infant formula plant. The decree is an agreement between FDA and Abbott on the steps ne
Read more →ABTAbbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented...
ABBOTT PARK , Ill. , May 11, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial partic
Read more →ABTAbbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity™ m system, which provides fast results in high volumes –...
ABBOTT PARK , Ill. , May 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received FDA clearance for its Alinity™ m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs). STIs, when left untreated, can l
Read more →ABTAbbott to Release Metabolic Nutrition Formulas At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas...
ABBOTT PARK , Ill. , April 29, 2022 /PRNewswire/ -- At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT ) is releasing limited quantities of metabolic nutrition formulas that were previously on hold following Abbott's recall of some powder infant form
Read more →ABTStudy Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent...
ABBOTT PARK , Ill. , April 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent atrial fibrillation (AFib) with the company's TactiCath™ Contact Force Ablatio
Read more →ABTNew Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin...
ABBOTT PARK , Ill. , April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle ® Libre system provides significant reductions in glycated hemoglobin (HbA1c) that are
Read more →ABTAbbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™...
ABBOTT PARK , Ill. , April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation
Read more →ABTAbbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin...
BARCELONA, Spain , April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management
Read more →ABTAbbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott ...
ABBOTT PARK , Ill. , April 26, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company's outstanding
Read more →ABTAbbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced...
ABBOTT PARK , Ill. , April 25, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbot
Read more →ABTAbbott Reports First-Quarter 2022 Results - Sales growth of 13.8 percent; organic sales growth of 17.5 percent - Global COVID-19 testing-related sales of $3.3 billion in the first quarter - Excluding COVID-1
Abbott Reports First-Quarter 2022 Results ABBOTT PARK, Ill., April 20, 2022 - Abbott today announced financial results for the first quarter ended March 31, 2022. "Our diversified business continues to perform well in a challenging environment," said Robert B. Ford, chairman an
Read more →ABTAbbott Reports First-Quarter 2022 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022....
ABBOTT PARK , Ill. , April 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2022 . "Our diversified business continues to perform well in a challenging environment," said Robert B. Ford , chairman and chief exec
Read more →ABTAbbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms Abbott's Aveir single chamber (VR) pacing system is the world's only leadless pacemaker with a unique mapping capability to assess correct...
ABBOTT PARK , Ill. , April 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms. This marks sig
Read more →ABTAbbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with ...
- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies - Initiative supports Abbott and LISC's commitment to increase diversity in healthcare and generate jobs and str
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens. The announcement...
ABBOTT PARK, Ill., March 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTAbbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin Abbott (NYSE: ABT) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for...
ABBOTT PARK , Ill. , March 24 , 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle® Libre system to include all people with diabetes who use insul
Read more →ABTAbbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ ...
ABBOTT PARK, Ill., Feb. 21, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure. With the
Read more →ABTAbbott Declares 393rd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. Abbott has increased its dividend...
ABBOTT PARK, Ill., Feb. 18, 2022 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 47 cents per share. This marks the 393 rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTAbbott Voluntarily Recalls Powder Formulas Manufactured at One Plant Abbott (NYSE: ABT) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis,...
ABBOTT PARK, Ill., Feb. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis, Mich. , one of the company's manufacturing facilities. The recall does not includ
Read more →ABTAbbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™...
ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™ pivotal clinical study. The implant of Abbott's investigational Aveir™ dual-chamber lead
Read more →ABTAbbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast - Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent - Global COVID-19 testing-related sales of $2.3 billi
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast ABBOTT PARK, Ill., Jan. 26, 2022 - Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022. "2021 was an outstanding year
Read more →ABTAbbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for...
ABBOTT PARK, Ill., Jan. 26, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021 , and issued its financial outlook for 2022. "2021 was an outstanding year for Abbott," said Robert B. Ford , chairman
Read more →ABTAbbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite...
ABBOTT PARK, Ill., Jan. 12, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and ac
Read more →ABTAbbott anuncia el futuro de los biowearables en el evento CES (Consumer Electronics Show) de Las Vegas Abbott hizo historia en el evento CES y presentó un discurso de apertura en el evento tecnológico más influyente del mundo; es la primera empresa del ...
LAS VEGAS , 6 de enero de 2022 /PRNewswire/ -- Abbott hizo historia en el evento CES y presentó un discurso de apertura en el evento tecnológico más influyente del mundo; es la primera empresa del cuidado de la salud en hacerlo. El presidente y director ejecutivo de Abbott , Rob
Read more →ABTAbbott Announces Future of Biowearables at Consumer Electronics Show Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do...
LAS VEGAS , Jan. 6, 2022 /PRNewswire/ -- Making CES history, Abbott (NYSE: ABT ) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do so. Abbott Chairman and Chief Executive Officer Robert B. Ford headlined the event, "Huma
Read more →ABTAbbott anuncia o Futuro dos Biowearables no CES (Consumer Electronics Show) A Abbott é a primeira empresa de cuidados para saúde a estar no palco principal do evento de tecnologia mais influente do mundo, fazendo história na...
LAS VEGAS , Jan. 6, 2022 /PRNewswire/ -- A Abbott é a primeira empresa de cuidados para saúde a estar no palco principal do evento de tecnologia mais influente do mundo, fazendo história na CES. O Presidente e CEO da Abbott, Robert B. Ford , apresentou o evento " Human-Powered H
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens. The announcement...
ABBOTT PARK, Ill., Jan. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra
Read more →ABTAbbott's Proclaim™ XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S. Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved new expanded magnetic resonance imaging (MRI)...
ABBOTT PARK, Ill., Jan. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has approved new expanded magnetic resonance imaging (MRI) compatibility for its Proclaim™ XR Spinal Cord Stimulation (SCS) System with Octrode™ le
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman...
ABBOTT PARK, Ill., Dec. 21, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) will present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022 . Robert B. Ford , chairman and chief executive officer, will present at 8 a.m. Central time . A live webca
Read more →ABTAbbott anuncia dispositivo Amplatzer™ Amulet™ para tratar pessoas com fibrilação atrial em risco de acidente vascular cerebral - Amulet é a primeira e única opção de tratamento minimamente invasivo a oferecer fechamento imediato do Apêndice Atrial Esquerdo (AAE), sem a...
- Amulet é a primeira e única opção de tratamento minimamente invasivo a oferecer fechamento imediato do Apêndice Atrial Esquerdo (AAE), sem a necessidade de medicamentos anticoagulantes após o implante - O dispositivo auxilia a prevenir a formação de coágulos sanguíneos e sua s
Read more →ABTAbbott Increases Quarterly Dividend for 50th Consecutive Year Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend, marking the company's 50th...
ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its board of directors has increased the company's quarterly common dividend, marking the company's 50 th consecutive year of dividend growth. Abbott's quarterly common dividend has been in
Read more →ABTAbbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman
Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman ABBOTT PARK, Ill., Dec. 10, 2021 - Abbott announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board, effective today. Miles D
Read more →ABTAbbott realiza pesquisa sobre o perfil do doador de sangue e plasma e visa inspirar ainda mais brasileiros a salvarem vidas A Abbott, empresa global de cuidados para a saúde, realizou uma pesquisa inédita para encorajar a doação rotineira de sangue e plasma, entender quais ...
SÃO PAULO, 25 de novembro de 2021 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, realizou uma pesquisa inédita para encorajar a doação rotineira de sangue e plasma, entender quais são as principais barreiras e atrair ainda mais atenção para esta importante cau
Read more →ABTAbbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics...
ABBOTT PARK, Ill., Nov. 16, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Car
Read more →ABTAbbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI) On Nov. 12, Abbott (NYSE: ABT) achieved the highest score out of 84 companies in its industry in the S&P Global Corporate Sustainability Assessment,...
ABBOTT PARK, Ill., Nov. 15, 2021 /PRNewswire/ -- On Nov. 12 , Abbott (NYSE: ABT ) achieved the highest score out of 84 companies in its industry in the S&P Global Corporate Sustainability Assessment, also called the Dow Jones Sustainability Index (DJSI). This was the ninth consec
Read more →ABTAbbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless...
ABBOTT PARK, Ill., Nov. 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms. The data shows the Avei
Read more →ABTPesquisa da Abbott revela que brasileiros apostaram em hábitos mais saudáveis durante a pandemia e que pretendem continuar cuidando da saúde nos próximos anos O ano de 2020 mostrou que a saúde, tanto física como mental, é o nosso principal bem, o valor mais precioso que temos. Diante de uma nova realidade,...
SÃO PAULO, 11 de novembro de 2021 /PRNewswire/ -- O ano de 2020 mostrou que a saúde, tanto física como mental, é o nosso principal bem, o valor mais precioso que temos. Diante de uma nova realidade, as pessoas passaram a repensar suas prioridades, adquiriram novos hábitos e refle
Read more →ABTAbbott y la American Diabetes Association® (Asociación Americana de Diabetes) lanzan la primera iniciativa comunitaria en su tipo en Columbus, Ohio, para promover el acceso a la atención y la tecnología para la diabetes Abbott (NYSE: ABT) y la American Diabetes Association® (Asociación Americana de Diabetes; ADA) anunciaron hoy el lanzamiento de su primera alianza...
ABBOTT PARK , Illinois , y ARLINGTON, Virginia , 9 de noviembre de 2021 /PRNewswire-HISPANIC PR WIRE/ -- Abbott (NYSE: ABT ) y la American Diabetes Association ® (Asociación Americana de Diabetes; ADA ) anunciaron hoy el lanzamiento de su primera alianza conjunta de salud comunit
Read more →ABTAbbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology Abbott (NYSE: ABT) and the American Diabetes Association® (ADA) announced today the launch of their first joint community health partnership. The...
ABBOTT PARK, Ill. and ARLINGTON, Va. , Nov. 9, 2021 /PRNewswire-HISPANIC PR WIRE/ -- Abbott (NYSE: ABT ) and the American Diabetes Association ® (ADA) announced today the launch of their first joint community health partnership. The community initiative, which is the first progra
Read more →ABTAbbott lanza una nueva iniciativa para impulsar la diversidad en la investigación médica y mejorar la atención entre las poblaciones subrepresentadas Abbott (NYSE: ABT) anunció hoy el lanzamiento de una nueva iniciativa diseñada para ayudar a crear un ecosistema de ensayos clínicos más inclusivo a...
ABBOTT PARK , Illinois , 4 de noviembre de 2021 /PRNewswire-HISPANIC PR WIRE/ -- Abbott (NYSE: ABT ) anunció hoy el lanzamiento de una nueva iniciativa diseñada para ayudar a crear un ecosistema de ensayos clínicos más inclusivo a través de nuevos enfoques para la capacitación, l
Read more →ABT雅培推出新举措以推动医学研究的多样性并改善代表不足人群的护理 雅培（纽约证券交易所股票代码：ABT）今天宣布启动一项新举措，旨在通过新的培训教育方法来帮助创建一个更具包容性的临床试验生态系统，改善美国的临床研究基础设施。这项努力建立在雅培的承诺之上，其致力于让过去在医学研究中代表性不足的人群参与进来，将通过增加试验过程中获得创新治疗方案的机会和增进新疗法对不同...
伊利诺伊州雅培科技园2021年11月4日 /美通社/ -- 雅培（纽约证券交易所股票代码：ABT）今天宣布启动一项新举措，旨在通过新的培训教育方法来帮助创建一个更具包容性的临床试验生态系统，改善美国的临床研究基础设施。这项努力建立在雅培的承诺之上，其致力于让过去在医学研究中代表性不足的人群参与进来，将通过增加试验过程中获得创新治疗方案的机会和增进新疗法对不同群体疗效的见解，来改善健康状况。 多元种族和文化背景的人占美国人口的 近40% ，他们受到心血管疾病和糖尿病等慢性疾病的影响尤其严重。但是，由于历史和社会障碍，这些群体 在临床试验中的代表性 仍然严
Read more →ABTAbbott 推出新計劃以推動醫學研究多元化及改善代表性不足群體的護理 Abbott (NYSE: ABT) 今天宣佈推出一項新計劃，旨在透過新的培訓方針、教育及改善美國臨床研究基礎設施來協助建立一個更共融的臨床試驗生態系統。這項工作建基於 Abbott...
伊利諾州雅培公園2021年11月3日 /美通社/ -- Abbott (NYSE: ABT ) 今天宣佈推出一項新計劃，旨在透過新的培訓方針、教育及改善美國臨床研究基礎設施來協助建立一個更共融的臨床試驗生態系統。這項工作建基於 Abbott 對歷來在醫學研究中代表性不足的參與群體的承諾，並透過增加試驗過程中可用的創新治療選擇，以及增加對不同群體如何回應新療法的見解來改善健康。 不同種族和文化背景的人佔美國人口 近 40% ，而他們受心血管疾病和糖尿病等慢性病的影響不成比例。然而，由於歷史和社會上的障礙，這些群體 在臨床試驗中的代表性仍然偏低 ，有時只佔
Read more →ABTAbbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new...
ABBOTT PARK, Ill., Nov. 3, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, education, and improving the clinical research infrastructure w
Read more →ABTAbbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance - Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent - GAAP diluted E
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance ABBOTT PARK, Ill., Oct. 20, 2021 - Abbott today announced financial results for the third quarter ended Sept. 30, 2021. "We achieved another quarter of strong growth over
Read more →ABTAbbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2021. Third-quarter sales of $10.9 billion increased 23.4...
ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2021 . "We achieved another quarter of strong growth overall and across all four of our major business areas," said Robert B. Ford , presi
Read more →ABTAbbott e Real Madrid se unem para apoiar a saúde e a nutrição de crianças em todo mundo Abbott se torna Parceiro de Ciências da Saúde e Nutrição do clube de futebol Real Madrid e Parceiro Global da Fundação Real Madrid A parceria...
ABBOTT PARK , Illinois e MADRID , 18 de outubro de 2021 /PRNewswire/ -- A Abbott anunciou hoje o contrato de três anos para ser a Parceira de Ciências da Saúde e Nutrição do clube de futebol Real Madrid e Parceira Global da Fundação Real Madrid, uma organização fundada pelo clube
Read more →ABTJason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Children's Health Jason Sudeikis, award-winning writer, producer, actor and star of Ted Lasso, is joining Abbott (NYSE: ABT) and Real Madrid at an event outside the...
NEW YORK , Oct. 18, 2021 /PRNewswire/ -- Jason Sudeikis , award-winning writer, producer, actor and star of Ted Lasso , is joining Abbott (NYSE: ABT ) and Real Madrid at an event outside the New York Stock Exchange (NYSE) today. Earlier in the day, Abbott and Real Madrid announc
Read more →ABTAbbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally Abbott (NYSE: ABT) today announced it has entered into a three-year agreement to be the Health Sciences and Nutrition Partner of the Real Madrid...
ABBOTT PARK, Ill. and MADRID , Oct. 18, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has entered into a three-year agreement to be the Health Sciences and Nutrition Partner of the Real Madrid Football Club and Global Partner of the Real Madrid Foundation—an organiz
Read more →ABTAbbott y Real Madrid se unen en apoyo de la salud y la nutrición infantil a nivel mundial Abbott se convierte en Socio de Ciencias de la Salud y Nutrición del Club de Futbol Real Madrid y en Socio Global de la Fundación Real Madrid La...
ABBOTT PARK , Illinois y MADRID , 18 de octubre de 2021 /PRNewswire/ -- Abbott anunció el día de hoy que ha celebrado un acuerdo de tres años para ser el Socio de Ciencias de la Salud y Nutrición del Club de Futbol Real Madrid y Socio Global de la Fundación Real Madrid-- una orga
Read more →ABTAbbott traz para o Brasil dispositivo de ritmo cardíaco com conectividade Bluetooth e monitoramento remoto contínuo A Abbott (NYSE: ABT) anuncia a chegada ao Brasil do dispositivo de última geração Neutrino cardioversor-desfibrilador implantável (CDI) e do...
SÃO PAULO, 7 de outubro de 2021 /PRNewswire/ -- A Abbott (NYSE: ABT ) anuncia a chegada ao Brasil do dispositivo de última geração Neutrino cardioversor-desfibrilador implantável (CDI) e do desfibrilador de terapia de ressincronização cardíaca (CRT-D), recentemente aprovados pela
Read more →ABTAbbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions Abbott (NYSE: ABT) announced today the creation of the Abbott Center for Malnutrition Solutions, an innovation hub focused on reducing malnutrition...
ABBOTT PARK, Ill., Sept. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the creation of the Abbott Center for Malnutrition Solutions, an innovation hub focused on reducing malnutrition around the world. The center, a collaboration between Abbott and external nutriti
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 23, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Portico™ with FlexNav™ transcatheter...
ABBOTT PARK, Ill., Sept. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe a
Read more →ABTAbbott Declares 391st Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share. This marks the 391st consecutive...
ABBOTT PARK, Ill., Sept. 15, 2021 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 45 cents per share. This marks the 391 st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive...
ABBOTT PARK, Ill., Sept. 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. W
Read more →ABTAbbott recebe aprovação da ANVISA para válvula Portico e sistema FlexNav para tratar de maneira minimamente invasiva pacientes com doença da válvula aórtica A Abbott anuncia que a Agência Nacional de Vigilância Sanitária (ANVISA) aprovou recentemente sua válvula Portico™ e seu sistema FlexNav™ para...
- O procedimento de implante da válvula aórtica por cateter (TAVI) trata pessoas com estenose aórtica grave e sintomática cujo risco cirúrgico é considerado elevado ou extremo - Com as aprovações de Portico™ e do novo sistema de entrega FlexNav™, a Abbott oferece ao mercado bras
Read more →ABTLate-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the...
ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company's Amplatzer™ Amulet Left Atrial Appendage (LAA) Occluder with the Watchman‡ de
Read more →ABTGUIDE-HF Study Data Show Abbott's CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits...
ABBOTT PARK, Ill., Aug. 27, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV hear
Read more →ABTAbbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer™ Amulet™ Left Atrial Appendage...
ABBOTT PARK, Ill., Aug. 16, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischem
Read more →ABTAbbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography...
U.S. clearance follows the recently attained CE Mark in Europe , providing broader access to the latest OCT imaging platform for interventional cardiologists seeking to utilize the latest in AI-powered technology. Ultreon Software integrates with Abbott's new Dragonfly OpStar ima
Read more →ABTAbbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible...
ABBOTT PARK, Ill., Aug. 2, 2021 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS application for use with compatible iPhones 1 , providing a comprehensive digital offering for its FreeStyle Libre 2 int
Read more →ABTNew Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations A new study conducted by The Ohio State University and Abbott (NYSE: ABT) showed that half of the adults surveyed living with diabetes did not...
ABBOTT PARK, Ill., July 29, 2021 /PRNewswire/ -- A new study conducted by The Ohio State University and Abbott (NYSE: ABT ) showed that half of the adults surveyed living with diabetes did not consume the daily recommended intake of protein, which is associated with lower diet qu
Read more →ABTAbbott Reports Second-Quarter 2021 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021. Second-quarter sales of $10.2 billion increased 39.5 ...
ABBOTT PARK, Ill., July 22, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2021 . "We're achieving very strong growth across our portfolio," said Robert B. Ford , president and chief executive officer, Abbott. "Pe
Read more →ABTAbbott Reports Second-Quarter 2021 Results - Sales growth of 39.5 percent; organic sales growth of 35.0 percent - GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS gro
Abbott Reports Second-Quarter 2021 Results ABBOTT PARK, Ill., July 22, 2021 - Abbott today announced financial results for the second quarter ended June 30, 2021. "We're achieving very strong growth across our portfolio," said Robert B. Ford, president and chief executive offic
Read more →ABTAbbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short...
ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S. In ad
Read more →ABTLate-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes Abbott (NYSE: ABT) today announced late-breaking data that showed FreeStyle Libre, the world's leading7 continuous glucose monitoring (CGM) system,...
ABBOTT PARK, Ill., June 25, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced late-breaking data that showed FreeStyle Libre, the world's leading 7 continuous glucose monitoring (CGM) system, can support health equity through access to more affordable, life-changing techno
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2021 financial results on Thursday, July 22, 2021, before the market opens. The announcement will ...
ABBOTT PARK, Ill., June 25, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2021 financial results on Thursday, July 22, 2021 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra
Read more →ABTPeople Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits A new Harris Poll survey finds the majority of adults in the U.S. who exercise intensely understand the importance of maintaining hydration...
ABBOTT PARK, Ill., June 24, 2021 /PRNewswire/ -- A new Harris Poll survey finds the majority of adults in the U.S. who exercise intensely understand the importance of maintaining hydration throughout a workout (93%) and that hydration is important for muscle recovery (89%), yet m
Read more →ABTAbbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit High school students who complete Abbott's award-winning summer internship program are now eligible to receive college credit for the experience in a ...
ABBOTT PARK, Ill., June 22, 2021 /PRNewswire/ -- High school students who complete Abbott's award-winning summer internship program are now eligible to receive college credit for the experience in a first-of-its-kind effort that can serve as a model for other companies to support
Read more →ABTAbbott Declares 390th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share. This marks the 390th consecutive...
ABBOTT PARK, Ill., June 11, 2021 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 45 cents per share. This marks the 390 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTAbbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump Abbott (NYSE: ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support...
For patients with advanced heart failure who are either awaiting a heart transplant or not eligible for transplantation, left ventricular assist devices (LVADs) remain a critical option that can extend survival and restore quality of life. To support patients and their physicians
Read more →ABTAbbott Issues Updated 2021 Outlook Abbott (NYSE: ABT) today announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower...
ABBOTT PARK, Ill., June 1, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower recent and projected COVID-19 diagnostic testing demand. This has been driven by sever
Read more →ABTAbbott Issues Updated 2021 Outlook Updated outlook reflects lower recent and projected demand for COVID-19 tests Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjus
Abbott Issues Updated 2021 Outlook ABBOTT PARK, Ill., June 1, 2021 - Abbott today announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower recent and projected COVID-19 diagnostic testing demand. This has been driven
Read more →ABTAbbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis Abbott (NYSE: ABT) today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, ...
ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, making the minimally invasive device available for people in Europe with severe a
Read more →ABTAbbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial Abbott (NYSE: ABT) today announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AFib)...
ABBOTT PARK, Ill., May 6, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AFib) and heart failure. The first-of-its-kind trial aims to provide new insights into mo
Read more →ABTAbbott Reports First-Quarter 2021 Results
Abbott Reports First-Quarter 2021 Results ABBOTT PARK, Ill., April 20, 2021 - Abbott today announced financial results for the first quarter ended March 31, 2021. "We're off to a very strong start to the year, with all four of our major businesses achieving strong growth," said
Read more →ABTAbbott Reports First-Quarter 2021 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021. First-quarter sales of $10.5 billion increased 35.3...
ABBOTT PARK, Ill., April 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2021 . "We're off to a very strong start to the year, with all four of our major businesses achieving strong growth," said Robert B. Ford
Read more →ABTAbbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today Abbott (NYSE: ABT) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the...
ABBOTT PARK, Ill., April 19, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the test to be available in the next few days online and in some stores. Broader natio
Read more →ABTWorld's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games Abbott (NYSE: ABT) announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running...
ABBOTT PARK, Ill., April 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running Team to support their athletic performance training program. Kipchoge and three NN
Read more →ABTAbbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the...
ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Eur
Read more →ABTAbbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as...
ABBOTT PARK, Ill., April 6, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with
Read more →ABTAbbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter,...
ABBOTT PARK, Ill., March 31, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non-prescription, asymptomatic use of its BinaxNOW™ COVID-19 Ag Self Test for dete
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2021 financial results on Tuesday, April 20, 2021, before the market opens. The announcement will...
ABBOTT PARK, Ill., March 29, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2021 financial results on Tuesday, April 20, 2021 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Cen
Read more →ABTAbbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants Abbott (NYSE: ABT) today announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific and public health...
ABBOTT PARK, Ill., March 11, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific and public health partnership dedicated to the early detection of, and rapid response to, future pan
Read more →ABTAbbott lança teste rápido de antígeno portátil, fácil de usar e com swab nasal, que pode fornecer resultados em até 15 minutos para ampliar os testes de COVID-19 no Brasil O dispositivo de teste rápido Panbio™ COVID-19 Ag da Abbott1 com coleta de amostra de swab nasal é uma ferramenta confiável e acessível para...
SÃO PAULO, 9 de março de 2021 /PRNewswire/ -- A Abbott anunciou hoje a aprovação pela Anvisa (Agência Nacional de Vigilância Sanitária) do seu dispositivo de teste rápido Panbio™ COVID-19 Ag, usando um swab nasal para coleta de amostras. O teste recebeu autorização para uso por p
Read more →ABTAbbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S. Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate ...
ABBOTT PARK, Ill., March 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treat
Read more →ABTAbbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity™ m Resp-4-Plex ...
ABBOTT PARK, Ill., March 5, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity ™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza
Read more →ABTPesquisadores da Abbott encontram grupo raro de pessoas com HIV controlado e que pode ser a chave para destravar a barreira da cura A Abbott anunciou hoje que uma equipe de cientistas encontrou um número excepcionalmente alto de pessoas na República Democrática do Congo (RDC) com...
ABBOTT PARK, Ill., 2 de março de 2021 /PRNewswire/ -- A Abbott anunciou hoje que uma equipe de cientistas encontrou um número excepcionalmente alto de pessoas na República Democrática do Congo (RDC) com teste positivo para anticorpos do HIV, mas com contagem de carga viral baixa
Read more →ABTInvestigadores de Abbott encuentran un grupo poco común de personas con VIH controlado que podrían ser la clave para descubrir la cura Abbott anunció hoy que un equipo de científicos ha encontrado un número inusualmente alto de personas de la República Democrática del Congo (RDC) que ...
ABBOTT PARK, Ill., 2 de marzo de 2021 /PRNewswire/ -- Abbott anunció hoy que un equipo de científicos ha encontrado un número inusualmente alto de personas de la República Democrática del Congo (RDC) que dan positivo en la prueba de anticuerpos contra el VIH, pero que tienen un n
Read more →ABTAbbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC)...
ABBOTT PARK, Ill., March 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for HIV antibodies, but have low to non-detectable viral load co
Read more →ABTAbbott anuncia aprovação no Brasil para uso de dois dispositivos para o coração que podem salvar vidas de bebês e crianças A Abbott (NYSE: ABT) anuncia que recebeu a aprovação da Anvisa (Agência Nacional de Vigilância Sanitária) para uso de dois de seus dispositivos...
SÃO PAULO, 23 de fevereiro de 2021 /PRNewswire/ -- A Abbott (NYSE: ABT ) anuncia que recebeu a aprovação da Anvisa (Agência Nacional de Vigilância Sanitária) para uso de dois de seus dispositivos pediátricos que salvam vidas. A válvula cardíaca mecânica rotativa Masters HP™ de 15
Read more →ABTAbbott Declares 389th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share. This marks the 389th consecutive...
ABBOTT PARK, Ill., Feb. 19, 2021 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 45 cents per share. This marks the 389 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTAbbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021 - Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales - Sales growth of
Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021 ABBOTT PARK, Ill., Jan. 27, 2021 - Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021. "Desp
Read more →ABTAbbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021 Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for...
ABBOTT PARK, Ill., Jan. 27, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2020 , and issued its financial outlook for 2021. "Despite challenging conditions, we achieved double-digit EPS growth, deli
Read more →ABTAbbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab Abbott (NYSE: ABT) announced today it has received CE Mark for two new uses of its Panbio™ COVID-19 Ag Rapid Test Device for the detection of the...
ABBOTT PARK, Ill., Jan. 26, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received CE Mark for two new uses of its Panbio ™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing. Panbio COVID-19 Ag's lab
Read more →ABTAbbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to...
Supported by more than 17 years of clinical trial data demonstrating safety and efficacy, and now on the fourth generation of product innovations, MitraClip is a first-of-its-kind device that clips together the leaflets, or flaps, of the mitral valve to reduce the backflow of blo
Read more →ABTAbbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient...
ABBOTT PARK, Ill., Jan. 14, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS
Read more →ABTAbbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution Abbott (NYSE: ABT) is announcing today the fulfillment of the federal government's order of 150 million BinaxNOW™ COVID-19 Ag tests. These rapid...
ABBOTT PARK, Ill., Jan. 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) is announcing today the fulfillment of the federal government's order of 150 million BinaxNOW ™ COVID-19 Ag tests. These rapid tests were distributed through the Department of Health and Human Services (HHS) to
Read more →ABTAbbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions Abbott (NYSE: ABT) has received 510(k) clearance for the first rapid handheld traumatic brain injury (TBI) blood test, which will help clinicians...
ABBOTT PARK, Ill., Jan. 11, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) has received 510(k) clearance for the first rapid handheld traumatic brain injury (TBI) blood test, which will help clinicians assess individuals with suspected mild TBIs, including concussions. The test will ru
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2020 financial results on Wednesday, Jan. 27, 2021, before the market opens. The announcement...
ABBOTT PARK, Ill., Jan. 6, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter 2020 financial results on Wednesday, Jan. 27, 2021 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra
Read more →ABTAs Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott (NYSE: ABT) ...
ABBOTT PARK, Ill., Dec. 22, 2020 /PRNewswire/ -- The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott (NYSE: ABT ) released findings today from a survey conducted by The Harris Poll, showing that
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021. Robert B. Ford, president...
ABBOTT PARK, Ill., Dec. 18, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 . Robert B. Ford , president and chief executive officer, will present at 9 a.m. Central time . A live webc
Read more →ABTFDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart...
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump to be used in pediatric patients with advanced refractory left ventricular hear
Read more →ABTAbbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for virtually guided ...
ABBOTT PARK, Ill.,, Dec. 16, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for virtually guided at-home use of its BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID
Read more →ABTAbbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test Abbott (NYSE: ABT) announced today it received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test. IgG...
ABBOTT PARK, Ill., Dec. 15, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test. IgG antibody testing that gives a quantitative result (measuring the amount of antibodies)
Read more →ABTAbbott lanza prueba de antígeno rápida, portátil y fácil de usar que puede ofrecer resultados en 15 minutos para ayudar a expandir el testeo de COVID-19 en Colombia El dispositivo de prueba rápida Panbio™ COVID-19 Ag de Abbott es una herramienta confiable y asequible para que los profesionales de la salud...
BOGOTÁ, Colombia , 15 de diciembre de 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) anunció que recibió la aprobación del Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) para su dispositivo de prueba rápida Panbio™ COVID-19 Ag para la detección del virus SARS-CoV
Read more →ABTAbbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health Because supporting the immune system is top of mind for many people, Abbott (NYSE: ABT) is launching a new Pedialyte formulation specifically...
ABBOTT PARK, Ill., Dec. 14, 2020 /PRNewswire/ -- Because supporting the immune system is top of mind for many people, Abbott (NYSE: ABT ) is launching a new Pedialyte formulation specifically designed with key nutrients to support immune health. Pedialyte with Immune Support was
Read more →ABTAbbott Increases Quarterly Dividend by 25% Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share,...
ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, reflecting a 25% increase. "Paying a strong and growing dividend is foundational to Abbot
Read more →ABTAbbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms - FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms1 to alert users when their...
- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms 1 to alert users when their glucose is high or low without scanning - Now for children (ages 4 and older) and adults with diabetes, this latest technology sust
Read more →ABTIMIP e Abbott anunciam parceria para salvar vidas de bebês e crianças A iniciativa Little Heroes (Pequenos Heróis) da Abbott foi desenvolvida para apoiar instituições em todo o mundo e oferecer melhores opções de...
SÃO PAULO, 23 de novembro de 2020 /PRNewswire/ -- O Instituto de Medicina Integral Professor Fernando Figueira (IMIP) se uniu à Abbott, empresa global de cuidados para à saúde, na campanha Little Heroes para o tratamento de cardiopatia congênita em bebês e crianças no Brasil. Lit
Read more →ABTAbbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes Today, Abbott (NYSE: ABT) and the American Diabetes Association® (ADA) announced that Abbott has become the first anchor sponsor of the Health Equity ...
ABBOTT PARK, Ill. and ARLINGTON, Va. , Nov. 18, 2020 /PRNewswire/ -- Today, Abbott (NYSE: ABT ) and the American Diabetes Association ® (ADA) announced that Abbott has become the first anchor sponsor of the Health Equity Now (HEN) platform to address health disparities for people
Read more →ABTAbbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI) For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index...
ABBOTT PARK, Ill., Nov. 16, 2020 /PRNewswire/ -- For the eighth consecutive year, Abbott (NYSE: ABT ) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability. As
Read more →ABTAbbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain Abbott (NYSE: ABT) today announced the launch of the IonicRF™ Generator – a new device recently cleared by the U.S. Food and Drug Administration to...
ABBOTT PARK, Ill., Nov. 10, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of the IonicRF™ Generator – a new device recently cleared by the U.S. Food and Drug Administration to deliver a non-surgical, minimally invasive treatment for the management of pain in
Read more →ABTEl revolucionario sistema FreeStyle Libre de Abbott recibe aprobación INVIMA en Colombia, para su uso en personas sin diabetes. Abbott anunció que el Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) aprobó el sistema FreeStyle Libre, la tecnología de...
BOGOTÁ, Colombia , 3 de noviembre de 2020 /PRNewswire/ -- Abbott anunció que el Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) aprobó el sistema FreeStyle Libre, la tecnología de monitoreo continuo de glucosa (CGM) líder en el mundo i , también para uso en
Read more →ABTAbbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device Abbott (NYSE: ABT), a global healthcare leader focused on creating life-changing technologies that help people lead fuller and healthier lives, has...
ABBOTT PARK, Ill., Oct. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ), a global healthcare leader focused on creating life-changing technologies that help people lead fuller and healthier lives, has received the 2020 Prix Galien USA Award for Best Medical Technology for its MitraC
Read more →ABTAbbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance - Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent - Sales growth in
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance ABBOTT PARK, Ill., Oct. 21, 2020 - Abbott today announced financial results for the third quarter ended Sept. 30, 2020. "Our strong results and increased guidance are a d
Read more →ABTAbbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2020. Third-quarter worldwide sales of $8.9 billion...
ABBOTT PARK, Ill., Oct. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2020 . "Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging condi
Read more →ABTImproved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows Researchers at the University of Illinois, Urbana-Champaign, Abbott (NYSE: ABT), and the U.S. Air Force Research Lab announced today the results of a ...
ABBOTT PARK, Ill., Oct. 19, 2020 /PRNewswire/ -- Researchers at the University of Illinois, Urbana-Champaign , Abbott (NYSE: ABT ), and the U.S. Air Force Research Lab announced today the results of a new study that found a direct link between physical fitness, cognitive performa
Read more →ABTAbbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company's...
ABBOTT PARK, Ill., Oct. 12, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company's AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test for use on the ARCHI
Read more →ABTAbbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health In a continuing effort to provide the facts about ID NOW to support public health interests, Abbott (NYSE: ABT) is sharing new interim clinical data...
ABBOTT PARK, Ill., Oct. 7, 2020 /PRNewswire/ -- In a continuing effort to provide the facts about ID NOW to support public health interests, Abbott (NYSE: ABT ) is sharing new interim clinical data results on its ID NOW COVID-19 rapid test. The results confirm the data submitted
Read more →ABTAbbott lança teste rápido de antígeno, portátil e fácil de usar, que pode fornecer resultados em até 15 minutos para ampliar os testes de COVID-19 no Brasil O dispositivo de teste rápido Panbio™ COVID-19 Ag da Abbott é uma ferramenta confiável e acessível para que profissionais de saúde possam detectar...
SÃO PAULO, 5 de outubro de 2020 /PRNewswire/ -- A Abbott anunciou hoje a aprovação pela Anvisa (Agência Nacional de Vigilância Sanitária) do seu dispositivo de teste rápido Panbio™ COVID-19 Ag para a detecção do vírus SARS-CoV-2 em pessoas com suspeita de estar com COVID-19. O te
Read more →ABTAbbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology,8 announced today it has secured CE Mark (Conformité...
ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved
Read more →ABTAbbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading ...
ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world. Known as MitraClip
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2020 financial results on Wednesday, Oct. 21, 2020, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2020 financial results on Wednesday, Oct. 21, 2020 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Declares 387th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share. This marks the 387th consecutive...
ABBOTT PARK, Ill., Sept. 17, 2020 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 36 cents per share. This marks the 387 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes Abbott (NYSE: ABT) is introducing the world's first glucose sport biosensor,i Libre Sense Glucose Sport Biosensor, which is designed for athletes to...
ABBOTT PARK, Ill., Sept. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) is introducing the world's first glucose sport biosensor, i Libre Sense Glucose Sport Biosensor, which is designed for athletes to continuously measure glucose to better understand the correlation between their
Read more →ABTAbbott recebe aprovação da Anvisa para uso de FreeStyle Libre em mulheres com diabetes gestacional A Abbott, empresa global de cuidados para a saúde e líder mundial em monitoramento contínuo de glicose, anuncia que a Anvisa (Agência Nacional de...
SÃO PAULO, 14 de setembro de 2020 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde e líder mundial em monitoramento contínuo de glicose, anuncia que a Anvisa (Agência Nacional de Vigilância Sanitária) autorizou o uso do sistema FreeStyle Libre para mulheres brasi
Read more →ABTAbbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold Abbott (NYSE: ABT) today announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit™ BTK ...
ABBOTT PARK, Ill., Sept. 3, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit™ BTK Everolimus Eluting Resorbable Scaffold System. This is the first Investigational
Read more →ABTAbbott's FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM),4 announced today its next-generation FreeStyle® Libre 2 integrated...
ABBOTT PARK, Ill., Sept. 1, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ), the worldwide leader in continuous glucose monitoring (CGM), 4 announced today its next-generation FreeStyle ® Libre 2 integrated continuous glucose monitoring (iCGM) system is now available to Medicare patient
Read more →ABTAbbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™...
ABBOTT PARK, Ill., Aug. 26, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott will sell t
Read more →ABTAbbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from...
ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluat
Read more →ABTAbbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of the company's Patient...
ABBOTT PARK, Ill., July 23, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of the company's Patient Controller app on compatible personal Apple‡ smartphone devices. At Abbott, this app
Read more →ABTAbbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2020. Second-quarter worldwide sales of $7.3 billion...
ABBOTT PARK, Ill., July 16, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2020 . "Our diversified business model has proven to be a true strength during this time," said Robert B. Ford , president and chief execu
Read more →ABTAbbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations - Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales - Growt
Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations ABBOTT PARK, Ill., July 16, 2020 - Abbott today announced financial results for the second quarter ended June 30, 2020. "Our diversified business model has proven to be a true strength during this time,"
Read more →ABTAbbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes...
ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair pro
Read more →ABTAbbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable...
ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillato
Read more →ABTAbbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced today that they have finalized an agreement to develop and commercialize...
ABBOTT PARK, Ill. and SAN DIEGO , June 29, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) and Tandem Diabetes Care (NASDAQ: TNDM ) announced today that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading 1 cont
Read more →ABTNew Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages Abbott (NYSE: ABT) today announced new data from the company's LightLab Initiative that showed optical coherence tomography (OCT) imaging...
ABBOTT PARK, Ill., June 26, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new data from the company's LightLab Initiative that showed optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel compared to traditional angiog
Read more →ABTNew Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies Abbott (NYSE: ABT) today announced late-breaking data on a number of its life-changing products to treat people with structural heart diseases. The...
ABBOTT PARK, Ill., June 25, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced late-breaking data on a number of its life-changing products to treat people with structural heart diseases. The data included findings on the MitraClip™ system for transcatheter mitral valve rep
Read more →ABTAbbott lança segundo teste laboratorial de anticorpos para COVID-19 para o sistema Alinity™ i no Brasil A Abbott, empresa global de cuidados para a saúde, anuncia que recebeu aprovação da Agência Nacional de Vigilância Sanitária (Anvisa) de seu teste de ...
SÃO PAULO, 25 de junho de 2020 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, anuncia que recebeu aprovação da Agência Nacional de Vigilância Sanitária (Anvisa) de seu teste de sorologia laboratorial SARS-CoV-2 IgG para detecção de anticorpos para o sistema Al
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2020 financial results on Thursday, July 16, 2020, before the market opens. The announcement will ...
ABBOTT PARK, Ill., June 23, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2020 financial results on Thursday, July 16, 2020 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Cen
Read more →ABTNew Data Show Use of Abbott's FreeStyle® Libre System Reduces All-Cause, Diabetic Ketoacidosis-Related Hospitalization Rates and Acute Diabetes Events - Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people...
- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system dramatically decreases diabetic ketoacidosis-related hospitalizations - Additio
Read more →ABTAbbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared...
ABBOTT PARK, Ill., June 15, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle ® Libre 2 integrated continuous glucose monitoring
Read more →ABTNew Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not Today, Abbott (NYSE: ABT) announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading3 continuous glucose...
ABBOTT PARK, Ill., June 13, 2020 /PRNewswire/ -- Today, Abbott (NYSE: ABT ) announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading 3 continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglob
Read more →ABTAbbott Declares 386th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share. This marks the 386th consecutive...
ABBOTT PARK, Ill., June 12, 2020 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 36 cents per share. This marks the 386 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTAbbott anuncia la obtención del registro sanitario en Colombia, de su prueba de anticuerpos de COVID-19, para uso en laboratorio Abbott anunció hoy, la obtención del registro sanitario del Instituto Nacional de Vigilancia de Alimentos y Medicamentos (Invima), para su prueba...
BOGOTÁ, Colombia , 25 de mayo de 2020 /PRNewswire/ -- Abbott anunció hoy, la obtención del registro sanitario del Instituto Nacional de Vigilancia de Alimentos y Medicamentos (Invima), para su prueba serológica para la detección del anticuerpo IgG, para uso en laboratorios, que i
Read more →ABTAbbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests Abbott (NYSE: ABT) announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW...
ABBOTT PARK, Ill., May 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain
Read more →ABTAbbott Announces Contract to Supply Millions of IgG Lab-Based Antibody Tests to the UK Government Abbott (NYSE: ABT) announced a government contract to supply millions of its laboratory-based IgG antibody tests to National Health Service (NHS)...
ABBOTT PARK, Ill., May 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced a government contract to supply millions of its laboratory-based IgG antibody tests to National Health Service (NHS) laboratories across the UK over the coming months. Abbott has capacity to provide sig
Read more →ABTAbbott anuncia aprovação da Anvisa e disponibilidade imediata de testes de anticorpos para COVID-19 no Brasil A Abbott, empresa global de cuidados para a saúde, anuncia que recebeu aprovação da Agência Nacional de Vigilância Sanitária (Anvisa) de seu teste de ...
SÃO PAULO, 19 de maio de 2020 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, anuncia que recebeu aprovação da Agência Nacional de Vigilância Sanitária (Anvisa) de seu teste de sorologia laboratorial para a detecção de anticorpos IgG, que identificam se uma pes
Read more →ABTAbbott Provides Update on ID NOW™ (NYSE: ABT) -- Abbott's ID NOW™ is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and...
ABBOTT PARK, Ill., May 14, 2020 /PRNewswire/ -- (NYSE: ABT ) -- Abbott's ID NOW ™ is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they're needed. The availability and ease-of-access of ID NOW, which deliver
Read more →ABTAbbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company's...
ABBOTT PARK, Ill., May 12, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company's molecular test for the novel coronavirus (COVID-19) for use on its new Alinity ™ m m
Read more →ABTResearch from University of Washington Demonstrates High Performance of Abbott's SARS-CoV-2 Antibody Blood Test Abbott (NYSE: ABT) announced today new research, published in the Journal of Clinical Microbiology, which found that its SARS-CoV-2 IgG lab-based...
ABBOTT PARK, Ill., May 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today new research, published in the Journal of Clinical Microbiology , which found that its SARS-CoV-2 IgG lab-based serology blood test had 99.9% specificity and 100% sensitivity for detecting the IgG
Read more →ABTAbbott anuncia la aprobación de su prueba de anticuerpos COVID-19, para uso en laboratorios Abbott (NYSE: ABT) anunció hoy que recibió la aprobación de la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) a la...
BUENOS AIRES , 7 de mayo de 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) anunció hoy que recibió la aprobación de la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) a la Directiva IVD (Disposición 2675/99) de su prueba en sangre de serología para uso en
Read more →ABTAbbott lança LibreLinkUp, aplicativo que conecta remotamente usuários do sistema FreeStyle Libre e cuidadores para o melhor gerenciamento do diabetes A Abbott, líder mundial em monitoramento contínuo da glicose (CGM), anuncia a mais recente inovação para o gerenciamento do diabetes no Brasil, o...
SÃO PAULO, 20 de abril de 2020 /PRNewswire/ -- A Abbott, líder mundial em monitoramento contínuo da glicose (CGM), anuncia a mais recente inovação para o gerenciamento do diabetes no Brasil, o aplicativo LibreLinkUp 1 . A ferramenta digital gratuita, LibreLinkUp, permite que pais
Read more →ABTAbbott Reports First-Quarter 2020 Results First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
Abbott Reports First-Quarter 2020 Results ABBOTT PARK, Ill., April 16, 2020 - Abbott today announced financial results for the first quarter ended March 31, 2020. "First and foremost, I want to thank our employees, our customers, and our suppliers for their extraordinary effort
Read more →ABTAbbott Reports First-Quarter 2020 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2020. First-quarter worldwide sales of $7.7 billion...
ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2020 . "First and foremost, I want to thank our employees, our customers, and our suppliers for their extraordinary efforts to maintain s
Read more →ABTAbbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow Abbott (NYSE: ABT) announced today the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG,...
ABBOTT PARK, Ill., April 15, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19). Antibody test
Read more →ABTAbbott Announces Virtual Attendance at Annual Meeting of Shareholders Abbott (NYSE: ABT) announced today that due to the public health impact of the coronavirus pandemic and to support the health and safety of its...
ABBOTT PARK, Ill., April 14, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that due to the public health impact of the coronavirus pandemic and to support the health and safety of its shareholders, employees and communities, the company will provide virtual attendance
Read more →ABTAbbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in...
ABBOTT PARK, Ill., April 9, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for
Read more →ABTAbbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading3 continuous glucose monitoring (CGM) technology, can...
ABBOTT PARK, Ill., April 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the FreeStyle Libre 14 day system, the world's leading 3 continuous glucose monitoring (CGM) technology, can now be used in the hospital setting 2 during the COVID-19 pandemic, according to
Read more →ABTAbbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest...
ABBOTT PARK, Ill., March 27, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2020 financial results on Thursday, April 16, 2020, before the market opens. The announcement will ...
ABBOTT PARK, Ill., March 19, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2020 financial results on Thursday, April 16, 2020 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:00 a.m. Ce
Read more →ABTAbbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's...
ABBOTT PARK, Ill., March 18, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000
Read more →ABTAbbott Aims to Optimize TAVI Implants with European Approval of FlexNav™ Delivery System for the Company's Portico™ Valve Abbott (NYSE: ABT) today announced it has received CE Mark for the new FlexNav™ delivery system for the company's Portico™ transcatheter aortic valve ...
ABBOTT PARK, Ill., March 5, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received CE Mark for the new FlexNav™ delivery system for the company's Portico™ transcatheter aortic valve implantation (TAVI) system, enabling marketing authorization in Europe . With th
Read more →ABTAbbott Declares 385th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share. This marks the 385th consecutive...
ABBOTT PARK, Ill., Feb. 21, 2020 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 36 cents per share. This marks the 385 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTNew Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes Abbott (NYSE: ABT) announced today that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies &...
MADRID , Feb. 20, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that four real-world data abstracts i,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid . The new data show that users of the FreeStyle Libre sy
Read more →ABTAbbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care Abbott (NYSE: ABT) and Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management ...
ABBOTT PARK, Ill. and ACTON, Mass. , Feb. 19, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) and Insulet Corporation (NASDAQ: PODD ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), announced today they are partnering
Read more →ABTAbbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac...
ABBOTT PARK, Ill., Feb. 18, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhy
Read more →ABTAbbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for ...
ABBOTT PARK, Ill., Feb. 4, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS). The
Read more →ABTAbbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved a new trial designed to assess its Amplatzer™...
ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved a new trial designed to assess its Amplatzer™ Amulet™ Left Atrial Appendage Occluder for people with atrial fibrillation (AF) – a cond
Read more →ABTAbbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation Abbott (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for...
ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its Tendyne ™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for use in Europe . This life-changing therapy treats significant mitral regurgitatio
Read more →ABTAbbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the...
ABBOTT PARK, Ill., Jan. 24, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an are
Read more →ABTNew Quality of Life and Functional Improvement Data From Abbott's BOLD and TRIUMPH Studies Reinforce Benefit of Proclaim™ XR Neurostimulation System In People Living with Chronic Pain Abbott (NYSE: ABT) announced positive results from a prospective, multicenter study, providing the scientific basis for the company's Proclaim™ XR...
LAS VEGAS , Jan. 23, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) announced positive results from a prospective, multicenter study, providing the scientific basis for the company's Proclaim™ XR recharge-free neurostimulation system for people living with chronic pain. Data from the B
Read more →ABTAbbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020 Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019. Fourth-quarter worldwide sales of $8.3 ...
ABBOTT PARK, Ill., Jan. 22, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019 . "Our focus on organic growth is driving top-tier performance," said Miles D. White , chairman and chief executive off
Read more →ABTAbbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020 Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent Fourth-quarter GAAP EPS growth from continuing o
Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020 ABBOTT PARK, Ill., Jan. 22, 2020 - Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2019. "Our focus on organic growth is driving top-tier performance," sa
Read more →ABTAbbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind clinical trial that will compare ...
ABBOTT PARK, Ill., Jan. 13, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind clinical trial that will compare the effectiveness of Abbott's minimally invasive MitraClip™ device – which has n
Read more →ABTFDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott's HeartMate 3...
ABBOTT PARK, Ill., Jan. 7, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open hear
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2019 financial results on Wednesday, Jan. 22, 2020, before the market opens. The announcement...
ABBOTT PARK, Ill., Jan. 2, 2020 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter 2019 financial results on Wednesday, Jan. 22, 2020 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Cen
Read more →ABTAbbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 36 cents per share – a 12.5% increase. This...
ABBOTT PARK, Ill., Dec. 13, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend to 36 cents per share – a 12.5% increase. This marks the 384 th consecutive quarterly dividend to be paid by Abbott since 1924.
Read more →ABTAbbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020 Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year ...
ABBOTT PARK, Ill., Nov. 13, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020 , after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100. He will remain
Read more →ABTAbbott Announces Robert B.
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020 ABBOTT PARK, Ill., Nov. 13, 2019 - Abbott today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year ten
Read more →ABTAbbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus Abbott (NYSE: ABT) announced today that a team of its scientists identified a new subtype of the human immunodeficiency virus (HIV), called HIV-1...
ABBOTT PARK, Ill., Nov. 6, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that a team of its scientists identified a new subtype of the human immunodeficiency virus (HIV), called HIV-1 Group M, subtype L. 1 The findings, published today in the Journal of Acquired Immune
Read more →ABTAbbott lança a campanha Restaure o ritmo da sua vida para falar sobre constipação intestinal A Abbott (NYSE: ABT), empresa global de cuidados para a saúde, está lançando a campanha Restaure o ritmo da sua vida para incentivar as pessoas a...
SÃO PAULO, 22 de outubro de 2019 /PRNewswire/ -- A Abbott (NYSE: ABT ), empresa global de cuidados para a saúde, está lançando a campanha Restaure o ritmo da sua vida para incentivar as pessoas a buscarem hábitos de vida mais saudáveis como forma de evitar a constipação intestina
Read more →ABTThe Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening Abbott (NYSE: ABT) today announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for...
ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for Abbott's most advanced blood and plasma screening technology, Alinity™ s System. The Aus
Read more →ABTAbbott Reports Third-Quarter 2019 Results Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity Cont
Abbott Reports Third-Quarter 2019 Results ABBOTT PARK, Ill., Oct. 16, 2019 - Abbott today announced financial results for the third quarter ended Sept. 30, 2019. "We're performing exceptionally well across several areas," said Miles D. White, chairman and chief executive office
Read more →ABTAbbott Reports Third-Quarter 2019 Results Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2019. Third-quarter worldwide sales of $8.1 billion...
ABBOTT PARK, Ill., Oct. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2019 . "We're performing exceptionally well across several areas," said Miles D. White , chairman and chief executive officer, Abbott. "We
Read more →ABTAbbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced today that they intend to develop and commercialize integrated diabetes...
ABBOTT PARK, Ill. and SAN DIEGO , Oct. 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and Tandem Diabetes Care (NASDAQ: TNDM ) announced today that they intend to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading 1 glucose sensing technolog
Read more →ABTAbbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous...
ABBOTT PARK, Ill. and SAN FRANCISCO , Oct. 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneerin
Read more →ABTHelping Kids Stay Healthy You probably have a benign habit that you can't explain — and you may not even remember when it started. Maybe you wet your toothbrush before...
ABBOTT PARK, Ill., Oct. 8, 2019 /PRNewswire/ -- You probably have a benign habit that you can't explain — and you may not even remember when it started. Maybe you wet your toothbrush before applying toothpaste, or wash your face first thing in the morning, or put your left shoe
Read more →ABTAbbott lança LacLev® em embalagem com seis comprimidos A Abbott, empresa global de cuidados para a saúde, apresenta nova embalagem com 6 comprimidos de LacLev, primeira lactase em comprimidos mastigáveis...
SÃO PAULO, 30 de setembro de 2019 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, apresenta nova embalagem com 6 comprimidos de LacLev, primeira lactase em comprimidos mastigáveis do mercado brasileiro 1 , para atender à crescente demanda de pessoas que desejam
Read more →ABTLate-Breaking Data Shows Abbott's MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life Abbott (NYSE: ABT) today announced new analyses of the landmark COAPTTM Trial that show the company's MitraClipTM device is cost effective and is...
SAN FRANCISCO , Sept. 29, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new analyses of the landmark COAPT TM Trial that show the company's MitraClip TM device is cost effective and is projected to increase both life-expectancy and quality of life compared to guideline
Read more →ABTNew Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves Abbott (NYSE: ABT) today announced new data that suggest Abbott's investigational TriClip™ device may offer physicians an effective minimally...
SAN FRANCISCO , Sept. 28, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new data that suggest Abbott's investigational TriClip™ device may offer physicians an effective minimally invasive repair option for patients suffering from a leaky tricuspid valve, a condition al
Read more →ABTFDA Approves Abbott's Low Dose, Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life* for People Living with Chronic Pain Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Proclaim XR™ recharge-free neurostimulation ...
ABBOTT PARK, Ill., Sept. 26, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Proclaim XR™ recharge-free neurostimulation system for people living with chronic pain. The Proclaim XR platform offers a l
Read more →ABTU.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors in Diagnosing Heart Attacks Faster and More Accurately Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug...
ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA). As one of the most researched troponin diagnostic tests, d
Read more →ABTNebulizador inAResp da Abbott oferece opção mais compacta e portátil para inalação A Abbott, empresa global de cuidados para a saúde, está lançando no Brasil o nebulizador portátil inAResp, tornando mais fácil e conveniente o...
SÃO PAULO, 19 de setembro de 2019 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, está lançando no Brasil o nebulizador portátil inAResp, tornando mais fácil e conveniente o tratamento respiratório. Além de produzir partículas finas no tamanho médio ideal para
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2019 financial results on Wednesday, Oct. 16, 2019, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 18, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2019 financial results on Wednesday, Oct. 16, 2019 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children Abbott (NYSE: ABT) today announced approvals in Europe for two of its life-saving pediatric devices. The Masters HP™ 15mm rotatable mechanical heart...
ABBOTT PARK, Ill., Sept. 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced approvals in Europe for two of its life-saving pediatric devices. The Masters HP™ 15mm rotatable mechanical heart valve and the Amplatzer Piccolo™ Occluder have received CE Mark and are now avai
Read more →ABTAbbott Named the Industry Leader in Sustainability for the Seventh Consecutive Year on the Dow Jones Sustainability Index (DJSI) Abbott (NYSE: ABT) has been named the Global Industry Leader in sustainability for the seventh consecutive year by the Dow Jones Sustainability Index ...
ABBOTT PARK, Ill., Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) has been named the Global Industry Leader in sustainability for the seventh consecutive year by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainabil
Read more →ABTAbbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Delivery Technologies to Help Change the Way Diabetes is Managed Abbott (NYSE: ABT) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how...
ABBOTT PARK, Ill. and PARIS , Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will ta
Read more →ABTAbbott's Revolutionary FreeStyle® Libre System Now Reimbursed in the Two Largest Provinces in Canada Abbott (NYSE: ABT), the global leader in sensor-based glucose monitoring, announced today that it has received public reimbursement in Ontario and...
- Provides broader access to FreeStyle Libre system for residents living with diabetes in Ontario and Quebec - FreeStyle Libre is the first sensor-based glucose monitoring system to be listed in any Canadian provincial health plan - The technology delivers accurate, real-time g
Read more →ABTAbbott Declares 383rd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 383rd consecutive...
ABBOTT PARK, Ill., Sept. 12, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 32 cents per share. This marks the 383 rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Announces New Data That Shows Artificial Intelligence Technology Can Help Doctors Better Determine Which Patients are Having a Heart Attack Abbott (NYSE: ABT) announced today that new research, published in the journal Circulation, found its algorithm could help doctors in hospital...
ABBOTT PARK, Ill., Sept. 10, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that new research, published in the journal Circulation , found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not,
Read more →ABTMinistry of Health of Rwanda, Society for Family Health Rwanda and Abbott Launch Pioneering Model of Primary Health Care Service Delivery in Rwanda The Ministry of Health of Rwanda, the non-profit organization Society for Family Health Rwanda and global healthcare company Abbott (NYSE: ABT) are...
KIGALI, Rwanda , Sept. 9, 2019 /PRNewswire/ -- The Ministry of Health of Rwanda , the non-profit organization Society for Family Health Rwanda and global healthcare company Abbott (NYSE: ABT ) are today announcing the grand opening of a second-generation health post in Gikundamvu
Read more →ABTHe's Back and He's Hydrated: Abbott and NFL Star Odell Beckham Jr. Partner for Pedialyte® Abbott (NYSE: ABT) announced today that it is teaming up with NFL star, Cleveland Browns wide receiver, and Pedialyte® fan, Odell Beckham Jr., to...
ABBOTT PARK, Ill., Sept. 6, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it is teaming up with NFL star, Cleveland Browns wide receiver, and Pedialyte ® fan, Odell Beckham Jr. , to serve as a creative director and ambassador for Pedialyte. Known for more than 50
Read more →ABTAbbott Launches World's First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves Abbott (NYSE: ABT) today announced the launch of the company's TRILUMINATE Pivotal trial to evaluate the safety and effectiveness of the company's...
ABBOTT PARK, Ill., Sept. 5, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of the company's TRILUMINATE Pivotal trial to evaluate the safety and effectiveness of the company's TriClip transcatheter tricuspid valve repair system for the treatment of severe tri
Read more →ABTAbbott lança plataforma molecular para testes rápidos de infecções respiratórias A Abbott, empresa global de cuidados para a saúde, lança no Brasil sua plataforma molecular point of care ID NOWTM com testes para a detecção rápida...
SÃO PAULO, 2 de setembro de 2019 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, lança no Brasil sua plataforma molecular point of care ID NOW TM com testes para a detecção rápida de doenças respiratórias, como a gripe, bronquiolite e a faringoamigdalite. ID N
Read more →ABTNew Study Finds Abbott's Blood Test Technology Could Help Detect Brain Injury Quickly, Even if CT Scan is Normal Abbott (NYSE: ABT) announced that a new study, published in Lancet Neurology, found that elevated levels of a protein measured with the company's...
ABBOTT PARK, Ill., Aug. 26, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced that a new study, published in Lancet Neurology , found that elevated levels of a protein measured with the company's blood test under development could help detect mild traumatic brain injuries (TBIs)
Read more →ABTTogether, We Can Increase the Number of Women in STEM: Here is a Tool to Help Companies Get Started We know the facts: Girls are less likely to be encouraged to study science, technology, engineering and math. Women who do pursue STEM degrees often...
ABBOTT PARK, Ill., Aug. 26, 2019 /PRNewswire/ -- We know the facts: Girls are less likely to be encouraged to study science, technology, engineering and math. Women who do pursue STEM degrees often don't take related jobs. And when women find work in a STEM industry, many leave w
Read more →ABTAbbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing Abbott (NYSE: ABT) and Intoximeters today announced an agreement for Intoximeters to market Abbott's SoToxaTM Mobile Test System – a handheld oral...
ABBOTT PARK, Ill., Aug. 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and Intoximeters today announced an agreement for Intoximeters to market Abbott's SoToxa TM Mobile Test System – a handheld oral fluid roadside testing solution that rapidly and reliably detects recent drug use
Read more →ABTAbbott Reports Second-Quarter 2019 Results Accelerated and sustainable growth driven by strong performance across portfolio Raising full-year guidance for organic sales growth to 7 to 8 percent Double-digit
Abbott Reports Second-Quarter 2019 Results Accelerated and sustainable growth driven by strong performance across portfolio Raising full-year guidance for organic sales growth to 7 to 8 percent Double-digit EPS growth exceeded expectations; raising full-year forecast Long-ter
Read more →ABTAbbott Reports Second-Quarter 2019 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019. Second-quarter worldwide sales of $8.0 billion...
ABBOTT PARK, Ill., July 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2019 . "Our sales growth accelerated and is sustainable," said Miles D. White , chairman and chief executive officer, Abbott. "We have gre
Read more →ABTAbbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart...
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip ™ heart valve repair device to treat mitral regurgitation. The latest approval for the fo
Read more →ABTAbbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System. This...
ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System. This new solution will bring the latest screening technology to U.S. blood and plasma ce
Read more →ABTNutrition Is the Missing Ingredient in Home Health Today, New Study Shows New research from Advocate Health Care and Abbott (NYSE: ABT) found that prioritizing nutrition care* for home health patients at risk for...
ABBOTT PARK, Ill., June 24, 2019 /PRNewswire/ -- New research from Advocate Health Care and Abbott (NYSE: ABT ) found that prioritizing nutrition care * for home health patients at risk for malnutrition had a dramatic impact on helping keep them out of the hospital - resulting in
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens. The announcement...
ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTCARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings The global humanitarian organization CARE, the healthcare company Abbott (NYSE: ABT) and its foundation the Abbott Fund today announced a three-year, ...
ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- The global humanitarian organization CARE, the healthcare company Abbott (NYSE: ABT ) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommun
Read more →ABTAbbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes Abbott (NYSE: ABT) today announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100...
ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the first and only rapid point-of-care te
Read more →ABTAbbott Declares 382ⁿᵈ Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 382nd consecutive...
ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 32 cents per share. This marks the 382 nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTNew Survey Shows Millennials Can Help Avoid Blood Shortages A new survey from Abbott (NYSE: ABT) finds that millennials may be the key to a growing public health problem: a shortage in donated blood. Of the...
ABBOTT PARK, Ill., June 13, 2019 /PRNewswire/ -- A new survey from Abbott (NYSE: ABT ) finds that millennials may be the key to a growing public health problem: a shortage in donated blood. Of the millennials surveyed, 12% say they are regularly donating blood. 2 As that number g
Read more →ABTAbbott lança Dupha Kids e Dupha Active, primeiras gomas mastigáveis de lactulose, para mulheres e crianças no Brasil Para contribuir com a manutenção da saúde intestinal de toda a família, a Abbott, empresa global de cuidados para a saúde, lança Dupha Kids e Dupha...
SÃO PAULO, 10 de junho de 2019 /PRNewswire/ -- Para contribuir com a manutenção da saúde intestinal de toda a família, a Abbott, empresa global de cuidados para a saúde, lança Dupha Kids e Dupha Active, primeiros suplementos alimentares à base de lactulose em forma de gomas masti
Read more →ABTNew Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes Today Abbott (NYSE: ABT) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring...
SAN FRANCISCO , June 8, 2019 /PRNewswire/ -- Today Abbott (NYSE: ABT ) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living w
Read more →ABTTRILUMINATE Study Shows Treatment with Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company's minimally invasive tricuspid valve repair...
PARIS , May 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive late-breaking data from its TRILUMINATE study of the company's minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a
Read more →ABTEspaço Vida, da Abbott, promove experiência interativa para apresentar tecnologias inovadoras que ajudam as pessoas a viver mais e de maneira saudável A Abbott (NYSE: ABT), empresa global de cuidados para a saúde, promove a segunda edição do Espaço Vida, um projeto multidisciplinar e interativo...
SÃO PAULO, 20 de maio de 2019 /PRNewswire/ -- A Abbott (NYSE: ABT ), empresa global de cuidados para a saúde, promove a segunda edição do Espaço Vida, um projeto multidisciplinar e interativo criado para apresentar as principais tecnologias e inovações da companhia, além de conta
Read more →ABTNew ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying ...
ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight. 1 The ketogenic or "keto" diet – a high fat, moderate protein and
Read more →ABTNearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this...
ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. Nearly 70% of graduates today have taken out a loan – and a recent survey o
Read more →ABTAbbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders Abbott (NYSE: ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing...
ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN ( B rain R esearch through A dvancing I nnovative N eurotechnologies) initiative to accelerate advancements in neuro
Read more →ABTAbbott to Present at UBS Global Healthcare Conference Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Brian Yoor, executive vice president of finance and ...
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Brian Yoor , executive vice president of finance and chief financial officer, will present at 10 a.m. Central time . A live audio we
Read more →ABTAbbott Launches Next-generation Detection Technology in the U.S. and Europe, Offering a Smarter Approach to 24/7 Heart Monitoring for People with Irregular Heartbeats Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular...
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ -- Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clear
Read more →ABTAbbott Receives WHO Prequalification Approval for Breakthrough HIV Point-of-Care Test Abbott (NYSE: ABT) announced today that m-PIMA™ HIV-1/2 VL, the world's first point-of-care viral load diagnostic test, has received the World Health ...
ABBOTT PARK, Ill., May 2, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that m-PIMA™ HIV-1/2 VL , the world's first point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval (WHO PQ). The test received CE Mark in D
Read more →ABTAbbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions Abbott (NYSE: ABT) today announced the next phase of partnership with the U.S. Department of Defense (DoD) and researchers from the Transforming...
ABBOTT PARK, Ill., April 30, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the next phase of partnership with the U.S. Department of Defense (DoD) and researchers from the T ransforming R esearch and C linical K nowledge in T raumatic B rain I njury (TRACK-TBI) Network
Read more →ABTNew Study Finds Abbott Blood Test Can Help Predict Future Cardiac Events in Adults with No Known Heart Disease Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance...
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms
Read more →ABTAbbott Reports First-Quarter 2019 Results Sales and EPS growth exceed guidance; projects strong full-year outlook Long-term growth drivers including FreeStyle Libre, MitraClip and Alinity achieved strong dou
Abbott Reports First-Quarter 2019 Results Sales and EPS growth exceed guidance; projects strong full-year outlook Long-term growth drivers including FreeStyle Libre, MitraClip and Alinity achieved strong double-digit growth Reported sales growth of 2.0 percent; organic sales g
Read more →ABTAbbott Reports First-Quarter 2019 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019. First-quarter worldwide sales of $7.5 billion...
ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2019 . "We're right on track with our expectations to start the year," said Miles D. White , chairman and chief executive officer, Abbott
Read more →ABTAbbott and the Abbott Fund Support Relief Efforts for Cyclone Idai Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts...
ABBOTT PARK, Ill., April 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts for Cyclone Idai in Southeast Africa , including Mozambique , Malawi and Zimbabw
Read more →ABTAbbott lanza en México la aplicación FreeStyle LibreLink para la medición de glucosa desde teléfonos inteligentes El día de hoy Abbott, la compañía global del cuidado de la salud, anunció la llegada a México de su app FreeStyle LibreLink. Esta innovación...
CIUDAD DE MÉXICO, 26 de marzo de 2019 /PRNewswire/ -- El día de hoy Abbott, la compañía global del cuidado de la salud, anunció la llegada a México de su app FreeStyle LibreLink. Esta innovación permitirá a los usuarios con diabetes monitorear su nivel de glucosa directamente des
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens. The announcement...
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTAbbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients Abbott (NYSE: ABT) announced today CE Mark for its Alinity™ m diagnostics system and assays. This new technology will help keep up with the growing...
ABBOTT PARK, Ill., March 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today CE Mark for its Alinity™ m diagnostics system and assays. This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexi
Read more →ABTNew Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess...
NEW ORLEANS , March 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing d
Read more →ABTNew Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device Abbott (NYSE: ABT) today announced positive late-breaking data from two separate analyses of the COAPT™ Trial showing additional key benefits from...
NEW ORLEANS , March 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive late-breaking data from two separate analyses of the COAPT ™ Trial showing additional key benefits from treatment with MitraClip ™ for heart failure patients with clinically significant seco
Read more →ABTAbbott Receives FDA Approval for Expanded Indication for MitraClip™ Device Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its...
ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip ™ device used to repair a leaky mitral valve without open-heart surg
Read more →ABTLate-Breaking Data Presentations at ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio Key medical devices across Abbott's (NYSE: ABT) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American...
ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ -- Key medical devices across Abbott's (NYSE: ABT ) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology's 68 th Annual Scientific Session (ACC 2019) from March 16 –
Read more →ABTAbbott's Latest Diagnostics Technology, Alinity, Selected by Regional Medical Laboratory, Inc. to Deliver Benefits to Hospitals and Patients Abbott (NYSE: ABT) today announced that Regional Medical Laboratory, Inc. (RML) will use the company's most advanced technology, Alinity ci-series,...
ABBOTT PARK, Ill., March 5, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that Regional Medical Laboratory, Inc. (RML) will use the company's most advanced technology, Alinity ci-series, to conduct diagnostic testing for millions of patients. RML, part of the Ascension
Read more →ABTAbbott to Present at Barclays Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Brian Yoor, executive vice president of...
ABBOTT PARK, Ill., Feb. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Brian Yoor , executive vice president of finance and chief financial officer, will present at 1:05 p.m. Central time . A
Read more →ABTAbbott Declares 381st Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 381st consecutive...
ABBOTT PARK, Ill., Feb. 22, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 32 cents per share. This marks the 381 st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTNew Real-World Evidence Analysis of Nearly Half a Million FreeStyle® Libre System Users Shows Higher Rates of Scanning Improves Glucose Control Abbott (NYSE: ABT) today announced data from three real-world evidence studies that provide a comprehensive look at the global use of the FreeStyle®...
BERLIN , Feb. 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced data from three real-world evidence studies that provide a comprehensive look at the global use of the FreeStyle ® Libre flash glucose monitoring system and its impact on health outcomes for people living
Read more →ABTAbbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin Abbott (NYSE: ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled...
ABBOTT PARK, Ill. and BAGSVÆRD, Denmark , Feb. 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health
Read more →ABTAbbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care Abbott (NYSE: ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B...
ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine ™ HBsAg 2 test for use with serum, plasma or whole blo
Read more →ABTAbbott lança novo aplicativo FreeStyle® LibreLink™ para monitoramento da glicose em smartphones no Brasil A Abbott (NYSE: ABT), empresa global de cuidados para a saúde, anuncia o lançamento do aplicativo FreeStyle® LibreLink™ nos sistemas Android e iOS...
SÃO PAULO , 18 de fevereiro de 2019 /PRNewswire/ -- A Abbott (NYSE: ABT ), empresa global de cuidados para a saúde, anuncia o lançamento do aplicativo FreeStyle ® LibreLink ™ nos sistemas Android e iOS (para versões a partir do iOS 11 para iPhone 7 e Android 5.0 e que tenham habi
Read more →ABTAbbott lança Aletam, suplemento de colágeno que ajuda no desempenho das articulações Quando as nossas articulações, conexões que existem entre dois ou mais ossos, estão saudáveis, somos capazes de levar uma vida ativa e fazer as...
SÃO PAULO, 30 de janeiro de 2019 /PRNewswire/ -- Quando as nossas articulações, conexões que existem entre dois ou mais ossos, estão saudáveis, somos capazes de levar uma vida ativa e fazer as coisas de que gostamos. O desgaste articular, no entanto, pode ocorrer à medida que env
Read more →ABTAbbott Reports 2018 Results and Issues Strong Forecast for 2019 Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent Issues financial outlook for 2019, reflecting double-digit EPS
Abbott Reports 2018 Results and Issues Strong Forecast for 2019 Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth ABBOTT PARK, Ill.,
Read more →ABTAbbott Reports 2018 Results and Issues Strong Forecast for 2019 Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2018, and issued financial outlook for 2019. Full-year...
ABBOTT PARK, Ill., Jan. 23, 2019 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2018 , and issued financial outlook for 2019. "2018 was another outstanding year for Abbott," said Miles D. White , chairman and chief ex
Read more →ABTAbbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor...
Similar to Abbott's other sensor enabled mapping and ablation treatment catheters, TactiCath (Sensor Enabled) SE delivers more precise images of the heart overlaid with real-time electrical activity information. The catheter also utilizes the advanced ergonomic design found in th
Read more →ABTJapanese Red Cross Society Selects Abbott Technology to Screen Country's Blood and Plasma Supply Abbott (NYSE: ABT) announced today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country's blood...
ABBOTT PARK, Ill., Jan. 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country's blood donations. The 8-year contract is for the exclusive supply of serological instrumenta
Read more →ABTAbbott To Acquire Cephea Valve Technologies, Inc. Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device...
ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with
Read more →ABTFDA Approves World's First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect) Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world's first medical...
ABBOTT PARK, Ill., Jan. 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world's first medical device that can be implanted in the tiniest babies (weighing as little as two pound
Read more →ABTAbbott and Malaria No More Work Together to End Malaria in Odisha, India Abbott (NYSE: ABT) announced today that it is supporting a partnership between the government of the eastern Indian state of Odisha and Malaria No...
ABBOTT PARK, Ill., Jan. 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it is supporting a partnership between the government of the eastern Indian state of Odisha and Malaria No More, providing technology, expertise and funding support to advance efforts to end
Read more →ABTGet Bubbly this New Year with Abbott's New Pedialyte® Sparkling Rush™ Powder Packs Flavored sparkling water is currently a taste bud darling, and fans can now enjoy a new effervescent option: Pedialyte® Sparkling Rush™ powder packs. ...
ABBOTT PARK, Ill., Dec. 19, 2018 /PRNewswire/ -- Flavored sparkling water is currently a taste bud darling, and fans can now enjoy a new effervescent option: Pedialyte ® Sparkling Rush™ powder packs. Abbott (NYSE: ABT ) developed this rehydration solution just in time for the hol
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2018 financial results on Wednesday, Jan. 23, 2019, before the market opens. The announcement...
ABBOTT PARK, Ill., Dec. 17, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter 2018 financial results on Wednesday, Jan. 23, 2019 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Raises Quarterly Dividend 14%, Increasing Payouts for 47 Straight Years The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent...
ABBOTT PARK, Ill., Dec. 14, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. This marks the 380 th consecutive quarterly dividend to be paid by Abbott
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019. Brian Yoor, executive vice president...
ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 . Brian Yoor , executive vice president of finance and Chief Financial Officer, will present at the conference at 11 a.
Read more →ABTNew Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant Abbott (NYSE: ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) ...
ABBOTT PARK, Ill., Nov. 15, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe . People battling complex chronic pain conditions
Read more →ABTAbbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common...
ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company's outstanding shares. B
Read more →ABTAbbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2...
ABBOTT PARK, Ill., Oct. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing 1,2 . These new assays enable the faste
Read more →ABTAbbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA)...
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the HeartMate 3 ™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure.
Read more →ABTAbbott Reports Third-Quarter 2018 Results Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent Third-quarter GAAP EPS from continuing operations of $0.31; adjusted EPS fro
Abbott Reports Third-Quarter 2018 Results Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent Third-quarter GAAP EPS from continuing operations of $0.31; adjusted EPS from continuing operations of $0.75 Strong growth and pipeline advancemen
Read more →ABTNew Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart...
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology , found a new blood test under de
Read more →ABTAbbott Reports Third-Quarter 2018 Results Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2018. Third-quarter worldwide sales of $7.7 billion...
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2018 . "We achieved another quarter of strong growth and our new product pipeline continues to be highly productive," said Miles D. White
Read more →ABTAbbott Names Robert B. Ford President, Chief Operating Officer Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a...
ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices,
Read more →ABTAbbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels1) or hyperglycemia...
ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ -- People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels 1 ) or hyperglycemia (high glucose levels 1 ) through the FreeStyle ® Libre 2 system, a continuous glucose
Read more →ABTAbbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance Cardiovascular diseases are the leading cause of death globally.1 Yet unlike other conditions, heart disease can be prevented if identified early and ...
ABBOTT PARK, Ill., Sept. 26, 2018 /PRNewswire/ -- Cardiovascular diseases are the leading cause of death globally. 1 Yet unlike other conditions, heart disease can be prevented if identified early and managed through lifestyle changes and medication as needed. To help people take
Read more →ABTOne-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company's Portico™...
SAN DIEGO , Sept. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company's Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aor
Read more →ABTLandmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation Abbott (NYSE: ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device...
SAN DIEGO , Sept. 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip ® device to guideline-directed medical therapy in select patients with secondary (or functional
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Declares 379th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 379th consecutive...
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 28 cents per share. This marks the 379 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI) For the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI),...
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- For the sixth consecutive year, Abbott (NYSE: ABT ) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and re
Read more →ABTWhere Life-Changing Technology Meets Sustainability Our goal at Abbott is not just to help people live their best lives through life-changing technology – it's also to make this important work...
ABBOTT PARK, Ill., Sept. 5, 2018 /PRNewswire/ -- Our goal at Abbott is not just to help people live their best lives through life-changing technology – it's also to make this important work sustainable for the future. For us, sustainability is about applying the power of our bus
Read more →ABTNew Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain Abbott (NYSE: ABT) today announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy...
Abbott's DRG therapy is a form of neurostimulation that specifically targets the dorsal root ganglion, a structure along the spinal column which is densely populated with nerves that transmit sensory information to the central nervous system. By blocking or disrupting pain signal
Read more →ABTAbbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity™ DBS system. Abbott (NYSE: ABT)...
ABBOTT PARK, Ill., Aug. 2, 2018 /PRNewswire/ -- Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity™ DBS system . Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) approval for an over-the-
Read more →ABTAbbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S. Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring ...
ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with
Read more →ABTAbbott Begins U.S. Pivotal Trial for the Tendyne Mitral Valve Replacement System to Treat Patients with Heart Valve Disease Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) ...
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the sa
Read more →ABTAbbott Reports Second-Quarter 2018 Results Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40 Second-quarter organic sales growth of 8.0 percent Second-quarter
Abbott Reports Second-Quarter 2018 Results Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40 Second-quarter organic sales growth of 8.0 percent Second-quarter adjusted EPS from continuing operations of $0.73, above previous guid
Read more →ABTAbbott Reports Second-Quarter 2018 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2018. Second-quarter worldwide sales of $7.8 billion...
ABBOTT PARK, Ill., July 18, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2018 . "All four of our businesses exceeded expectations and contributed to strong growth overall," said Miles D. White , chairman and chi
Read more →ABTAbbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading ...
- Innovations designed to allow doctors to treat more types of cases and anatomies - MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair - Mitral regurgitation, the most common heart valve disease, affects o
Read more →ABTAbbott Announces Freedom 2 Save Program for Employees to Address Student Debt Historic levels of student debt have forced many people to choose between saving for their futures and paying off school loans. Abbott (NYSE: ABT)...
ABBOTT PARK, Ill., June 26, 2018 /PRNewswire/ -- Historic levels of student debt have forced many people to choose between saving for their futures and paying off school loans. Abbott (NYSE: ABT ) today announced a groundbreaking program that addresses the student debt crisis and
Read more →ABTNew Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle ...
ORLANDO, Fla. , June 25, 2018 /PRNewswire/ -- Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle Libre system, the company's revolutionary continuous glucose monitor (CGM), and its
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018, before the market opens. The announcement...
ABBOTT PARK, Ill., June 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Declares 378th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 378th consecutive...
ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 28 cents per share. This marks the 378 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug.
Read more →ABTAbbott promove Espaço Vida, um projeto multidisciplinar e interativo para os cuidados para a saúde em São Paulo A Abbott (NYSE: ABT), empresa global de cuidados para a saúde, está apresentando em São Paulo o Espaço Vida, com o propósito de receber uma série de...
SÃO PAULO, 4 de junho de 2018 /PRNewswire/ -- A Abbott (NYSE: ABT ), empresa global de cuidados para a saúde, está apresentando em São Paulo o Espaço Vida, com o propósito de receber uma série de discussões relacionadas a temas de cuidados para a saúde. Além disso, o visitante vi
Read more →ABTAbbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 ...
ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with informat
Read more →ABTNewest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation...
ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE Sierra TM , the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. X
Read more →ABTAbbott's Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve ...
PARIS , May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionabl
Read more →ABTFive-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE)...
PARIS , May 22, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott's fractional flow reserve (FFR) diagnostic
Read more →ABTAbbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™....
Arrhythmias are abnormal heart rhythms caused by improperly conducted electrical signals in the heart. In the U.S., more than 7 million people have an irregular heartbeat. 1 Abnormal heart rhythms, which include conditions such as atrial fibrillation, make the heart beat too fast
Read more →ABTAbbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease Abbott (NYSE: ABT) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the...
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary
Read more →ABTLevantamento de FreeStyle Libre da Abbott revela redução nos níveis de hipo e hiperglicemia em brasileiros com diabetes A Abbott, empresa global de cuidados para saúde, realizou um levantamento com aproximadamente 7.000 pessoas com diabetes no Brasil que utilizam o...
SÃO PAULO, 23 de abril de 2018 /PRNewswire/ -- A Abbott, empresa global de cuidados para saúde, realizou um levantamento com aproximadamente 7.000 pessoas com diabetes no Brasil que utilizam o FreeStyle Libre, sistema que elimina a necessidade das rotineiras picadas nos dedos 1 .
Read more →ABTAbbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023 Abbott (NYSE: ABT) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. The partnership will extend into 2023,...
LONDON , April 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. The partnership will extend into 2023, with the new four-year agreement beginning in 2019. Abbott became the first title sponsor of
Read more →ABTAbbott Reports First-Quarter 2018 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2018. First-quarter worldwide sales of $7.4 billion...
ABBOTT PARK, Ill., April 18, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2018 . "We're off to a strong start to the year as we forecasted," said Miles D. White , chairman and chief executive officer, Abbott. "W
Read more →ABTAbbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals Let's be honest – as adults, our busy schedules can get in the way of our own self-care, and that includes getting the right nutrition. The numbers...
ABBOTT PARK, Ill., April 17, 2018 /PRNewswire/ -- Let's be honest – as adults, our busy schedules can get in the way of our own self-care, and that includes getting the right nutrition. The numbers back this up: more than 1 in 3 adults over 50 still aren't getting the protein the
Read more →ABTAbbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease Abbott (NYSE: ABT) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided ...
ABBOTT PARK, Ill., April 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by high-resolution light-based imaging technology—called optical coherence tomo
Read more →ABTAbbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial ...
ABBOTT PARK, Ill., March 29, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS ™ HF System . The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018, before the market opens. The announcement...
ABBOTT PARK, Ill., March 21, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTNew Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device...
ORLANDO, Fla. , March 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-ter
Read more →ABTAbbott to Present at the Barclays Capital 2018 Global Healthcare Conference Abbott (NYSE: ABT) will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018. Brian Yoor, executive vice...
ABBOTT PARK, Ill., March 1, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018 . Brian Yoor , executive vice president, finance and chief financial officer, will present at 2:20 p.m. Central
Read more →ABTAbbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive...
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn. , Feb. 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) and Surmodics (NASDAQ: SRDX ) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVe
Read more →ABTAbbott Declares 377th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 377th consecutive...
ABBOTT PARK, Ill., Feb. 16, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 28 cents per share. This marks the 377 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTAbbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone™ and Android™ Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones2 (both iPhone and...
ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones 2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle ® Libre system
Read more →ABTAbbott Reports Fourth-Quarter 2017 Results Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2017. Fourth-quarter worldwide sales of $7.6 billion...
ABBOTT PARK, Ill., Jan. 24, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter ended Dec. 31, 2017 . "2017 was a great year for us – we performed well, our new product pipeline was highly productive and we took some very important s
Read more →ABTAbbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare Patients Abbott (NYSE: ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is...
ABBOTT PARK, Ill., Jan. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the FreeStyle ® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM syste
Read more →ABTNew FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra...
ABBOTT PARK, Ill., Jan. 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MP™ Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Fortify Assu
Read more →ABTAbbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration Abbott (NYSE: ABT) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining the Alinity hq standalone...
ABBOTT PARK, Ill., Jan. 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining t he Alinity hq standalone hematology analyzer, which obtained CE Mark earlier this year. The new Alinity h-seri
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018, before the market opens. The announcement...
ABBOTT PARK, Ill., Dec. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Raising Quarterly Dividend for 46th Straight Year The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 28 cents per share from 26.5 cents per share. ...
ABBOTT PARK, Ill., Dec. 15, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend to 28 cents per share from 26.5 cents per share. This marks the 376 th consecutive quarterly dividend to be paid by Abbott since
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2018. Brian Yoor, executive vice president of ...
ABBOTT PARK, Ill., Dec. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 36 th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2018 . Brian Yoor , executive vice president of finance and Chief Financial Officer, will present at the conference at 6 p.m.
Read more →ABTAbbott apresenta LacLev®, primeira lactase mastigável no Brasil para intolerância à lactose Para melhorar o conforto das pessoas intolerantes à lactose ao ingerir produtos lácteos, a Abbott, empresa global de cuidados para a saúde, apresenta ...
SÃO PAULO, 21 de novembro de 2017 /PRNewswire/ -- Para melhorar o conforto das pessoas intolerantes à lactose ao ingerir produtos lácteos, a Abbott, empresa global de cuidados para a saúde, apresenta o LacLev ® , a primeira lactase em comprimidos mastigáveis do mercado brasileiro
Read more →ABTAbbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan Abbott (NYSE: ABT) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for...
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease
Read more →ABTAbbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry ...
ABBOTT PARK, Ill., Oct. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics. These innovative testing solutions were designed to
Read more →ABTAnalysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary...
DENVER , Oct. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more
Read more →ABTAbbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1] Abbott (NYSE: ABT) today announced it received CE Mark for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE...
ABBOTT PARK, Ill., Oct. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it received CE Mark for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. CE Mark allows sale of the device in the European Unio
Read more →ABTAbbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S. Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's...
ABBOTT PARK, Ill., Oct. 23, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM) , the world's first and only smartphone compatible ICM designed to help physicians remotely iden
Read more →ABTA Great Place to Do Great Things: Developing Game-Changing Technology at Abbott Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal...
ABBOTT PARK, Ill., Oct. 19, 2017 /PRNewswire/ -- Science has spoken: Abbott (NYSE: ABT ) is, again, among the best science-based companies to work for in the world. For the 14 th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an ev
Read more →ABTAbbott Reports Third-Quarter 2017 Results Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2017. Third-quarter worldwide sales of $6.8 billion...
ABBOTT PARK, Ill., Oct. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2017 . "We're very pleased with our performance and the steady cadence of innovative new product launches that are contributing to growth,
Read more →ABTPatients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System Abbott (NYSE: ABT) today announced the U.S. launch of the company's Proclaim™ DRG Neurostimulator System, a new device designed to deliver...
ABBOTT PARK, Ill., Oct. 16, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the U.S. launch of the company's Proclaim™ DRG Neurostimulator System , a new device designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering fro
Read more →ABTAbbott Completes Cash Tender Offer for Series B Convertible Perpetual Preferred Stock of Alere Inc. Abbott (NYSE: ABT) announced today that it has successfully completed its previously announced tender offer to purchase for cash all outstanding...
ABBOTT PARK, Ill., Oct. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has successfully completed its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Al
Read more →ABTAbbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B ...
ABBOTT PARK, Ill., Oct. 2, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Ale
Read more →ABTAbbott Acquisition of Alere Set to Close on Tuesday, October 3, 2017 Abbott (NYSE: ABT) announced today it intends to close the acquisition of Alere, Inc., on Tuesday, Oct. 3, 2017. The announcement follows receipt of...
ABBOTT PARK, Ill., Sept. 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it intends to close the acquisition of Alere, Inc., on Tuesday, Oct. 3, 2017 . The announcement follows receipt of all regulatory clearances necessary for closing. The transaction establishes A
Read more →ABTNo More Routine Finger Sticks(1) for Americans with Diabetes: Abbott′s FreeStyle® Libre Approved in the U.S. Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre Flash Glucose Monitoring System ...
ABBOTT PARK, Ill., Sept. 27, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre Flash Glucose Monitoring System as a replacement 1 for blood glucose monitoring (BGM) for adults with diabetes
Read more →ABTAbbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of...
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott's most widely-used implantable cardioverter defibrillators (ICD) and associate
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2017 financial results on Wednesday, Oct. 18, 2017, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 20, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2017 financial results on Wednesday, Oct. 18, 2017 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Declares 375th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share. This marks the 375th consecutive...
ABBOTT PARK, Ill., Sept. 14, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 26.5 cents per share. This marks the 375 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable
Read more →ABTFreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service Abbott (NYSE: ABT) today announced that the FreeStyle® Libre system is now available for reimbursement in the United Kingdom (UK). The National...
ABBOTT PARK, Ill., Sept. 13, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the FreeStyle ® Libre system is now available for reimbursement in the United Kingdom (UK). The National Health Service (NHS) Business Services Authority has approved the listing on the Dru
Read more →ABTAbbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI) For the fifth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI),...
ABBOTT PARK, Ill., Sept. 7, 2017 /PRNewswire/ -- For the fifth consecutive year, Abbott (NYSE: ABT ) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and res
Read more →ABTRevolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the...
ABBOTT PARK, Ill., Aug. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle ® Libre glucose monitoring system effective September 1, 2017 . The revolutiona
Read more →ABTAbbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of...
ABBOTT PARK, Ill., Aug. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occ
Read more →ABTAbbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver...
ABBOTT PARK, Ill., Aug. 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Te
Read more →ABTAbbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3™ Left...
ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3 ™ Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new o
Read more →ABTPessoas com diabetes e hipertensão consideram-se empoderadas em relação a sua saúde, revela pesquisa da Abbott A Abbott, empresa global de cuidados para a saúde, marca seus 80 anos no Brasil convidando os brasileiros a refletir sobre a importância da conquista ...
SÃO PAULO, 24 de agosto de 2017 /PRNewswire/ -- A Abbott, empresa global de cuidados para a saúde, marca seus 80 anos no Brasil convidando os brasileiros a refletir sobre a importância da conquista e manutenção da sua saúde e seus principais desafios. Para tanto, a empresa ideali
Read more →ABTNorth West London Pathology and Abbott Partner for Diagnostics Products and Services, including Alinity™, in Three NHS Trusts North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust, and Abbott (NYSE: ABT) announced today that they signed a $252...
LONDON , Aug. 15, 2017 /PRNewswire/ -- North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust, and Abbott (NYSE: ABT ) announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and c
Read more →ABTAbbott Reports Second-Quarter 2017 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2017. Second-quarter worldwide sales of $6.6 billion...
ABBOTT PARK, Ill., July 20, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2017 . "Halfway through the year, we're on track with all of our key priorities, including the integration of St. Jude and growth contribu
Read more →ABTAbbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. Abbott (NYSE: ABT) announced today that it is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual ...
ABBOTT PARK, Ill., July 17, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $4
Read more →ABTAbbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes...
ABBOTT PARK, Ill. and MILPITAS, Calif. , July 13, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle ® Libre glu
Read more →ABTAbbott Secures Health Canada License for FreeStyle® Libre System for People with Diabetes Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose...
ABBOTT PARK, Ill., June 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the Health Canada license of its FreeStyle ® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes. The first-of-its-kind system
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2017 financial results on Thursday, July 20, 2017, before the market opens. The announcement will ...
ABBOTT PARK, Ill., June 21, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2017 financial results on Thursday, July 20, 2017 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra
Read more →ABTAbbott Declares 374th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share. This marks the 374th consecutive...
ABBOTT PARK, Ill., June 9, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 26.5 cents per share. This marks the 374 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Au
Read more →ABTAbbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ Abbott (NYSE: ABT) today announced CE Mark of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, developed to make it easier for...
Arrhythmias develop when electrical signals that regulate heart rhythms become disrupted or change, making the heart develop an irregular heartbeat. A patient with AF is at increased risk for stroke because the rapid heartbeat can let blood pool in the heart, which can cause clot
Read more →ABTAbbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first smartphone...
ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced CE Mark and first use of the new Confirm Rx™ Insertable Cardiac Monitor (ICM) , the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmia
Read more →ABTAbbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle® Libre—Abbott's revolutionary...
As part of the evaluation published in July 2016 , the French Health Technology Assessment (HTA) body – Haute Autorité de Santé (HAS) – issued a positive opinion stating that FreeStyle Libre provides added clinical value (category of ASAIII) over the current standard of care for
Read more →ABTAbbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery More than 48 million surgeries happen in the U.S. each year,1 and for many of those patients, food is off the table in the hours prior to their...
ABBOTT PARK, Ill., April 26, 2017 /PRNewswire/ -- More than 48 million surgeries happen in the U.S. each year, 1 and for many of those patients, food is off the table in the hours prior to their procedure. According to a new survey of 1,015 Americans, supported by Abbott, a major
Read more →ABTAbbott Reports First-Quarter 2017 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2017. Reported diluted EPS from continuing operations...
ABBOTT PARK, Ill., April 19, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2017 . "Our first quarter results reflect a strong start to the year," said Miles D. White , chairman and chief executive officer, Abbott
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2017 financial results on Wednesday, April 19, 2017, before the market opens. The announcement...
ABBOTT PARK, Ill., March 22, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2017 financial results on Wednesday, April 19, 2017 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTLate-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS™ HF System as an effective...
WASHINGTON , March 19, 2017 /PRNewswire/ -- New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS ™ HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of hea
Read more →ABTLate-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease Abbott (NYSE: ABT) today announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in...
WASHINGTON , March 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the United States . MitraClip treats peop
Read more →ABTAbbott to Present at Barclays Capital 2017 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017. Brian Yoor, executive vice...
ABBOTT PARK, Ill., March 8, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017 . Brian Yoor , executive vice president, finance and chief financial officer, will present at 9:15 a.m. Central time
Read more →ABTNew Study Results May Lead to a New Standard of Care for In Vitro Fertilization Treatment New study results published in Human Reproduction could pave the way for an additional treatment option for the estimated 1.5 million women worldwide ...
ABBOTT PARK, Ill., March 8, 2017 /PRNewswire/ -- New study results published in Human Reproduction could pave the way for an additional treatment option for the estimated 1.5 million women worldwide who undergo in vitro fertilization (IVF) treatment each year 1 , 2 . In the Lotus
Read more →ABTAbbott Announces Results of Early Tenders and Consents in Exchange Offers and Execution of Supplemental Indenture Abbott (NYSE: ABT) announced today that, as of 5:00 p.m. New York City time, on March 6, 2017, the aggregate principal amounts of each series of...
ABBOTT PARK, Ill., March 7, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that, as of 5:00 p.m. New York City time, on March 6, 2017 , the aggregate principal amounts of each series of notes listed in the table below issued by St. Jude Medical, LLC (successor to St. Ju
Read more →ABTAbbott Commences Exchange Offers and Consent Solicitations for St. Jude Medical, LLC Notes Abbott (NYSE:ABT) announced today that it has commenced offers to exchange all validly tendered and accepted notes of the following series issued by...
ABBOTT PARK, Ill., Feb. 21, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has commenced offers to exchange all validly tendered and accepted notes of the following series issued by St. Jude Medical, LLC (successor to St. Jude Medical, Inc. - STJ) for notes to b
Read more →ABTAbbott Declares 373rd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share. This marks the 373rd consecutive...
ABBOTT PARK, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 26.5 cents per share. This marks the 373 rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable M
Read more →ABTReal-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose Monitoring and Improved Glucose Control for People with Diabetes Abbott (NYSE: ABT) today announced the results of real-world use data[1] showing that people who scan more frequently using Abbott′s FreeStyle® Libre ...
PARIS , Feb. 15, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the results of real-world use data[1] showing that people who scan more frequently using Abbott′s FreeStyle ® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood suga
Read more →ABTU.S. FDA Grants Abbott the First Commercial Authorization for a Molecular Test to Detect Zika Virus Using Whole Blood Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime ZIKA test, ...
ABBOTT PARK, Ill., Feb. 2, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTi m e ZIKA test, to detect Zika virus in whole blood (when collected alongside a patient-matched
Read more →ABTAbbott Announces U.S. Approval for its Assurity MRI™ Pacemaker, the World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the...
ABBOTT PARK, Ill., Feb. 1, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI™ pacemaker and the Tendril™ MRI pacing lead. Patients implanted with the
Read more →ABTAbbott Reports Fourth-Quarter 2016 Results Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2016. Reported diluted EPS from continuing operations...
ABBOTT PARK, Ill., Jan. 25, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter ended Dec. 31, 2016 . "2016 was a very important year for Abbott," said Miles D. White , chairman and chief executive officer, Abbott. "We achieved our f
Read more →ABTNew Study Demonstrates Spinal Cord Stimulation Can Reduce or Stabilize Opioid Use Among Chronic Pain Patients New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic...
ABBOTT PARK, Ill., Jan. 20, 2017 /PRNewswire/ -- New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain. In a new study, researchers examined opioid usage data from more than 5,400 pa
Read more →ABTAbbott Announces European Launch of the Proclaim™ DRG Neurostimulation System for the Management of Chronic Neuropathic Pain Abbott (NYSE: ABT) today announced the European launch of the new Proclaim™ DRG Neurostimulation System, designed to deliver dorsal root ganglion...
ABBOTT PARK, Ill., Jan. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the European launch of the new Proclaim™ DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering from chronic neuropathic pain. Through the P
Read more →ABTNew Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success over Traditional Spinal Cord Stimulation New data published in the January edition of Pain has confirmed the superiority of Abbott's dorsal root ganglion (DRG) stimulation therapy over...
ABBOTT PARK, Ill., Jan. 17, 2017 /PRNewswire/ -- New data published in the January edition of Pain has confirmed the superiority of Abbott's dorsal root ganglion (DRG) stimulation therapy over traditional spinal cord stimulation (SCS) for patients suffering from complex regional
Read more →ABTAbbott Announces U.S. Launch and First Commercial Use of the New EnSite™ Precision Cardiac Mapping System Abbott (NYSE: ABT) announced today the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL...
When physicians use catheter ablation to treat abnormal heart rhythms, a small area of heart tissue under the tip of the ablation catheter is heated by radio-frequency energy, creating a lesion or tiny scar. As a result, this tissue is no longer capable of conducting or sustainin
Read more →ABTAbbott Announces CE Mark for its Alinity s Blood and Plasma Screening System Abbott (NYSE: ABT) announced today its Alinity™ s System for blood and plasma screening received CE Mark and is now available in Europe and other...
ABBOTT PARK, Ill., Jan. 10, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today its Alinity™ s System for blood and plasma screening received CE Mark and is now available in Europe and other countries that recognize CE Mark. The new testing solution is designed to screen blo
Read more →ABTAbbott Announces CE Mark for its Alinity ci-series Diagnostic Systems Abbott (NYSE: ABT) announced today its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics have obtained CE Mark and...
ABBOTT PARK, Ill., Jan. 10, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics have obtained CE Mark and are now available in Europe and other countries that recognize CE Mark. These innov
Read more →ABTAbbott Obtient la Certification CE pour ses Systèmes de Diagnostic de la Série « Alinity ci » Abbott a annoncé aujourd'hui que ses automates de chimie clinique et d'immunoanalyse de la série « Alinity ci » ont obtenu la certification CE et...
LA NOUVELLE GÉNÉRATION DE SYSTÈMES HARMONISÉS, ASSOCIÉE AUX SERVICES PROFESSIONNELS ALINIQ LANCÉS RÉCEMMENT, APPORTENT UNE SOLUTION UNIQUE POUR AIDER LES LABORATOIRES ET LES HÔPITAUX À OBTENIR DE MEILLEURES PERFORMANCES MESURABLES EN MATIERE DE SANTE. LA GAMME ALINITY OFFRE UNE
Read more →ABTAbbott Completes the Acquisition of St. Jude Medical Abbott (NYSE: ABT) announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical...
ABBOTT PARK, Ill., Jan. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provides Abbott with expanded opportunities for future
Read more →ABTAbbott Acquisition of St. Jude Medical Set to Close on January 4, 2017 Abbott (NYSE: ABT) announced today it intends to close the acquisition of St. Jude Medical, Inc., on Wednesday, Jan. 4, 2017. The announcement...
ABBOTT PARK, Ill., Dec. 30, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it intends to close the acquisition of St. Jude Medical, Inc., on Wednesday, Jan. 4, 2017 . The announcement follows receipt of all regulatory clearances necessary for closing. The transaction e
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2016 financial results on Wednesday, Jan. 25, 2017, before the market opens. The...
ABBOTT PARK, Ill., Dec. 21, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2016 financial results on Wednesday, Jan. 25, 2017 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call a
Read more →ABTAbbott Raising Quarterly Dividend for 45th Straight Year The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. ...
ABBOTT PARK, Ill., Dec. 9, 2016 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. This marks the 372 nd consecutive quarterly dividend to be paid by Abbott since
Read more →ABTAbbott Seeks to Terminate Alere Acquisition Abbott (NYSE: ABT) has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the...
ABBOTT PARK, Ill., Dec. 7, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement. In the 10 months following the Jan. 30, 2016 , signing of the a
Read more →ABTStudy: Hospital Nutrition Program Shortens Patient Stays and Reduces Readmissions While proper nutrition is vital to staying healthy, its importance becomes more critical for patients recovering in the hospital. A new study by...
DOWNERS GROVE, Ill. and ABBOTT PARK, Ill., Dec. 6, 2016 /PRNewswire/ -- While proper nutrition is vital to staying healthy, its importance becomes more critical for patients recovering in the hospital. A new study by Advocate Health Care and Abbott (NYSE: ABT ) found that optimiz
Read more →ABTAbbott Announces CE Mark for i-STAT Alinity, a Pioneering, Handheld Blood Testing Platform Abbott (NYSE: ABT) announced today its i-STAT® Alinity™ System, an innovative, handheld blood testing platform, received CE Mark and is now for sale...
To address these needs, Abbott developed i-STAT Alinity to be intelligent, intuitive and easy to use, empowering healthcare professionals to provide high-quality care for people across the globe. First-of-its kind, patented features include: In today's pressure-packed healthcare
Read more →ABTAbbott's Absorb™ Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan Abbott (NYSE: ABT) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the company's Absorb bioresorbable...
ABBOTT PARK, Ill., Nov. 7, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to tr
Read more →ABTA Great Place to Work, According to Science Don't trust us, trust Science: Abbott is among the best science-based companies to work for in the world. Experience the interactive Multimedia News...
ABBOTT PARK, Ill., Oct. 27, 2016 /PRNewswire/ -- Don't trust us, trust Science : Abbott is among the best science-based companies to work for in the world. Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/7962251-science-names-abbo
Read more →ABTNew Study: Babies Fed Infant Formula with 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies Good nutrition helps build the foundation for a child's ability to learn, grow and thrive. For babies, the best nutrition is breast milk – there's...
ABBOTT PARK, Ill., Oct. 26, 2016 /PRNewswire/ -- Good nutrition helps build the foundation for a child's ability to learn, grow and thrive. For babies, the best nutrition is breast milk – there's nothing in the world like it – in part due to special prebiotics called human milk o
Read more →ABTAbbott Reports Third-Quarter 2016 Results Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2016. Third-quarter worldwide sales of $5.3 billion...
ABBOTT PARK, Ill., Oct. 19, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2016 . "Strong performance in Established Pharmaceuticals and Medical Devices led our sales growth this quarter," said Miles D. White , ch
Read more →ABTSt. Jude Medical and Abbott to Sell Portion of Vascular Closure and Electrophysiology Businesses to Terumo Corporation Abbott (NYSE: ABT) and St. Jude Medical, Inc. (NYSE: STJ) announced today an agreement in principle to sell certain products to Terumo Corporation....
ABBOTT PARK, Ill. and ST. PAUL, Minn. , Oct. 18, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) and St. Jude Medical, Inc. (NYSE: STJ ) announced today an agreement in principle to sell certain products to Terumo Corporation. The transaction reflects a purchase price of approximately $
Read more →ABTAbbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a...
ABBOTT PARK, Ill., Sept. 28, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2016 financial results on Wednesday, Oct. 19, 2016, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 21, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2016 financial results on Wednesday, Oct. 19, 2016 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTMalnutrition Adds $15.5 Billion Annually to Direct U.S. Medical Costs Healthcare spending in the U.S. is higher than any other country,2 and a major contributor of that cost is treating chronic diseases. One barrier to...
ABBOTT PARK, Ill., Sept. 21, 2016 /PRNewswire/ -- Healthcare spending in the U.S. is higher than any other country, 2 and a major contributor of that cost is treating chronic diseases. One barrier to better health for people living with a chronic disease is malnutrition, and new
Read more →ABTFueling Performance with Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes While some endurance, strength and physique athletes try to minimize their intake of fat, others are embracing a high-fat, ketogenic nutrition plan....
ABBOTT PARK, Ill., Sept. 20, 2016 /PRNewswire/ -- While some endurance, strength and physique athletes try to minimize their intake of fat, others are embracing a high-fat, ketogenic nutrition plan. To help those athletes build stronger, leaner bodies and meet endurance goals, EA
Read more →ABTAbbott to Sell Abbott Medical Optics to Johnson & Johnson for $4.325 Billion Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash....
ABBOTT PARK, Ill., Sept. 16, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. "We've been actively and strategically shaping our portfolio, which has recen
Read more →ABTAbbott Declares 371st Consecutive Quarterly Dividend The board of directors of Abbott today declared a quarterly common dividend of 26 cents per share. This marks the 371st consecutive quarterly...
ABBOTT PARK, Ill., Sept. 15, 2016 /PRNewswire/ -- The board of directors of Abbott today declared a quarterly common dividend of 26 cents per share. This marks the 371 st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2016 ,
Read more →ABTAbbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI) For the fourth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI),...
ABBOTT PARK, Ill., Sept. 8, 2016 /PRNewswire/ -- For the fourth consecutive year, Abbott (NYSE: ABT ) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and re
Read more →ABTAbbott to Present at Wells Fargo Healthcare Conference Abbott (NYSE: ABT) will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016. Brian Yoor, senior vice president, finance ...
ABBOTT PARK, Ill., Aug. 24, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016 . Brian Yoor , senior vice president, finance and chief financial officer, will present at 7:45 a.m. Central time . A live
Read more →ABTAbbott Unveils Alinity™, its Unified Family of Innovative Next-Generation Diagnostics Systems Abbott (NYSE: ABT) announced today the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical...
ABBOTT PARK, Ill., Aug. 2, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnosti
Read more →ABTAbbott Reports Second-Quarter 2016 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2016. Second-quarter worldwide sales of $5.3 billion...
ABBOTT PARK, Ill., July 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2016 . "It was a good quarter," said Miles D. White , chairman and chief executive officer, Abbott. "We're particularly pleased with the s
Read more →ABTFDA Approves the Tecnis Symfony® Intraocular Lenses, the First and Only Extended Depth of Focus Lenses for People with Cataracts Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of...
ABBOTT PARK, Ill., July 15, 2016 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony ® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfo
Read more →ABTFDA approves Abbott's Absorb™ bioresorbable stent, the only fully dissolving heart stent Abbott announced today that the U.S. Food and Drug Administration has approved the company's Absorb bioresorbable heart stent, making the...
ABBOTT PARK, Ill., July 5, 2016 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery d
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2016 financial results on Wednesday, July 20, 2016, before the market opens. The announcement...
ABBOTT PARK, Ill., June 22, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2016 financial results on Wednesday, July 20, 2016 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Announces Positive Results from Groundbreaking Study of FreeStyle® Libre System for People with Type 1 Diabetes Abbott (NYSE: ABT) today announced the results of the IMPACT clinical trial, which demonstrated that the FreeStyle® Libre system met its primary...
NEW ORLEANS , June 13, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the results of the IMPACT clinical trial, which demonstrated that the FreeStyle ® Libre system met its primary endpoint of a reduction in time spent in hypoglycemia (low glucose levels, defined as <70
Read more →ABTAbbott Declares 370th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26 cents per share. This marks the 370th consecutive...
ABBOTT PARK, Ill., June 10, 2016 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 26 cents per share. This marks the 370 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTNew Curate™ Kids Combines Wholesome Ingredients and Kid-Friendly Flavors to Help Parents Win Snack-time Parents know that kids need good nutrition to be their healthiest and grow to their full potential but when you're constantly on the go, it can be...
ABBOTT PARK, Ill., May 10, 2016 /PRNewswire/ -- Parents know that kids need good nutrition to be their healthiest and grow to their full potential but when you're constantly on the go, it can be hard to find wholesome snacking options that kids will actually eat. With the launch
Read more →ABTA Clever Way to Add Nutrition to Your Toddler's Favorite Foods: Go & Grow by Similac® Food Mix-Ins™ Eating a balanced, nutritious diet is the foundation for healthy growth, and ideally, every toddler would happily gobble up nutrient-rich foods like...
ABBOTT PARK, Ill., May 9, 2016 /PRNewswire/ -- Eating a balanced, nutritious diet is the foundation for healthy growth, and ideally, every toddler would happily gobble up nutrient-rich foods like broccoli and sweet potatoes. But in reality, it can take a while for certain foods t
Read more →ABTAbbott Announces Positive Results from Pivotal Study of Tecnis® Symfony IOL for Cataract Surgery Today Abbott (NYSE: ABT) announced that its pivotal clinical trial of the company's Tecnis® Symfony 1-Piece Acrylic Intraocular Lens (IOL) met its...
NEW ORLEANS , May 8, 2016 /PRNewswire/ -- Today Abbott (NYSE: ABT ) announced that its pivotal clinical trial of the company's Tecnis ® Symfony 1-Piece Acrylic Intraocular Lens (IOL) met its primary endpoint of improved intermediate vision. Data from this study showed that people
Read more →ABTAbbott to Present at Deutsche Bank Health Care Conference Abbott (NYSE: ABT) will present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016. Tom Freyman, executive vice...
ABBOTT PARK, Ill., May 4, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Deutsche Bank 41 st Annual Health Care Conference on Thursday, May 5, 2016 . Tom Freyman , executive vice president, finance and administration, and Brian Yoor , senior vice president, finance
Read more →ABTAmerica's Health Check-up: AARP and Abbott Survey Finds Half of Adults 50-Plus Wish They Had More Strength and Energy to Enjoy Daily Activities While Americans are redefining what it means to age well and stay healthy, many adults 50 and over are still feeling the effects of aging. AARP and...
ABBOTT PARK, Ill. and WASHINGTON , May 4, 2016 /PRNewswire/ -- While Americans are redefining what it means to age well and stay healthy, many adults 50 and over are still feeling the effects of aging. AARP and Abbott surveyed 1,480 Americans aged 50 years and older and found tha
Read more →ABTWhat's the Secret to Living a Full Life? A New Global Survey Reveals Family Comes First If you have ever asked yourself, What makes me feel most fulfilled? you are not alone. Nearly 2 million people recently answered that question in a ...
ABBOTT PARK, Ill., April 26, 2016 /PRNewswire/ -- If you have ever asked yourself, "What makes me feel most fulfilled?" you are not alone. Nearly 2 million people recently answered that question in a new survey by Abbott, the global healthcare company. The goal of the survey was
Read more →ABTAbbott Introduces New Services and Tools to Help Labs Deliver Greater Operational Productivity Abbott (NYSE: ABT) today announced the global launch of AlinIQ, the first in a series of new innovations that Abbott will be bringing to diagnostics...
ABBOTT PARK, Ill., April 21, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the global launch of AlinIQ, the first in a series of new innovations that Abbott will be bringing to diagnostics customers around the world over the next few years. AlinIQ is a first-of-its-kin
Read more →ABTAbbott Reports First-Quarter 2016 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2016. Adjusted diluted EPS from continuing operations,...
ABBOTT PARK, Ill., April 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2016 . "We're off to a good start to the year and are raising our full-year adjusted EPS guidance range," said Miles D. White , chairman
Read more →ABTAbbott Launches EAS® Myoplex® Sports Nutrition Line Designed for Performance Abbott's (NYSE: ABT) EAS® Sports Nutrition is helping serious athletes train harder through nine redesigned Myoplex products that deliver the...
ABBOTT PARK, Ill., April 7, 2016 /PRNewswire/ -- Abbott's (NYSE: ABT ) EAS ® Sports Nutrition is helping serious athletes train harder through nine redesigned Myoplex products that deliver the nutrition athletes need before, during and after workouts. The new line, available now
Read more →ABTNew Research Shows Abbott's High Sensitive Troponin Test First to Measure Impact of Mental Stress on the Heart The stresses of life have long been thought to increase a person's risk of heart disease.3 But the question remains how to measure the impact of...
ABBOTT PARK, Ill., April 4, 2016 /PRNewswire/ -- The stresses of life have long been thought to increase a person's risk of heart disease. 3 But the question remains how to measure the impact of different types of stress on the heart. Now, new research conducted at Emory Universi
Read more →ABTAbbott Introduces Ensure® Enlive®, Pairing the Latest in Science and Nutrition to Improve Health People today are living and enjoying life longer– by 2050, the U.S. population over age 65 is projected to almost double to nearly 84 million.1 But...
ABBOTT PARK, Ill., March 29, 2016 /PRNewswire/ -- People today are living and enjoying life longer– by 2050, the U.S. population over age 65 is projected to almost double to nearly 84 million. 1 But as more than 60 percent of this group have two or more chronic conditions, 2 stay
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2016 financial results on Wednesday, April 20, 2016, before the market opens. The announcement...
ABBOTT PARK, Ill., March 28, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2016 financial results on Wednesday, April 20, 2016 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTAbbott's Absorb™, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee Abbott (NYSE: ABT) announced today that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with...
WASHINGTON , March 15, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting co
Read more →ABTAbbott to Present at Barclays Capital 2016 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Capital 2016 Global Healthcare Conference on Thursday, March 17, 2016. Brian Yoor, senior vice...
ABBOTT PARK, Ill., March 14, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Capital 2016 Global Healthcare Conference on Thursday, March 17, 2016 . Brian Yoor , senior vice president, finance and chief financial officer, will present at 9:15 a.m. Central ti
Read more →ABTAbbott, Hennepin County Medical Center and University of Minnesota Collaborate to Launch the Nation's Largest, Single-Center Prospective Study on Concussion and Traumatic Brain Injury According to the Centers for Disease Control and Prevention (CDC), every year, there are an estimated 2.2 million emergency department visits for...
ABBOTT PARK, Ill., March 9, 2016 /PRNewswire/ -- According to the Centers for Disease Control and Prevention (CDC), every year, there are an estimated 2.2 million emergency department visits for traumatic brain injuries (TBI).[1] For people with head injuries, quick evaluation an
Read more →ABTAbbott Declares 369th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26 cents per share. This marks the 369th consecutive...
ABBOTT PARK, Ill., Feb. 19, 2016 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 26 cents per share. This marks the 369 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTAbbott Receives Approval in Australia for FreeStyle® Libre--the Revolutionary Glucose Monitoring System for People with Diabetes Today, Abbott (NYSE:ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle®...
ABBOTT PARK, Ill., Feb. 16, 2016 /PRNewswire/ -- Today, Abbott (NYSE: ABT ) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle ® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technolo
Read more →ABTAbbott Introduces New 'Foodie' Inspired Snack Brand: Curate As snacks and smaller meals continue to be a big part of daily diets, people continue to look for snacks that are nutritious – made with wholesome,...
ABBOTT PARK, Ill., Feb. 9, 2016 /PRNewswire/ -- As snacks and smaller meals continue to be a big part of daily diets, people continue to look for snacks that are nutritious – made with wholesome, real food ingredients – but also have rich, complex flavors. With this in mind, Abbo
Read more →ABTChildren in Europe Now Have Access to First-Of-Its-Kind Diabetes Sensing Technology - Eliminates Routine Finger Pricks(i) Today, Abbott (NYSE: ABT) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system...
ABBOTT PARK, Ill., Feb. 4, 2016 /PRNewswire/ -- Today, Abbott (NYSE: ABT ) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old. ii This means that
Read more →ABTAbbott Reports Fourth-Quarter 2015 Results Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2015. Adjusted diluted EPS from continuing operations,...
ABBOTT PARK, Ill., Jan. 28, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter ended Dec. 31, 2015 . "In 2015, we achieved top-tier sales and earnings growth despite a challenging currency environment," said Miles D. White , chairma
Read more →ABTSpecialized nutrition supplement is associated with a 50 percent lower death rate in patients with heart or lung disease, new study shows Results from a new clinical trial show that a specialized oral nutrition supplement was associated with a 50 percent lower death rate in older...
ABBOTT PARK, Ill., Jan. 18, 2016 /PRNewswire/ -- Results from a new clinical trial show that a specialized oral nutrition supplement was associated with a 50 percent lower death rate in older malnourished patients with a heart or lung disease 90 days following hospitalization. Th
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2015 financial results on Thursday, Jan. 28, 2016, before the market opens. The...
ABBOTT PARK, Ill., Jan. 7, 2016 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2015 financial results on Thursday, Jan. 28, 2016 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2016. Brian Yoor, senior vice president, finance and...
ABBOTT PARK, Ill., Dec. 15, 2015 /PRNewswire/ -- Abbott will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11 , 2016. Brian Yoor, senior vice president, finance and chief financial officer, will make a formal presentation on the company at 10:30 am
Read more →ABTAbbott and UC San Francisco Discover New Virus is Linked to Hepatitis C Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2...
ABBOTT PARK, Ill., Dec. 11, 2015 /PRNewswire/ -- Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV). This r
Read more →ABTAbbott Raising Quarterly Dividend for 44th Straight Year The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly dividend to 26 cents per share from 24 cents per share. This...
ABBOTT PARK, Ill., Dec. 11, 2015 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly dividend to 26 cents per share from 24 cents per share. This marks the 368 th consecutive quarterly dividend to be paid by Abbott since 1924. Th
Read more →ABTAre We Doing Everything We Can For Malnourished Patients? An apple a day keeps the doctor away. It's an expression many people are familiar with, reinforcing the importance of good nutrition for a healthy...
ABBOTT PARK, Ill., Dec. 8, 2015 /PRNewswire/ -- "An apple a day keeps the doctor away." It's an expression many people are familiar with, reinforcing the importance of good nutrition for a healthy life. But for many older adults at nutritional risk, an apple a day isn't enough. I
Read more →ABTPesquisa inédita da Abbott revela que 52% dos brasileiros estão felizes atualmente, apenas 10% deles afirmam estar satisfeitos Você está feliz? Acha que vive em todo o seu potencial? O que te motiva? Família, amor, profissão? Para entender melhor a percepção que o brasileiro...
SÃO PAULO, 26 de novembro de 2015 /PRNewswire/ -- Você está feliz? Acha que vive em todo o seu potencial? O que te motiva? Família, amor, profissão? Para entender melhor a percepção que o brasileiro tem a respeito da própria vida, e o que almeja para ser mais feliz, a Abbott, emp
Read more →ABTHealth is a Marathon, not a Sprint Well known for its culture, theater, and cuisine, New York is also one of the 25 healthiest cities in the United States. It's this fitness side that...
ABBOTT PARK, Ill., Oct. 30, 2015 /PRNewswire/ -- Well known for its culture, theater, and cuisine, New York is also one of the 25 healthiest cities in the United States . It's this fitness side that will be on show this weekend with the TCS New York City Marathon. Photo - http:/
Read more →ABT'Science' Says Abbott Is a Top Employer The journal Science today recognized Abbott (NYSE: ABT) as a Top 20 Employer. The global healthcare company ranked No. 14 overall, receiving high...
ABBOTT PARK, Ill., Oct. 29, 2015 /PRNewswire/ -- The journal Science today recognized Abbott (NYSE: ABT ) as a Top 20 Employer . The global healthcare company ranked No. 14 overall, receiving high marks for social responsibility, employee loyalty, and having a work culture that a
Read more →ABTAbbott fait équipe avec la star du football Cristiano Ronaldo pour inciter les jeunes à faire un don de sang Le sang est un élément essentiel pour la vie, mais de nombreuses personnes n'y pensent seulement qu'au moment où le besoin est critique. Chaque...
REJOIGNEZ LE MOUVEMENT : #BETHE1DONOR À FAIRE DON DE SANG ET CONTRIBUER À SAUVER UNE VIE ABBOTT PARK , Illinois , 22 octobre 2015 /PRNewswire/ -- Le sang est un élément essentiel pour la vie, mais de nombreuses personnes n'y pensent seulement qu'au moment où le besoin est critiq
Read more →ABTAbbott se une al astro de fútbol Cristiano Ronaldo para inspirar a jóvenes a donar sangre La sangre es un componente esencial de la vida, sin embargo, muchas personas no piensan en ello hasta que tienen una necesidad crítica. Anualmente se ...
ABBOTT PARK , Illinois , 22 de octubre de 2015 /PRNewswire/ -- La sangre es un componente esencial de la vida, sin embargo, muchas personas no piensan en ello hasta que tienen una necesidad crítica. Anualmente se realizan 234 millones de operaciones mayores en todo el mundo, much
Read more →ABTAbbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire Young People to Donate Blood Blood is an essential component for life, but many people do not think about it until the need is critical. Each year 234 million major operations...
JOIN THE MOVEMENT: #BETHE1DONOR TO DONATE BLOOD AND POTENTIALLY HELP SAVE A LIFE ABBOTT PARK, Ill., Oct. 22, 2015 /PRNewswire/ -- Blood is an essential component for life, but many people do not think about it until the need is critical. Each year 234 million major operations ar
Read more →ABTAbbott se alia à estrela do futebol Cristiano Ronaldo para inspirar os jovens a doar sangue O sangue é um elemento essencial para a vida, mas muita gente não pensa sobre isso até que uma necessidade se torne crítica. A cada ano, 234 milhões...
JUNTE-SE AO MOVIMENTO #BETHE1DONOR PARA DOAR SANGUE E, POSSIVELMENTE, AJUDAR A SALVAR UMA VIDA ABBOTT PARK , Illinois , 22 de outubro de 2015 /PRNewswire/ -- O sangue é um elemento essencial para a vida, mas muita gente não pensa sobre isso até que uma necessidade se torne críti
Read more →ABTAbbott Teams, con la star del calcio Cristiano Ronaldo, uniti per stimolare i giovani a donare sangue Il sangue è una componente essenziale della vita, ma molte persone non se ne rendono conto fino a quando non diventa una necessità fondamentale. Ogni ...
ADERISCI AL MOVIMENTO #BETHE1DONOR PER DONARE SANGUE E FORSE SALVARE UNA VITA ABBOTT PARK , Illinois , 22 ottobre 2015 /PRNewswire/ -- Il sangue è una componente essenziale della vita, ma molte persone non se ne rendono conto fino a quando non diventa una necessità fondamentale.
Read more →ABTAbbott und Cristiano Ronaldo arbeiten zusammen, um junge Menschen zum Blut spenden anzuregen Blut ist DER Saft des Lebens, doch vielen Menschen wird dies erst bewusst, wenn die Lage kritisch ist. Jährlich werden weltweit 234 Millionen größere ...
JEDER KANN TEILNEHMEN: #BETHE1DONOR, UM BLUT ZU SPENDEN UND LEBEN ZU RETTEN ABBOTT PARK , Illinois , 22. Oktober 2015 /PRNewswire/ -- Blut ist DER Saft des Lebens, doch vielen Menschen wird dies erst bewusst, wenn die Lage kritisch ist. Jährlich werden weltweit 234 Millionen grö
Read more →ABTAbbott Reports Third-Quarter 2015 Results Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2015. Third-quarter worldwide sales of $5.2 billion...
ABBOTT PARK, Ill., Oct. 21, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2015 . "Despite currency headwinds, we are on track to deliver the financial commitments we set at the beginning of the year," said Miles
Read more →ABTCristiano Ronaldo é embaixador do movimento mundial para a doação de sangue: #BeThe1Donor O sangue é um componente essencial para a vida, mas a maioria das pessoas não o valoriza até ser realmente necessário. Todos os anos são efetuadas...
- Movimento lançado para inspirar jovens em todo mundo para a doação regular de sangue e ajudar potencialmente a salvar uma vida. - Ligue-se a este movimento usando #BeThe1Donor ou através do Facebook em https://www.facebook.com/bethe1donor . ABBOTT PARK , Illinois , 22 de outu
Read more →ABTAbbott colabora con la estrella del fútbol Cristiano Ronaldo para alentar a los jóvenes a donar sangre La sangre es un componente fundamental para la vida, sin embargo mucha gente no piensa en ello hasta que la necesidad es crucial. Cada año, se...
ÚNATE AL MOVIMIENTO: #BETHE1DONOR PARA DONAR SANGRE Y CONTRIBUIR A SALVAR UNA VIDA ABBOTT PARK , Illinois , 22 de octubre de 2015 /PRNewswire/ -- La sangre es un componente fundamental para la vida, sin embargo mucha gente no piensa en ello hasta que la necesidad es crucial. Cad
Read more →ABTNew York Road Runners and Abbott Partner for 2015 TCS New York City Marathon New York Road Runners and global healthcare company Abbott (NYSE: ABT) will partner for the 2015 TCS New York City Marathon, set for Sunday, Nov. 1....
NEW YORK , Oct. 15, 2015 /PRNewswire/ -- New York Road Runners and global healthcare company Abbott (NYSE: ABT ) will partner for the 2015 TCS New York City Marathon, set for Sunday, Nov. 1 . The partnership complements Abbott's existing title sponsorship of the global Abbott Wor
Read more →ABTAbbott Announces Positive Clinical Results of Absorb™, the Naturally Dissolving Heart Stent Abbott (NYSE: ABT) announced today positive one-year clinical results from the ABSORB III trial, which compared the safety and effectiveness of...
SAN FRANCISCO , Oct. 12, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today positive one-year clinical results from the ABSORB III trial, which compared the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ® , Abbott's market-leading, meta
Read more →ABTAbbott Celebrates Living Fully Through the Power of Health as an Official Sponsor of the 2015 Bank of America Chicago Marathon In its second year as an Official Sponsor of the Bank of America Chicago Marathon, Abbott (NYSE: ABT) will again demonstrate its commitment to...
ABBOTT PARK, Ill., Oct. 1, 2015 /PRNewswire/ -- In its second year as an Official Sponsor of the Bank of America Chicago Marathon, Abbott (NYSE: ABT ) will again demonstrate its commitment to helping people achieve their goals through good health. From experienced runners and whe
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2015 financial results on Wednesday, Oct. 21, 2015, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 30, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2015 financial results on Wednesday, Oct. 21, 2015 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTWhat Does It Mean to Live Fully? What does it look like to really live a full life – one that enriches and satisfies, that provides happiness and enables achievement? Abbott is...
ABBOTT PARK, Ill., Sept. 22, 2015 /PRNewswire/ -- What does it look like to really live a full life – one that enriches and satisfies, that provides happiness and enables achievement? Abbott is talking to one million people worldwide to find out. And the answers aren't as simple
Read more →ABTAbbott Marks 15 Years of Helping Career-Minded Moms Reach Their Full Professional Potential Abbott's (NYSE: ABT) commitment to support working mothers with progressive benefits and extraordinary career opportunities was recognized today by...
ABBOTT PARK, Ill., Sept. 22, 2015 /PRNewswire/ -- Abbott's (NYSE: ABT ) commitment to support working mothers with progressive benefits and extraordinary career opportunities was recognized today by Working Mother magazine. Abbott has been a mainstay on Working Mother's "100 Best
Read more →ABTAbbott Declares 367th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 24 cents per share. This marks the 367th consecutive...
ABBOTT PARK, Ill., Sept. 17, 2015 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 24 cents per share. This marks the 367 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Named Industry Leader for Responsible and Sustainable Business for Three Consecutive Years on the Dow Jones Sustainability Index (DJSI) For the third consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI),...
ABBOTT PARK, Ill., Sept. 10, 2015 /PRNewswire/ -- For the third consecutive year, Abbott (NYSE: ABT ) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate responsibility and su
Read more →ABTAbbott Completes Acquisition of Tendyne Holdings, Inc. Abbott (NYSE: ABT) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on...
ABBOTT PARK, Ill., Sept. 2, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Abbott acquired the
Read more →ABTAbbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and...
LONDON , Sept. 1, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ® , Abbott's market-
Read more →ABTNew Concussion Survey Reveals Majority of Adults are Unable to Recognize Common Concussion Symptoms With students heading back to school and the fall sports season approaching, surprising new data from Abbott's Concussion IQ Survey reveals that a...
ABBOTT PARK, Ill., Aug. 24, 2015 /PRNewswire/ -- With students heading back to school and the fall sports season approaching, surprising new data from Abbott's Concussion IQ Survey reveals that a large number of adults in the United States lack basic understanding about concussio
Read more →ABTAbbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions Abbott (NYSE: ABT) announced today that it has entered into an agreement to purchase Tendyne Holdings, Inc., a private medical device company focused ...
ABBOTT PARK, Ill., July 30, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has entered into an agreement to purchase Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Under the t
Read more →ABTAbbott Partners with the 2015 BMW BERLIN-MARATHON to Celebrate the Power of Health The organizers of the BMW BERLIN-MARATHON today proudly announced a new partnership with the global healthcare company Abbott (NYSE: ABT), which...
BERLIN , July 24, 2015 /PRNewswire/ -- The organizers of the BMW BERLIN -MARATHON today proudly announced a new partnership with the global healthcare company Abbott (NYSE: ABT ), which became an Official Sponsor of the 2015 BMW BERLIN -MARATHON, one of six iconic races in the Ab
Read more →ABTAbbott Reports Second-Quarter 2015 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2015. Second-quarter worldwide sales of $5.2 billion...
ABBOTT PARK, Ill., July 22, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2015 . Second-quarter worldwide sales of $5.2 billion increased 10.8 percent on an operational basis and 2.2 percent on a reported basis.
Read more →ABTAbbott's iDesign System Creates 3-D Map of the Eye for Precise, Personalized LASIK Vision Treatment Abbott (NYSE: ABT) announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The...
ABBOTT PARK, Ill., July 20, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2015 financial results on Wednesday, July 22, 2015, before the market opens. The announcement...
ABBOTT PARK, Ill., July 1, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2015 financial results on Wednesday, July 22, 2015 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra
Read more →ABTAbbott Affirms its Support for Mylan Standalone Strategy and Will Vote its Mylan Shares in Favor of Mylan's Proposed Acquisition of Perrigo Abbott (NYSE: ABT) today confirmed its continued support for Mylan N.V's growth strategy by stating its intent to vote its 14.5 percent stake in...
ABBOTT PARK, Ill., June 16, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) today confirmed its continued support for Mylan N.V's growth strategy by stating its intent to vote its 14.5 percent stake in Mylan in favor of Mylan's proposed acquisition of Perrigo. "We chose Mylan to acquir
Read more →ABTAbbott Declares 366th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 24 cents per share. This marks the 366th consecutive...
ABBOTT PARK, Ill., June 12, 2015 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 24 cents per share. This marks the 366 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTAbbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease Abbott announced today that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1™, which combines the...
PARIS , May 19, 2015 /PRNewswire/ -- Abbott announced today that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1 ™ , which combines the world's first fully dissolving stent with a next-generation delivery catheter to help doctors t
Read more →ABTAbbott's First-of-its-Kind Blood Test to Aid in Detecting Early Pregnancy Could Help Doctors Make Faster Treatment Decisions for Women Women account for nearly 60 percent of visits to emergency departments (ED) in the United States.1 In emergency situations, it is critical for...
Traditionally, clinicians rely on urine-based pregnancy testing, but collecting a sample from a woman in an emergency setting can be difficult, especially if she is dehydrated, in pain or even unconscious. Now, a simple new blood test, known as the i-STAT ® Total β-hCG, can rapi
Read more →ABTAbbott Reports First-Quarter 2015 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2015. First-quarter worldwide sales of $4.9 billion...
ABBOTT PARK, Ill., April 22, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2015 . "We're off to a good start this year, with particularly strong performance in our branded generics, international nutrition and gl
Read more →ABTNew Blood Glucose Meter Provides People with Diabetes an Accurate, Affordable Solution for Glucose Testing-Without Insurance Copays The cost of insurance premiums and employee medical claims continues to rise in the United States, which is especially challenging for people living...
ABBOTT PARK, Ill., April 15, 2015 /PRNewswire/ -- The cost of insurance premiums and employee medical claims continues to rise in the United States , which is especially challenging for people living with chronic conditions such as diabetes. For people with diagnosed diabetes, av
Read more →ABTAbbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide Today, Abbott (NYSE: ABT) and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests...
ABBOTT PARK, Ill., April 14, 2015 /PRNewswire/ -- Today, Abbott (NYSE: ABT ) and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of ex
Read more →ABTBoston Athletic Association And Abbott Announce Multiple-Year Sponsorship Of The Boston Marathon The Boston Athletic Association (B.A.A.) today proudly announced the beginning of a robust sponsorship agreement with global healthcare company...
BOSTON , April 13, 2015 /PRNewswire/ -- The Boston Athletic Association (B.A.A.) today proudly announced the beginning of a robust sponsorship agreement with global healthcare company Abbott (NYSE: ABT ) to become an Official Sponsor of the Boston Marathon. Abbott, devoted to de
Read more →ABTFirst-of-its-Kind Diabetes Technology Revolutionizes How Glucose Data is Collected and Analyzed for People in India India has the third highest population of obesity, trailing only the United States and China.[1] Nutrition, lifestyle and demographic transitions in...
ABBOTT PARK, Ill., April 2, 2015 /PRNewswire/ -- India has the third highest population of obesity, trailing only the United States and China.[1] Nutrition, lifestyle and demographic transitions in India have led to a decline in overall health[2]—and for many, that also means a r
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2015 financial results on Wednesday, April 22, 2015, before the market opens. The announcement...
ABBOTT PARK, Ill., April 1, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2015 financial results on Wednesday, April 22, 2015 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott's MitraClip® System Shown to Mend Hearts and Improve Lives in People in the United States About three years ago, Betty Vaughn of Golden Valley, Minn., started to feel light-headed, fatigued and out of breath when she walked up and down the ...
SAN DIEGO , March 15, 2015 /PRNewswire/ -- About three years ago, Betty Vaughn of Golden Valley, Minn. , started to feel light-headed, fatigued and out of breath when she walked up and down the stairs. After visiting her doctor, the 89-year-old was diagnosed with degenerative mit
Read more →ABTAbbott Declares 365th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 24 cents per share. This marks the 365th consecutive...
ABBOTT PARK, Ill., Feb. 20, 2015 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 24 cents per share. This marks the 365 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTAbbott to Present at Cowen and Company 35th Annual Health Care Conference Abbott (NYSE: ABT) will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015. Scott White, senior vice...
ABBOTT PARK, Ill., Feb. 19, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 . Scott White , senior vice president, international nutrition, and Brian Yoor , vice president, investor relati
Read more →ABTAbbott to Present at Leerink Global Healthcare Conference Abbott (NYSE: ABT) will present at the Leerink Global Healthcare Conference on Thursday, Feb. 12, 2015. Thomas C. Freyman, executive vice president,...
ABBOTT PARK, Ill., Feb. 4, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Leerink Global Healthcare Conference on Thursday, Feb. 12 , 2015. Thomas C. Freyman, executive vice president, finance and chief financial officer, will present at 1:15 p.m. Central time . A
Read more →ABTAbbott Launches New Options for People with Cataracts in the United States Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS® Multifocal...
ABBOTT PARK, Ill., Jan. 30, 2015 /PRNewswire/ -- Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States . The new TECNIS ® Multifocal IOLs, developed by Abbott (NYSE: ABT ), provide people with cataracts options to ha
Read more →ABTAbbott Reports Fourth-Quarter 2014 Results Abbott today announced financial results for the fourth quarter ended Dec. 31, 2014. Diluted EPS, excluding specified items, was $0.71 in the fourth...
ABBOTT PARK, Ill., Jan. 29, 2015 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2014 . "We ended 2014 with good momentum, well positioned for a step-up in operational sales growth in 2015," said Miles D. White , chairman and chief
Read more →ABTAbbott Announces Results of Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022 Abbott (NYSE: ABT) announced today the results of the tender offer and related consent solicitation commenced by its wholly-owned subsidiary, Abbott...
ABBOTT PARK, Ill., Jan. 15, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the results of the tender offer and related consent solicitation commenced by its wholly-owned subsidiary, Abbott Laboratories ( Chile ) Holdco (Dos) SpA, a Chilean corporation ("ALH"), to purcha
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter and Full-Year 2014 Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2014 financial results on Thursday, Jan. 29, 2015, before the market opens. The...
ABBOTT PARK, Ill., Jan. 8, 2015 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2014 financial results on Thursday, Jan. 29, 2015 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at
Read more →ABTAbbott Announces Early Results of Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022 Abbott (NYSE: ABT) today reported early results for the tender offer and related consent solicitation commenced by its wholly-owned subsidiary,...
ABBOTT PARK, Ill., Dec. 30, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today reported early results for the tender offer and related consent solicitation commenced by its wholly-owned subsidiary, Abbott Laboratories ( Chile ) Holdco (Dos) SpA, a Chilean corporation ("ALH"), to purc
Read more →ABTAbbott Completes Acquisition of Topera, Inc. Abbott (NYSE: ABT) today announced that it has completed its acquisition of Topera, Inc., a private, venture-backed medical device company focused on ...
ABBOTT PARK, Ill., Dec. 22, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has completed its acquisition of Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis an
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2015. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Dec. 18, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12 , 2015. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on t
Read more →ABTAbbott Commences Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022 Abbott (NYSE: ABT) today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ( ALH ), has ...
ABBOTT PARK, Ill., Dec. 15, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its wholly-owned subsidiary, Abbott Laboratories ( Chile ) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Notes Offer"), in which it is offering to
Read more →ABTAbbott Completes Acquisition of Veropharm Abbott (NYSE: ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a...
ABBOTT PARK, Ill., Dec. 12, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to gr
Read more →ABTAbbott Announces Increase in Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. This...
ABBOTT PARK, Ill., Dec. 12, 2014 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. This marks the 364 th consecutive quarterly dividend to be paid by Abbott since 1924. T
Read more →ABTIRIDICA, la plataforma de pruebas pionera de Abbott para enfermedades infecciosas, ya está disponible en Europa Abbott anunció hoy que su innovadora plataforma de diagnóstico, denominada IRIDICA, ya está disponible en Europa y en otros países en los que se...
- IRIDICA puede cambiar la forma de detectar e identificar las causas de infecciones graves como la sepsis y la neumonía - Puede suministrar a los médicos la información necesaria para iniciar en menos tiempo el tratamiento adecuado para pacientes gravemente enfermos - Puede ay
Read more →ABTAbbott's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe Abbott (NYSE: ABT) today announced its innovative diagnostic platform, known as IRIDICA, is now available in Europe and other CE-Mark recognized...
ABBOTT PARK, Ill., Dec. 11, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced its innovative diagnostic platform, known as IRIDICA, is now available in Europe and other CE-Mark recognized countries. The new platform can identify more than 1,000 infection-causing pathogens
Read more →ABTAbbotts wegweisende Plattform für die Diagnostik von Infektionskrankheiten, IRIDICA, jetzt auch in Europa Abbott kündigte heute an, dass seine innovative Diagnoseplattform IRIDICA jetzt in Europa und anderen Staaten mit CE-Kennzeichnung zugänglich ist....
- IRIDICA hat das Potenzial, die Art und Weise zu ändern, wie Pathogene, die schwere Infektionen wie Sepsis und Pneumonie auslösen, erkannt und identifiziert werden. - Kann Ärzten die nötigen Informationen liefern, die zu einem früheren Behandlungsbeginn Schwerkranker mit geeign
Read more →ABTLa plate-forme d'Abbott, IRIDICA, pionnière en matière d'analyses des maladies infectieuses désormais disponible en Europe - IRIDICA est capable de changer la façon de détecter et d'identifier les causes d'infections graves, comme la septicémie et la pneumonie, en...
- IRIDICA est capable de changer la façon de détecter et d'identifier les causes d'infections graves, comme la septicémie et la pneumonie, en réanimation - Elle peut fournir aux médecins des informations essentielles pour commencer à traiter plus rapidement les patients, graveme
Read more →ABTImpact of Malnutrition in U.S. at $157 Billion Annually Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of...
ABBOTT PARK, Ill., Dec. 4, 2014 /PRNewswire/ -- Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition 1 . Because of the impact on patient health, disease-associated mal
Read more →ABTPeople with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment...
ABBOTT PARK, Ill., Nov. 17, 2014 /PRNewswire/ -- People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances
Read more →ABTAbbott to Present at Credit Suisse 2014 Healthcare Conference Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Nov. 4, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a formal presentation on t
Read more →ABTAbbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market Abbott (NYSE: ABT) today announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company...
ABBOTT PARK, Ill., Oct. 29, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the dia
Read more →ABTAbbott Reports Third-Quarter 2014 Results Abbott today announced financial results for the third quarter ended Sept. 30, 2014. Diluted EPS, excluding specified items, was $0.62 in the third...
ABBOTT PARK, Ill., Oct. 22, 2014 /PRNewswire/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2014 . "We reported another quarter of sequential sales growth, including improved performance in our branded generics pharmaceuticals and nutrition bu
Read more →ABTNew Large-Scale Study Will Look at How Nutrition Can Help Keep Patients from Returning to the Hospital At a time when hospitals are under increasing pressure to improve patient outcomes, Advocate Health Care -- one of the nation's leading health...
ABBOTT PARK, Ill., Oct. 20, 2014 /PRNewswire/ -- At a time when hospitals are under increasing pressure to improve patient outcomes, Advocate Health Care -- one of the nation's leading health systems -- is embarking on a major research program with Abbott (NYSE: ABT ) to demonstr
Read more →ABTAbbott Acknowledged by Science Magazine as a Top Employer Abbott (NYSE: ABT) today was named one of the Top 20 Employers by the journal Science. The global healthcare company ranked No. 12 overall, receiving ...
ABBOTT PARK, Ill., Oct. 16, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today was named one of the Top 20 Employers by the journal Science. The global healthcare company ranked No. 12 overall, receiving high marks for treating employees with respect and social responsibility. This
Read more →ABTAbbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors Abbott (NYSE: ABT) and the World Marathon Majors announced a new partnership with Abbott becoming the race series' first-ever title sponsor. The...
ABBOTT PARK, Ill., Oct. 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) and the World Marathon Majors announced a new partnership with Abbott becoming the race series' first-ever title sponsor. The series – comprising six of the largest and most renowned marathons in the world: Toky
Read more →ABTAbbott Goes Extra Mile in Commitment to Helping People Live Healthy Lives as an Official Sponsor of 2014 Bank of America Chicago Marathon Abbott (NYSE: ABT) today announced a new partnership with the 2014 Bank of America Chicago Marathon, underscoring the company's commitment to helping ...
ABBOTT PARK, Ill., Oct. 1, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced a new partnership with the 2014 Bank of America Chicago Marathon, underscoring the company's commitment to helping people achieve their goals through good health. Abbott's presence throughout the
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2014 financial results on Wednesday, Oct. 22, 2014, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Oct. 1, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2014 financial results on Wednesday, Oct. 22, 2014 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central
Read more →ABTAbbott culmina la adquisición de CFR Pharmaceuticals y anuncia los resultados de la OPA de las acciones de CFR Abbott ha adquirido el control de CFR Pharmaceuticals, duplicando con creces su presencia en el mercado de farmacéuticos genéricos de marca en...
ABBOTT PARK , Illinois , 26 de septiembre de 2014 /PRNewswire/ -- Abbott ha adquirido el control de CFR Pharmaceuticals, duplicando con creces su presencia en el mercado de farmacéuticos genéricos de marca en Latinoamérica y expandiendo aún más la presencia de la empresa en estos
Read more →ABTAbbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares Abbott (NYSE: ABT) has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and...
ABBOTT PARK, Ill., Sept. 26, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. Through purchase
Read more →ABTExpiration of the U.S. Tender Offer for CFR Pharmaceuticals S.A. Abbott today announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a...
ABBOTT PARK, Ill., Sept. 24, 2014 /PRNewswire/ -- Abbott today announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation, and for the purchase from all holders, wherever resident, of C
Read more →ABTAbbott Included In Top 10 Best Companies by Working Mother Magazine Abbott's (NYSE: ABT) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The...
ABBOTT PARK, Ill., Sept. 16, 2014 /PRNewswire/ -- Abbott's (NYSE: ABT ) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The healthcare company was named among the Top 10 companies in Working Mother 's 100 Be
Read more →ABTAbbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more...
ABBOTT PARK, Ill., Sept. 15, 2014 /PRNewswire/ -- Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent,
Read more →ABTABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the...
WASHINGTON , Sept. 14, 2014 /PRNewswire/ -- Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leadin
Read more →ABTAbbott Announces New $3 Billion Share Repurchase Program, Declares Dividend Abbott's (NYSE: ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend. Abbott's board has...
ABBOTT PARK, Ill., Sept. 11, 2014 /PRNewswire/ -- Abbott's (NYSE: ABT ) board of directors has approved a new share repurchase program and declared a quarterly common dividend. Abbott's board has authorized the repurchase of up to $3 billion of the corporation's common shares. T
Read more →ABTAbbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI) For the second consecutive year, Abbott (NYSE: ABT) was named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one...
ABBOTT PARK, Ill., Sept. 11, 2014 /PRNewswire/ -- For the second consecutive year, Abbott (NYSE: ABT ) was named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate responsibility and sustai
Read more →ABTNew Abbott Technology May Uncover the Root of Critical Infections and Cut Health Care Costs A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people...
WASHINGTON , Sept. 8, 2014 /PRNewswire/ -- A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million).[1] Th
Read more →ABTAbbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a...
ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system
Read more →ABTAbbott Commences Tender Offer for All Outstanding Ordinary Shares and American Depositary Shares of CFR Pharmaceuticals S.A. Abbott (NYSE: ABT) today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ( ALH ), has ...
ABBOTT PARK, Ill., Aug. 25, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that its wholly-owned subsidiary, Abbott Laboratories ( Chile ) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Offer"), in which it is offering to purcha
Read more →ABTAccess to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage Determination The Centers for Medicare & Medicaid Services (CMS) recently issued a National Coverage Determination (NCD) that extends coverage for Medicare...
ABBOTT PARK, Ill., Aug. 12, 2014 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) recently issued a National Coverage Determination (NCD) that extends coverage for Medicare beneficiaries in the United States to Transcatheter Mitral Valve Repair with Abbott's (NY
Read more →ABTAbbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment. To help laboratories ...
ABBOTT PARK, Ill., July 28, 2014 /PRNewswire/ -- Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment. To help laboratories with increasing demands, Abbott (NYSE: ABT ) is developing diagnostic solutions f
Read more →ABTAbbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E Nutrition needs are greater when breastfeeding than any other time in a woman's life, including pregnancy, yet new research reveals diet alone may...
ABBOTT PARK, Ill., July 24, 2014 /PRNewswire/ -- Nutrition needs are greater when breastfeeding than any other time in a woman's life, including pregnancy, yet new research reveals diet alone may not be enough to meet the high nutritional needs during this important time for mom
Read more →ABTAbbott Reports Second-Quarter 2014 Results Abbott today announced financial results for the second quarter ended June 30, 2014. Ongoing diluted EPS was $0.54 in the second quarter,...
ABBOTT PARK, Ill., July 16, 2014 /PRNewswire/ -- Abbott today announced financial results for the second quarter ended June 30, 2014 . "We're ahead of our expectations through the first half of the year and are raising our EPS guidance range as we continue to shape the company f
Read more →ABTAbbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of ...
ABBOTT PARK, Ill., July 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's d
Read more →ABTAbbott Builds Long-Term Commitment in China Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE:...
ABBOTT PARK, Ill., July 10, 2014 /PRNewswire/ -- Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT ) has made in China , deepening its commitment in the country. In June, Abbott op
Read more →ABTAbbott and Fonterra to Form Strategic Alliance for Dairy Farming in China Abbott (NYSE: ABT) and Fonterra Co-operative Group Ltd today announced the signing of an agreement to develop a proposed dairy farm hub in China. The ...
ABBOTT PARK, Ill. and AUCKLAND, New Zealand , July 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) and Fonterra Co-operative Group Ltd today announced the signing of an agreement to develop a proposed dairy farm hub in China . The strategic alliance, which is subject to Chinese regu
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2014 financial results on Wednesday, July 16, 2014, before the market opens. The announcement...
ABBOTT PARK, Ill., June 25, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2014 financial results on Wednesday, July 16, 2014 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Receives CE Mark for TECNIS® Symfony Extended Range of Vision Intraocular Lens for Cataract Patients Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the TECNIS® Symfony Extended Range of Vision...
ABBOTT PARK, Ill., June 24, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received CE Marking (Conformite Europeenne) in Europe for the TECNIS ® Symfony Extended Range of Vision intraocular lens (IOL) for the treatment of cataract patients who may also have a di
Read more →ABTAbbott to Acquire Veropharm Abbott (NYSE: ABT) today announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the ...
ABBOTT PARK, Ill., June 23, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holdi
Read more →ABTAbbott Declares 362nd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 22 cents per share. This marks the 362nd consecutive...
ABBOTT PARK, Ill., June 13, 2014 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 22 cents per share. This marks the 362 nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug
Read more →ABTAbbott to Present at William Blair 34th Annual Growth Stock Conference Abbott (NYSE: ABT) will present at the William Blair 34th Annual Growth Stock Conference on Wednesday, June 11, 2014. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., June 4, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the William Blair 34 th Annual Growth Stock Conference on Wednesday, June 11, 2014 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will present at 4:40 p.m. Ce
Read more →ABTAbbott Expands Latin American Presence and Branded Generics Portfolio with Acquisition of CFR Pharmaceuticals Abbott (NYSE: ABT) today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling...
ABBOTT PARK, Ill., May 16, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Ab
Read more →ABTPromising Preliminary Data Show Abbott's Innovative Testing Platform May Identify Life-Threatening Infections Faster Than Current Methods Abbott (NYSE: ABT) today announced initial results that suggest its innovative testing platform, known as IRIDICA (currently in development),...
BARCELONA, Spain , May 12, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced initial results that suggest its innovative testing platform, known as IRIDICA (currently in development), produces results consistent with the current standard of care in just hours. Currently, t
Read more →ABTAbbott Facility Receives Top International Award for Operational Excellence Abbott (NYSE: ABT) has been awarded the Shingo Prize, an international award for operational excellence, by the Shingo Institute at the Jon M....
ABBOTT PARK, Ill., May 8, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) has been awarded the Shingo Prize, an international award for operational excellence, by the Shingo Institute at the Jon M. Huntsman School of Business at Utah State University . Abbott's vascular devices manufact
Read more →ABTAbbott Reports First-Quarter 2014 Results Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2014. Ongoing diluted EPS was $0.41 in the first quarter,...
ABBOTT PARK, Ill., April 16, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2014 . "We are off to a good start, and we continue to expect accelerating performance beginning in the second quarter as we target anoth
Read more →ABTAbbott Announces FDA Clearance for a New Test to Help Physicians Quickly and Accurately Diagnose Diabetes Abbott (NYSE: ABT) announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and ...
ABBOTT PARK, Ill., April 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has receiv
Read more →ABTAbbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™...
ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States , Japan and China . Co
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2014 financial results on Wednesday, April 16, 2014, before the market opens. The announcement...
ABBOTT PARK, Ill., April 1, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2014 financial results on Wednesday, April 16, 2014 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with...
ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ -- Abbott today announced that its Supera ® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).
Read more →ABTAbbott Declares 361st Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 22 cents per share. (Photo:...
ABBOTT PARK, Ill., Feb. 21, 2014 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 22 cents per share. (Photo: http://photos.prnewswire.com/prnh/20140221/CG69503-INFO ) This marks the 361 st consecutive quarterly dividen
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter and Full-Year 2013 Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2013 financial results on Wednesday, Jan. 22, 2014, before the market opens. The...
ABBOTT PARK, Ill., Jan. 6, 2014 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2013 financial results on Wednesday, Jan. 22, 2014 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2014. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Dec. 19, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2014 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a formal presentation on
Read more →ABTA Space Age View into Human Vision: Abbott's iDesign Dx System Now Available for U.S. Ophthalmologists and Patients With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in...
ABBOTT PARK, Ill., Dec. 17, 2013 /PRNewswire/ -- With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second scan to determine the patient's visual abnormalities. This highly
Read more →ABTAbbott Named Top Dealmaker for Sixth Consecutive Year by The Deal The Deal, a business unit of TheStreet, has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the sixth consecutive year....
ABBOTT PARK, Ill., Nov. 18, 2013 /PRNewswire/ -- The Deal , a business unit of TheStreet, has named Abbott (NYSE: ABT ) as one of its Most Admired Corporate Dealmakers for the sixth consecutive year. Abbott was recognized by The Deal as the best all-around dealmaker in healthcare
Read more →ABTExperience ″A Day in the Life″ of an Insulin-using Patient with Diabetes through Interactive Infographic In honor of World Diabetes Day, Abbott has created an interactive infographic to help raise awareness about what life can be like for an...
ABBOTT PARK, Ill., Nov. 14, 2013 /PRNewswire/ -- In honor of World Diabetes Day, Abbott has created an interactive infographic to help raise awareness about what life can be like for an insulin-using patient who has diabetes. (Photo: http://photos.prnewswire.com/prnh/20131114/AQ
Read more →ABTAbbott Supports Relief Efforts in the Philippines Abbott (NYSE: ABT) and its philanthropic foundation the Abbott Fund are providing $450,000 in grants and healthcare products to deliver immediate...
ABBOTT PARK, Ill., Nov. 13, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) and its philanthropic foundation the Abbott Fund are providing $450,000 in grants and healthcare products to deliver immediate relief to the Philippines in the aftermath of Typhoon Haiyan. The Abbott Fund is pro
Read more →ABTTiesto Teams Up with Music Saves Lives® and Abbott to Encourage Young People to Donate Blood With advances in medical treatments and an aging population, the demand for donated blood continues, as fewer people are becoming lifelong donors.2...
ABBOTT PARK, Ill., Nov. 12, 2013 /PRNewswire/ -- With advances in medical treatments and an aging population, the demand for donated blood continues, as fewer people are becoming lifelong donors. 2 In an effort to raise awareness about blood donation and encourage young adults to
Read more →ABTSimilac® Partners with National Association of Hispanic Nurses® to Launch StrongMoms® Español (NYSE: ABT) – With Hispanic babies now accounting for more than 25 percent of births in the United States according to the U.S. Census, there is an...
Similac, the number one infant formula brand in the U.S., is trying to meet that resource need with the launch of StrongMoms Español, a free program that provides Hispanic moms relevant, Spanish-language resources that can help them give their babies a great nutritional start, wh
Read more →ABTPartners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti Partners In Health (PIH), Abbott and its foundation, the Abbott Fund, today announced the opening of a new nutrition production facility in the...
CORPORANT, Haiti , Nov. 6, 2013 /PRNewswire/ -- Partners In Health (PIH), Abbott and its foundation, the Abbott Fund, today announced the opening of a new nutrition production facility in the Central Plateau in Haiti . The centerpiece of a broader partnership between PIH, Abbott
Read more →ABTAbbott's MitraClip® Treatment Demonstrates Positive Results for Patients with Degenerative Mitral Regurgitation at Prohibitive Risk for Surgery Abbott today announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional...
ABBOTT PARK, Ill., Oct. 30, 2013 /PRNewswire/ -- Abbott today announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional improvements for patients treated with the company's first-in-class, catheter-based MitraCl
Read more →ABTAbbott's First-In-Class MitraClip® Device Now Available for U.S. Patients Abbott today announced that its first-in-class, catheter-based MitraClip® therapy has received U.S. Food and Drug Administration (FDA) approval and...
ABBOTT PARK, Ill., Oct. 25, 2013 /PRNewswire/ -- Abbott today announced that its first-in-class, catheter-based MitraClip ® therapy has received U.S. Food and Drug Administration (FDA) approval and will launch immediately in the United States , providing physicians with a breakth
Read more →ABTAbbott Again Recognized by Science Magazine as One of the Top Employers in the Healthcare Industry Abbott (NYSE: ABT) today was again named one of the Top 20 Employers by the journal Science. The annual survey is based on the views of working...
ABBOTT PARK, Ill., Oct. 24, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today was again named one of the Top 20 Employers by the journal Science. The annual survey is based on the views of working scientists and identifies companies with the best reputations as employers. Abbott ra
Read more →ABTNew Study Demonstrates Importance of Oral Nutritional Supplements in Helping Hospitals Achieve Medicare Readmission Reduction Requirements (NYSE: ABT) – In the U.S., one in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually.i To...
ABBOTT PARK, Ill., Oct. 18, 2013 /PRNewswire/ -- (NYSE: ABT ) – In the U.S., one in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually. i To reduce this impact, the Affordable Care Act (ACA) has introduced hospital penaltie
Read more →ABTAbbott Reports Third-Quarter 2013 Results Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter adjusted diluted EPS was $0.55, above the previous ...
ABBOTT PARK, Ill., Oct. 16, 2013 /PRNewswire/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2013 . "We continued to have strong earnings performance, in spite of a supplier recall that impacted our International Nutrition business," said Miles
Read more →ABTNew Study Shows Oral Nutritional Supplement Use in Pediatric Inpatients Is Associated with Decreases in Length of Hospital Stay, Costs (NYSE: ABT) – A new study has found that the use of oral nutritional supplements provided to pediatric patients during hospitalization was associated ...
The 11-year retrospective study (2000-2010) was analyzed using the Premier Research Database, which contains data on more than half a million hospitalized pediatric cases for patients aged 2 to 8 years. This study is the latest in health economics and outcomes research to illustr
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2013 financial results on Wednesday, Oct. 16, 2013, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 25, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2013 financial results on Wednesday, Oct. 16, 2013 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™ Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone ...
ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System ™ . The new icon-driven system provides sleek design, visual
Read more →ABTAbbott Ranked Among Top 10 Best Companies by Working Mother Magazine Abbott (NYSE: ABT) today was named among the Top 10 companies in Working Mother magazine's 100 Best Companies list. This is the thirteenth...
ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today was named among the Top 10 companies in Working Mother magazine's 100 Best Companies list. This is the thirteenth consecutive year that Abbott has been included in the prestigious ranking, which recognize
Read more →ABTAbbott Named the Leading Healthcare Company on the Dow Jones Sustainability Index (DJSI) Abbott (NYSE: ABT) announced today that it was named an Industry Group Leader in the 2013 Dow Jones Sustainability Index (DJSI), one of the most...
ABBOTT PARK, Ill., Sept. 12, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it was named an Industry Group Leader in the 2013 Dow Jones Sustainability Index (DJSI), one of the most prestigious benchmarks for worldwide corporate sustainability. As the leader in the
Read more →ABTAbbott Declares 359th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 14 cents per share. This marks the 359th consecutive...
ABBOTT PARK , Ill. , Sept. 12, 2013 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 14 cents per share. This marks the 359 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable
Read more →ABTNew Data Suggests Abbott's High Sensitive Troponin Test May Help Doctors More Accurately Diagnose Heart Attacks in Women Abbott (NYSE: ABT) announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive...
AMSTERDAM , Sept. 4, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presentin
Read more →ABTOral Nutritional Supplements in the Hospital Demonstrate Significant Health and Cost Benefits in New Research Abbott (NYSE: ABT) A recent health economics and outcomes study, conducted by leading health economists and supported by Abbott, found that oral...
ABBOTT PARK, Ill., Aug. 30, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) A recent health economics and outcomes study, conducted by leading health economists and supported by Abbott , found that oral nutritional supplements provided to patients during hospitalization were associated
Read more →ABTAbbott Completes Acquisition of IDEV Technologies Abbott (NYSE: ABT) today announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing...
ABBOTT PARK, Ill., Aug. 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeon
Read more →ABTAbbott Completes Acquisition of OptiMedica Abbott (NYSE: ABT) today announced that it has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic ...
ABBOTT PARK, Ill., Aug. 19, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic device company. "OptiMedica's Catalys system enhances Abbott's leadership posit
Read more →ABTAbbott Partners with Music Saves Lives® to Encourage Young Donors to Give the Gift of Blood Blood transfusion is a life-saving treatment that helps save millions of lives every year. The need for blood is great: Approximately every two...
ABBOTT PARK, Ill., Aug. 15, 2013 /PRNewswire/ -- Blood transfusion is a life-saving treatment that helps save millions of lives every year. The need for blood is great: Approximately every two seconds, someone in the United States (U.S.) requires a blood transfusion. 1,2 However,
Read more →ABTNew Data for Abbott's Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk Abbott (NYSE: ABT) announced today promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at this year's...
HOUSTON , July 30, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at this year's American Association for Clinical Chemistry (AACC) annual meeting in Houston, Texas . The stu
Read more →ABTAbbott Features Solutions to Help Labs Prepare for the Evolving Healthcare Landscape at the American Association for Clinical Chemistry Lab Expo As U.S. healthcare providers navigate a changing healthcare climate, clinical laboratories are playing an increasingly important role in helping them ...
HOUSTON , July 29, 2013 /PRNewswire/ -- As U.S. healthcare providers navigate a changing healthcare climate, clinical laboratories are playing an increasingly important role in helping them prevent medical errors, lower readmission rates, and improve patient care. At the American
Read more →ABTAbbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System™ Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its FreeStyle Precision Pro Blood...
Addresses Hospital Needs for Cross-Contamination Control Dual-Band Wireless Connectivity Enables Real-Time Access to Test Results and Improves Staff Workflow Designed with Higher Performance Characteristics 2D Barcode Technology for Patient Identification About Abbott Diabete
Read more →ABTAbbott Reports Second-Quarter 2013 Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2013. Second-quarter adjusted diluted EPS was $0.46, above ...
ABBOTT PARK, Ill., July 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2013 . "All things considered, including headwinds from foreign exchange and a mixed global economy, this was a good quarter," said Miles
Read more →ABTAbbott to Enter Laser Cataract Surgery Market through Acquisition of OptiMedica Abbott (NYSE: ABT) today announced it has entered into an agreement to purchase OptiMedica Corporation, a privately held, Silicon Valley-based...
ABBOTT PARK, Ill., July 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has entered into an agreement to purchase OptiMedica Corporation, a privately held, Silicon Valley-based ophthalmic device company. The acquisition will enable Abbott to expand its vision care
Read more →ABTAbbott to Acquire IDEV Technologies to Expand Global Peripheral Technology Portfolio Abbott (NYSE: ABT) today announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on...
ABBOTT PARK, Ill., July 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascula
Read more →ABTAbbott Announces Approval of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System in Japan Abbott (NYSE: ABT) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the XIENCE Xpedition™ Everolimus...
ABBOTT PARK, Ill., July 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD), the
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2013 financial results on Wednesday, July 17, 2013, before the market opens. The announcement...
ABBOTT PARK, Ill., June 28, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2013 financial results on Wednesday, July 17, 2013 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Announces New Test to Help Doctors Determine Personalized Treatment Path for Patients with Hepatitis C Abbott announced today that it has introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the United States....
ABBOTT PARK, Ill., June 20, 2013 /PRNewswire/ -- Abbott announced today that it has introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the United States . Abbott's fully automated RealTi m e HCV Genotype II test determines the specific type
Read more →ABTAbbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb™ Bioresorbable...
ABBOTT PARK, Ill., June 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb™ Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most
Read more →ABTAbbott to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference Abbott (NYSE: ABT) will present at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference on Wednesday, June 19, 2013. Thomas C....
ABBOTT PARK, Ill., June 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference on Wednesday, June 19, 2013 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will pa
Read more →ABTAbbott to Present at William Blair 33rd Annual Growth Stock Conference Abbott (NYSE: ABT) will present at the William Blair 33rd Annual Growth Stock Conference on Tuesday, June 11, 2013. Brian Yoor, vice president,...
ABBOTT PARK, Ill., June 4, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the William Blair 33 rd Annual Growth Stock Conference on Tuesday, June 11, 2013 . Brian Yoor , vice president, investor relations, and David Forrest , executive vice president, nutritional produc
Read more →ABTTwo Real-World European Studies of Abbott's Minimally Invasive MitraClip® Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation Abbott today announced publication of positive outcomes from two European post-approval studies of the first-in-class catheter-based MitraClip®...
ABBOTT PARK, Ill., June 4, 2013 /PRNewswire/ -- Abbott today announced publication of positive outcomes from two European post-approval studies of the first-in-class catheter-based MitraClip ® therapy for the treatment of mitral regurgitation (MR). Results from ACCESS-EU, a Europ
Read more →ABTAbbott to Present at Goldman Sachs 34th Annual Global Healthcare Conference Abbott (NYSE: ABT) will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11, 2013. Thomas C. Freyman, executive ...
ABBOTT PARK, Ill., May 31, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Goldman Sachs 34 th Annual Global Healthcare Conference on Tuesday, June 11, 2013 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will participate in a 35-
Read more →ABTAbbott to Present at Deutsche Bank 38th Annual Health Care Conference Abbott (NYSE: ABT) will participate in the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29, 2013. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., May 22, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will participate in the Deutsche Bank 38 th Annual Health Care Conference on Wednesday, May 29, 2013 . Thomas C. Freyman , executive vice president, finance and chief financial officer, and Scott White , senior v
Read more →ABTAbbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind...
ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due t
Read more →ABTAbbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes Abbott (NYSE: ABT) today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid ...
ABBOTT PARK, Ill., May 9, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients a
Read more →ABTAbbott to Present at UBS Global Healthcare Conference Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013. Thomas C. Freyman, executive vice president,...
ABBOTT PARK, Ill., May 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013 . Thomas C. Freyman , executive vice president, finance and chief financial officer, and Brian Blaser , executive vice president, dia
Read more →ABTAbbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric Intraocular Lens for Cataract Patients Abbott (NYSE: ABT) today announced that the TECNIS® Toric 1-Piece intraocular lens (IOL) has received U.S. Food and Drug Administration (FDA)...
ABBOTT PARK, Ill., April 18, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the TECNIS ® Toric 1-Piece intraocular lens (IOL) has received U.S. Food and Drug Administration (FDA) approval and is launching in the United States for the treatment of cataract patients
Read more →ABTAbbott Reports First-Quarter 2013 Results Abbott today announced financial results for the first quarter ended March 31, 2013. First-quarter adjusted diluted EPS was $0.42, at the high end of ...
ABBOTT PARK, Ill., April 17, 2013 /PRNewswire/ -- Abbott today announced financial results for the first quarter ended March 31, 2013 . "Strong performance in Nutrition and Diagnostics, as well as overall results in emerging markets, led our sales growth this quarter," said Mile
Read more →ABTAbbott Introduces Next Generation Laboratory Automation Solution to Help Meet Increased Testing Demand Abbott (NYSE: ABT) today announced the global launch of the ACCELERATOR® a3600, a next generation automation solution, to help laboratories address...
ABBOTT PARK, Ill., April 16, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the global launch of the ACCELERATOR ® a 3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling increased volume. Advances in t
Read more →ABTAbbott Initiates Voluntary Recall of FreeStyle InsuLinx® Blood Glucose Meters in the United States Abbott (NYSE: ABT) today announced it is initiating a voluntary recall of FreeStyle InsuLinx® Blood Glucose Meters in the United States. The company...
ABBOTT PARK, Ill., April 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it is initiating a voluntary recall of FreeStyle InsuLinx ® Blood Glucose Meters in the United States . The company has determined that at extremely high blood glucose levels of 1024 mg/dL and
Read more →ABTAbbott's Galectin-3 Test Provides Doctors in Europe with New Tool for Assessing the Prognosis of Chronic Heart Failure Patients Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of...
ABBOTT PARK, Ill., April 10, 2013 /PRNewswire/ -- Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partne
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2013 financial results on Wednesday, April 17, 2013, before the market opens. The announcement...
ABBOTT PARK, Ill., April 1, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2013 financial results on Wednesday, April 17, 2013 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTNew Abbott Test Can Help Doctors Detect the Presence of Two Important Health Issues Abbott (NYSE: ABT) today announced that the ARCHITECT AFP test, which may help doctors detect serious birth defects and the progression of testicular ...
ABBOTT PARK, Ill., March 28, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the ARCHITECT AFP test, which may help doctors detect serious birth defects and the progression of testicular cancer, received U.S. Food and Drug Administration (FDA) approval. Biomarkers,
Read more →ABTFDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory...
ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment w
Read more →ABTNew Data Reinforce Strong Long-Term Clinical Performance of Abbott's Absorb™ Bioresorbable Vascular Scaffold Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb™ Bioresorbable Vascular Scaffold (BVS). Three-year...
SAN FRANCISCO , March 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive long-term results for the company's innovative Absorb™ Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at
Read more →ABTAbbott's Minimally Invasive MitraClip® System for Mitral Regurgitation Demonstrates Positive Clinical and Quality-of-Life Results for Patients Too High Risk for Surgery Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the...
SAN FRANCISCO , March 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip ® System for the treatment of mitr
Read more →ABTAbbott to Present at Barclays Capital 2013 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Capital 2013 Global Healthcare Conference on Thursday, March 14, 2013. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., March 7, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Capital 2013 Global Healthcare Conference on Thursday, March 14 , 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, will present at 7:30 a.m. Ce
Read more →ABTAbbott Introduces Nutrition for Active Kids - Kidz ZonePerfect® Nutrition Bars Abbott's (NYSE: ABT) ZonePerfect brand today introduces a new line of nutrition bars for active kids, Kidz ZonePerfect. Built directly with the help...
ABBOTT PARK, Ill., March 5, 2013 /PRNewswire/ -- Abbott's (NYSE: ABT ) ZonePerfect brand today introduces a new line of nutrition bars for active kids, Kidz ZonePerfect . Built directly with the help of parents and their children, Kidz ZonePerfect features five grams of protein,
Read more →ABTAbbott to Collaborate with Janssen and Pharmacyclics on Development of Companion Test for Investigational Leukemia Therapy Abbott (NYSE: ABT) announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbott's...
ABBOTT PARK, Ill., Feb. 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in develop
Read more →ABTAbbott Declares 357th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 14 cents per share. This marks the 357th consecutive...
ABBOTT PARK, Ill., Feb. 15, 2013 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 14 cents per share. This marks the 357 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May
Read more →ABTNew Survey Reveals Eight in 10 Fitness Enthusiasts Are Not Doing Enough to Aid Recovery After Exercise (NYSE: ABT) - A national survey of fitness enthusiasts who exercise three or more times a week show a strong dedication to reaching fitness goals;...
ABBOTT PARK, Ill., Feb. 12, 2013 /PRNewswire/ -- (NYSE: ABT ) - A national survey of fitness enthusiasts who exercise three or more times a week show a strong dedication to reaching fitness goals; however the vast majority -- 82 percent-- admitted to falling short when it comes t
Read more →ABTAbbott Reports Fourth-Quarter and Full-Year 2012 Results Abbott today announced financial results for the fourth quarter ended Dec. 31, 2012. Fourth-quarter diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Jan. 23, 2013 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2012 . "In 2012, we achieved a significant milestone in Abbott's 125-year history with the creation of AbbVie while delivering another year of strong r
Read more →ABTAbbott and AbbVie Named to S&P Dividend Aristocrats Indices Abbott (NYSE: ABT) has once again been named to the S&P 500 Dividend Aristocrats and S&P High Yield Dividend Aristocrats Indices. The S&P 500...
ABBOTT PARK, Ill., Jan. 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) has once again been named to the S&P 500 Dividend Aristocrats and S&P High Yield Dividend Aristocrats Indices. The S&P 500 Dividend Aristocrats comprises companies in the S&P 500 that have increased dividends e
Read more →ABTNew Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluating Potential Heart Attacks An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a...
ABBOTT PARK, Ill., Jan. 9, 2013 /PRNewswire/ -- An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes. 1 Time is a critical factor in diagnosing and treating people who may be having a potential heart at
Read more →ABTAbbott Initiates Clinical Trial of Absorb™ in the United States Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled...
ABBOTT PARK, Ill., Jan. 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the initiation of the ABSORB III clinical trial in patients in the United States . This randomized, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United
Read more →ABTAbbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System Abbott (NYSE: ABT) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration...
ABBOTT PARK, Ill., Jan. 3, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the XIENCE Xpedition ™ Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States , providing physici
Read more →ABTAbbott Completes Separation of Research-Based Pharmaceuticals Business Abbott (NYSE: ABT) today announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new...
ABBOTT PARK, Ill., Jan. 2, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie will begin trading independently on the New
Read more →ABTAbbott and AbbVie to Present at Financial Conferences Abbott (NYSE: ABT) and AbbVie will present at financial conferences in January 2013. Abbott will present at the 31st Annual J.P. Morgan Healthcare...
ABBOTT PARK, Ill., Dec. 21, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and AbbVie will present at financial conferences in January 2013 . Abbott will present at the 31 st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2013 . Thomas C. Freyman , executive vice preside
Read more →ABTAbbott Announces New Testosterone Test to Measure the Hormone at Low Levels Testosterone is an important androgen hormone in the health and well-being of men and women. Testosterone levels are associated with sexual...
Published studies have shown, however, that many currently available testosterone tests are not sensitive enough to measure low levels of testosterone. This limits the clinical utility of these tests. To address this need and help physicians accurately measure the wide range of t
Read more →ABTAbbott Declares 356th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared its 356th consecutive quarterly cash dividend. The quarterly dividend is $0.14 per share, ...
ABBOTT PARK, Ill., Dec. 14, 2012 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared its 356 th consecutive quarterly cash dividend. The quarterly dividend is $0.14 per share, payable Feb. 15, 2013 , to shareholders of record on Jan. 15, 2013 . The manage
Read more →ABTNew Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks Acute chest pain is one of the most common reasons people seek emergency care, and time is a critical factor in diagnosing and treating people who...
ABBOTT PARK, Ill., Dec. 13, 2012 /PRNewswire/ -- Acute chest pain is one of the most common reasons people seek emergency care, and time is a critical factor in diagnosing and treating people who may be having a heart attack. The latest generation of diagnostic tests in developme
Read more →ABTAbbott Announces Effectiveness of AbbVie Form 10 Registration Statement Abbott (NYSE: ABT) announced today that the Securities and Exchange Commission (SEC) has declared effective the Form 10 Registration Statement filed...
ABBOTT PARK, Ill., Dec. 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the Securities and Exchange Commission (SEC) has declared effective the Form 10 Registration Statement filed by AbbVie Inc., its research-based pharmaceuticals business. Abbott expects to com
Read more →ABTAbbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie Stock Abbott (NYSE: ABT) announced today that its board of directors has approved the separation of its research-based pharmaceuticals business, which will ...
ABBOTT PARK, Ill., Nov. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that its board of directors has approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie Inc., and declared a special dividend distribution of all of
Read more →ABTAbbott Announces Final Results for Partial Debt Tender Offers Abbott (NYSE: ABT) announced today the final results of its previously pending offers to purchase for cash up to an aggregate principal amount (in...
ABBOTT PARK, Ill., Nov. 27, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the final results of its previously pending offers to purchase for cash up to an aggregate principal amount (in each case, the "Series Tender Cap") of $944,000,000 of its 5.125% Notes due April 2
Read more →ABTAbbott Announces Results for Any and All Debt Tender Offers Abbott (NYSE: ABT) announced today the results of its previously pending offers to purchase for cash any and all of its outstanding 4.35% Notes due...
ABBOTT PARK, Ill., Nov. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the results of its previously pending offers to purchase for cash any and all of its outstanding 4.35% Notes due March 2014 (the "2014 Notes"), 2.70% Notes due May 2015 (the "2015 Notes"), 5.875%
Read more →ABTAbbott Announces Phase 3 Hepatitis C Program Details Abbott (NYSE: ABT) today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical...
ABBOTT PARK, Ill., Nov. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Associatio
Read more →ABTAbbott Announces Results of Analysis Exploring the Use of HUMIRA® (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis Abbott today announced results from a post-hoc analysis of HUMIRA® (adalimumab) data in early and long-standing moderate-to-severe rheumatoid...
ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott today announced results from a post-hoc analysis of HUMIRA ® (adalimumab) data in early and long-standing moderate-to-severe rheumatoid arthritis (RA) patients from three randomized, controlled trials — DE019, OPTIMA and PRE
Read more →ABTAbbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Abbott (NYSE: ABT) today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3...
ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of HUMIRA ® (adalimumab). The study evaluated improvements in physica
Read more →ABTAbbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting® Results from Abbott's phase 2b clinical trial, Aviator, demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all...
ABBOTT PARK, Ill., Nov. 10, 2012 /PRNewswire/ -- Results from Abbott's phase 2b clinical trial, "Aviator," demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR 12 ) in all 8- and 12-week arms, with combinations of direct acting antivirals (DAAs) given
Read more →ABTAbbott Announces Early Tender Results for Partial Debt Tender Offers and Extends Any and All Debt Tender Offers Abbott (NYSE: ABT) announced today the results, as of the early tender deadline of 5 p.m., New York City Time, on Nov. 8, 2012 (the Early Tender...
ABBOTT PARK, Ill., Nov. 9, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the results, as of the early tender deadline of 5 p.m. , New York City Time, on Nov. 8, 2012 (the "Early Tender Date"), of its previously announced offers to purchase for cash up to an aggregate p
Read more →ABTAbbott Announces Consideration for Debt Tender Offers Abbott (NYSE: ABT) announced today the reference yield and the total consideration for the nine series of notes subject to the previously announced...
ABBOTT PARK, Ill., Nov. 8, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the reference yield and the total consideration for the nine series of notes subject to the previously announced tender offers (the "Tender Offers") to purchase for cash (i) any and all of its out
Read more →ABTAbbott Announces Pricing of AbbVie's $14.7 Billion Private Placement Notes Offering Abbott (NYSE: ABT) announced today that its wholly-owned subsidiary, AbbVie Inc., priced the private placement offering launched on Nov. 5, 2012, of...
ABBOTT PARK, Ill., Nov. 5, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that its wholly-owned subsidiary, AbbVie Inc., priced the private placement offering launched on Nov. 5, 2012 , of $3.5 billion of 1.20% senior notes due 2015 (the "2015 Notes"), $4 billion of 1.7
Read more →ABTAbbott and the Abbott Fund Donate $1 Million in Funding and Products to Support Hurricane Sandy Relief Efforts Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in funding and product donations to support relief efforts in...
ABBOTT PARK, Ill., Nov. 2, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and its foundation, the Abbott Fund, are providing $1 million in funding and product donations to support relief efforts in response to Hurricane Sandy. The Abbott Fund grants will be provided to longstanding rel
Read more →ABTAbbott Introduces Ensure Complete™ Shakes For Adults Abbott (NYSE: ABT), the global healthcare company and producer of the number one doctor-recommended brand of oral nutrition supplements, is launching ...
ABBOTT PARK, Ill., Oct. 30, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ), the global healthcare company and producer of the number one doctor-recommended brand of oral nutrition supplements, is launching Ensure Complete. Ensure Complete shakes offer 4-in-1 nutrition that provides ta
Read more →ABTAbbott Announces Cash Tender Offers for Notes Abbott (NYSE: ABT) announced today that it has commenced cash tender offers (the Tender Offers ) for nine series of its outstanding notes. The...
ABBOTT PARK, Ill., Oct. 26, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has commenced cash tender offers (the "Tender Offers") for nine series of its outstanding notes. The Tender Offers are being made pursuant to an Offer to Purchase, dated Oct. 26, 2012 (t
Read more →ABTAbbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis® ALK Break Apart FISH Probe Kit, allowing...
ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will expand the current CE-IVD product labeling for its Vysis ® ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test
Read more →ABTAbbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA® (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA®...
ABBOTT PARK, Ill., Oct. 22, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA® (adalimumab) ULTRA 1 and ULTRA 2 studies. Adult patients with moderately to severely acti
Read more →ABTAbbott Reports Double Digit Earnings Per Share Growth in the Third Quarter Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2012. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Oct. 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2012 . "Abbott delivered another quarter of strong results with ongoing earnings per share up more than 10 percent, despite a challenging
Read more →ABTAbbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naive and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study Abbott (NYSE: ABT) today announced initial results from Aviator, a phase 2b study of its interferon-free, investigational regimen for the treatment ...
ABBOTT PARK Ill ., Oct. 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12
Read more →ABTAbbott Awards Two Scholarships to Inspirational Students Living with Cystic Fibrosis Abbott (NYSE: ABT) announced today the winners of the CFCareForward Thriving Undergraduate and Graduate Scholarship award. Mark Moening, a Virginia...
ABBOTT PARK, Ill., Oct. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the winners of the CF CareForward Thriving Undergraduate and Graduate Scholarship award. Mark Moening, a Virginia Beach, Va. resident, and Wesley McSparin , a native of Paducah, Ky. , were unveil
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2012 financial results on Wednesday, Oct. 17, 2012, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Oct. 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2012 financial results on Wednesday, Oct. 17, 2012 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central
Read more →ABTAbbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for inducing and sustaining...
ABBOTT PARK, Ill., Sept. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA ® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative
Read more →ABTAbbott Announces International Launch of the Absorb™ Bioresorbable Vascular Scaffold Abbott (NYSE: ABT) announced today that Absorb™, the world's first drug eluting bioresorbable vascular scaffold (BVS), is now widely available across ...
ABBOTT PARK, Ill., Sept. 25, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that Absorb™, the world's first drug eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America . Absorb is a first-of-its-k
Read more →ABTThe Journal Science Again Recognizes Abbott as One of the Top Employers in the Biotech and Pharmaceutical Industry Abbott (NYSE: ABT) today was again named one of the Top 20 Employers by the journal Science. Based on the views of working scientists, this...
ABBOTT PARK, Ill., Sept. 21, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today was again named one of the Top 20 Employers by the journal Science. Based on the views of working scientists, this prestigious annual survey identifies the most respected employers in the biotechnology an
Read more →ABTAbbott Named to Working Mother Magazine's 'Best Companies' List for Twelve Consecutive Years Abbott (NYSE: ABT) today was once again named one of the 100 Best Companies by Working Mother magazine. This is the twelfth consecutive year that...
ABBOTT PARK, Ill., Sept. 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today was once again named one of the 100 Best Companies by Working Mother magazine. This is the twelfth consecutive year that Abbott has been included on the prestigious list, which recognizes companies for pr
Read more →ABTAbbott Declares 355th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 355th consecutive...
ABBOTT PARK, Ill., Sept. 13, 2012 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 51 cents per share. This marks the 355 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable No
Read more →ABTAbbott Recognized for Leading Citizenship Performance for Eighth Consecutive Year by Dow Jones Sustainability Indexes Abbott (NYSE: ABT) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the eighth...
ABBOTT PARK, Ill., Sept. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the eighth consecutive year. As a member of the Dow Jones Sustainability World Index, Abbott ran
Read more →ABTAccording to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives According to a recent national survey of more than 2,000 men, 52 percent say they usually see a doctor when something needs to be fixed, and the...
NEW YORK , Sept. 12, 2012 /PRNewswire/ -- According to a recent national survey of more than 2,000 men, 52 percent say they usually see a doctor when something needs to be "fixed," and the majority (63 percent) report that prolonged, severe pain is the main "breaking point" for w
Read more →ABTAbbott to Collaborate with Astellas in CMV Vaccine Trial Abbott (NYSE: ABT) announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial ...
ABBOTT PARK, Ill., Sept. 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax TM ), an investigational vaccine licensed from Vical Incor
Read more →ABTAbbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels Abbott (NYSE: ABT) announced today CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility. With a ...
ABBOTT PARK, Ill., Aug. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2 nd Generation Testosterone Assay can accurate
Read more →ABTAbbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent Abbott (NYSE: ABT) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment...
ABBOTT PARK, Ill., Aug. 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease. The company is launching the product immediately in CE
Read more →ABTPublic Voting Now Open to Help Grant Two $20,000 Abbott CFCareForward Scholarships to Students with Cystic Fibrosis Abbott (NYSE: ABT) has selected 40 undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 CFCareForward...
ABBOTT PARK, Ill., Aug. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) has selected 40 undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 CF CareForward Scholarship for use during the 2012-2013 academic year. Recipients were chosen based o
Read more →ABTAbbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the Omnilink Elite® Vascular Balloon-Expandable Stent System for the ...
ABBOTT PARK, Ill., Aug. 7, 2012 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the Omnilink Elite ® Vascular Balloon-Expandable Stent System for the treatment of iliac artery disease, a form of peripheral artery disease (PAD) that
Read more →ABTAbbott Reports Strong Second Quarter Results Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2012. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., July 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2012 . "Abbott continues to deliver strong results as we remain on track to separate into two leading health care companies," said Miles D
Read more →ABTAbbott Focuses on the Importance of Information Management and Automation at the American Association for Clinical Chemistry Lab Expo Abbott (NYSE: ABT) will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry...
ABBOTT PARK, Ill., July 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19 , in Los Angeles, Calif. Solutions to further enh
Read more →ABTAbbott Introduces OneLab, a Novel Integrated Web-Based Software Platform to Manage the Vast Amounts of Information Flowing Through the Lab As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology ...
ABBOTT PARK, Ill., July 11, 2012 /PRNewswire/ -- As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, today Abbott
Read more →ABTAbbott Announces New Test for the Management of Patients with Diabetes More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27...
ABBOTT PARK, Ill., July 10, 2012 /PRNewswire/ -- More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment effica
Read more →ABTAbbott Receives FDA Approval for Healon EndoCoat Protective Gel for Cataract Surgery Abbott announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the U.S. Food and Drug Administration...
ABBOTT PARK, Ill., July 3, 2012 /PRNewswire/ -- Abbott announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the U.S. Food and Drug Administration approval of Healon EndoCoat OVD, a device intended for use as a surgical aid in cat
Read more →ABTAbbott, The Abbott Fund And Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, And More Than 150,000 HIV Cases Prevented In Children Direct Relief International, the global health care company Abbott (NYSE: ABT) and its foundation, the Abbott Fund, today announced that they have...
SANTA BARBARA, Calif. and ABBOTT PARK, Ill., June 27, 2012 /PRNewswire/ -- Direct Relief International, the global health care company Abbott (NYSE: ABT ) and its foundation, the Abbott Fund, today announced that they have reached a major milestone of distributing 20 million rapi
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2012 financial results on Wednesday, July 18, 2012, before the market opens. The announcement...
ABBOTT PARK, Ill., June 27, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2012 financial results on Wednesday, July 18, 2012 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTAbbott Introduces New Limited Ingredient Nutrition Bar - Perfectly Simple™ by ZonePerfect® Abbott's ZonePerfect brand introduces a new line of nutrition bars, Perfectly Simple. With 10 or fewer ingredients and an excellent source of...
ABBOTT PARK, Ill., June 26, 2012 /PRNewswire/ -- Abbott's ZonePerfect brand introduces a new line of nutrition bars, Perfectly Simple . With 10 or fewer ingredients and an excellent source of protein, the bars are free of gluten, preservatives and added coloring. Perfectly Simpl
Read more →ABTAbbott Again Named One of the Best Workplaces in Europe The Great Place to Work® Institute named Abbott (NYSE: ABT) one of the Best Multinational Workplaces in Europe at its European Awards event in Berlin....
BERLIN , June 20, 2012 /PRNewswire/ -- The Great Place to Work® Institute named Abbott (NYSE: ABT ) one of the Best Multinational Workplaces in Europe at its European Awards event in Berlin . The company was specifically honored for workplace leadership in Belgium , Denmark , Ire
Read more →ABTAbbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for...
DUBLIN , June 18, 2012 /PRNewswire/ -- Today Abbott (NYSE: ABT ) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim ana
Read more →ABTAbbott Declares 354th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 354th consecutive...
ABBOTT PARK, Ill., June 8, 2012 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 51 cents per share. This marks the 354th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug.
Read more →ABTAbbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active...
BERLIN , June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ank
Read more →ABTAbbott Announces 10-Year Data Evaluating HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis Abbott (NYSE: ABT) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for...
BERLIN , June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA).
Read more →ABTAbbott Introduces Ensure Clear™ to Help Adults Fill Dietary Gaps (NYSE: ABT) -- As an alternate option to its traditional shakes, Abbott is introducing new Ensure Clear™, a fruit-flavored nutrition beverage...
ABBOTT PARK, Ill., June 5, 2012 /PRNewswire/ -- (NYSE: ABT ) -- As an alternate option to its traditional shakes, Abbott is introducing new Ensure Clear™, a fruit-flavored nutrition beverage available in peach and blueberry pomegranate flavors. Ensure Clear offers three times mor
Read more →ABTAbbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical...
ABBOTT PARK, Ill., June 5, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients wi
Read more →ABTAbbott Again Recognized as One of the 'Best Places to Work in Industry' by The Scientist Magazine Abbott (NYSE: ABT) was once again named one of the Best Places to Work in Industry by The Scientist magazine. Abbott ranked No. 14 on the 2012 list....
ABBOTT PARK, Ill., June 1, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) was once again named one of the "Best Places to Work in Industry" by The Scientist magazine. Abbott ranked No. 14 on the 2012 list. This is the ninth time that Abbott has been on the list since The Scientist firs
Read more →ABTAbbott to Present at Goldman Sachs 33rd Annual Global Healthcare Conference Abbott (NYSE: ABT) will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012. Thomas C. Freyman,...
ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012 . Thomas C. Freyman , executive vice president, finance and chief financial officer and John M. Leonard , M.D.
Read more →ABTAbbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European...
ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany , from 6-9 June, 2012 .
Read more →ABTAbbott Launches PediaSure SideKicks® Clear for Picky Eaters All children need proper nutrients, but a child's picky eating habits can make getting the right nutrition challenging for parents and kids alike....
ABBOTT PARK, Ill., May 16, 2012 /PRNewswire/ -- All children need proper nutrients, but a child's picky eating habits can make getting the right nutrition challenging for parents and kids alike. Abbott (NYSE: ABT ) is introducing a new option for picky eaters' routine with PediaS
Read more →ABTAbbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy Abbott (NYSE: ABT) today announced that the XIENCE PRIME™ and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe ...
PARIS , May 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the XIENCE PRIME™ and the XIENCE V ® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent impl
Read more →ABTAbbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Now Available in Canada Device is the First Blood Glucose System in North America to Offer Mealtime Insulin Calculator TORONTO, May 9, 2012 /PRNewswire/ - Abbott today...
Device is the First Blood Glucose System in North America to Offer Mealtime Insulin Calculator TORONTO , May 9, 2012 /PRNewswire/ - Abbott today announced that its new FreeStyle InsuLinx Blood Glucose Monitoring System 1 is now available in diabetes centres and select pharmacies
Read more →ABTAbbott Reaches Settlement Agreement on Depakote Abbott (NYSE: ABT) has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding...
ABBOTT PARK, Ill., May 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia , to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing pra
Read more →ABTAbbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will...
ABBOTT PARK, Ill. and AARHUS, Denmark , May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma. AP214 is in development to pr
Read more →ABTAbbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India Abbott (NYSE: ABT), one of India's largest health care companies, today announced plans to establish its first nutrition research and development...
MUMBAI and BANGALORE, India , May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ), one of India 's largest health care companies, today announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene, India 's leading cont
Read more →ABTAbbott to Present at Deutsche Bank 37th Annual Health Care Conference Abbott (NYSE: ABT) will participate in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8, 2012. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., May 2, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will participate in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8 , 2012. Thomas C. Freyman , executive vice president, finance and chief financial officer and John M. Leonard , M.D., seni
Read more →ABTNew Products from Abbott's EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals (NYSE: ABT) – When it comes to maximizing recovery and accomplishing fitness goals, exercise enthusiasts identify building muscle or getting lean and ...
ABBOTT PARK, Ill., April 25, 2012 /PRNewswire/ -- (NYSE: ABT ) – When it comes to maximizing recovery and accomplishing fitness goals, exercise enthusiasts identify building muscle or getting lean and toned as main objectives. However, reaching these goals depends as much on prop
Read more →ABTAbbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States Abbott (NYSE: ABT) and St. Jude Medical (NYSE: STJ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S....
ABBOTT PARK , Ill. and ST. PAUL, Minn. , April 23, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and St. Jude Medical (NYSE: STJ ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiolo
Read more →ABTAbbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or...
"This is a major advancement and expansion of our Femtosecond laser technology," said Jim Mazzo , senior vice president, Abbott Medical Optics. "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership p
Read more →ABTAbbott Presents Positive Results from Phase 2 Pilot Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced complete data from the study known as Pilot – Abbott's initial interferon-free study of its ...
ABBOTT PARK, Ill. and WATERTOWN, Mass. , April 19, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" – Abbott 's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepa
Read more →ABTAbbott Presents Positive Results from Interferon-Free Phase 2 Co-Pilot Study for the Treatment of Hepatitis C Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced data from Co-Pilot, an interferon-free, Phase 2 study of Abbott's direct-acting antiviral...
ABBOTT PARK, Ill., and WATERTOWN, Mass. , April 19, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and Enanta Pharmaceuticals announced data from "Co-Pilot," an interferon-free, Phase 2 study of Abbott's direct-acting antiviral medicines for the treatment of hepatitis C (HCV) that foun
Read more →ABTAbbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2012. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., April 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2012 . "Abbott is off to a strong start in 2012, delivering double-digit ongoing earnings-per-share growth," said Miles D. White , chairm
Read more →ABTAbbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer Abbott (NYSE: ABT) announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a ...
ABBOTT PARK, Ill., April 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need:
Read more →ABTAbbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical Trial Abbott (NYSE: ABT) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's...
ABBOTT PARK, Ill., April 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients trea
Read more →ABTAbbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan Abbott (NYSE: ABT) today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation...
ABBOTT PARK, Ill., April 9, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System for the treatment of coronar
Read more →ABTAbbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at...
ABBOTT PARK Ill ., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress™ 2012 (ILC 2012), the annual meeting of the Euro
Read more →ABTAbbott's PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking Abbott (NYSE: ABT) announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput...
WIESBADEN, Germany , March 30, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID™ instrument, along with three assays for use on the system: PLEX-ID Viral I
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2012 financial results on Wednesday, April 18, 2012, before the market opens. The announcement...
ABBOTT PARK, Ill., March 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2012 financial results on Wednesday, April 18, 2012 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTAbbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company Abbott (NYSE: ABT) today announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it ...
ABBOTT PARK, Ill., March 21, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the lat
Read more →ABTAbbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012 Abbott (NYSE: ABT) today announced the company's schedule of key presentations at the American College of Cardiology's (ACC) 61st Annual Scientific...
ABBOTT PARK, Ill., March 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the company's schedule of key presentations at the American College of Cardiology's (ACC) 61st Annual Scientific Session and i2 Summit 2012, to be held March 24 – 27 in Chicago . Presentations w
Read more →ABTAbbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa Abbott (NYSE: ABT) today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational...
ABBOTT PARK, Ill., March 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradeniti
Read more →ABTAbbott's New FreeStyle InsuLinx Blood Glucose Monitoring System Receives FDA Clearance Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose...
ALAMEDA, Calif. , March 8, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System,(1) the first from Abbott to include a touch-screen interface, aut
Read more →ABTAbbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the Absolute Pro® Vascular Self-Expanding Stent System...
ABBOTT PARK, Ill., March 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) approved the Absolute Pro® Vascular Self-Expanding Stent System for the treatment of iliac artery disease, a form of peripheral artery disease (PA
Read more →ABTAbbott to Present at Barclays Capital 2012 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Capital 2012 Global Healthcare Conference on Wednesday, March 14, 2012. John M. Leonard, M.D., senior ...
ABBOTT PARK, Ill., March 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Capital 2012 Global Healthcare Conference on Wednesday, March 14 , 2012. John M. Leonard, M.D., senior vice president, pharmaceuticals, research and development, will make a formal p
Read more →ABTAbbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy Abbott (NYSE: ABT) announced today that it will collaborate with Merck to evaluate the use of a FISH (fluorescence in situ hybridization)-based...
ABBOTT PARK, Ill., March 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will collaborate with Merck to evaluate the use of a FISH (fluorescence in situ hybridization)-based companion diagnostic test to aid in the development of a Merck investigational cancer
Read more →ABTAbbott to Collaborate on Rapid Molecular Test to Identify Serious Infections in Bones and Joints Abbott (NYSE: ABT) announced today it will collaborate with Genetics Laboratory, Inc. (GenLab) on the development of a molecular diagnostic test that ...
ABBOTT PARK, Ill., March 5, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it will collaborate with Genetics Laboratory, Inc. (GenLab) on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopedic infectio
Read more →ABTAbbott's STARLIMS Business Acquires Distribution Partners to Build International Presence As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin...
ABBOTT PARK, Ill., March 2, 2012 /PRNewswire/ -- As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin America and Africa , STARLIMS Technologies ( http://www.starlims.com ), an Abbott
Read more →ABTAbbott to Build Nutrition Manufacturing Facility in Ohio Abbott (NYSE: ABT) today announced plans to build a nutrition manufacturing facility in Tipp City, Ohio, to produce two of the company's...
ABBOTT PARK, Ill., March 1, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced plans to build a nutrition manufacturing facility in Tipp City, Ohio , to produce two of the company's fastest-growing adult brands, Ensure® and Glucerna®, for the North America market. Abbott wi
Read more →ABTAbbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases Abbott (NYSE: ABT) and Galapagos (Euronext: GLPG) announced today that they have entered into a global collaboration to develop and commercialize an...
ABBOTT PARK, Ill. and MECHELEN, Belgium , Feb. 29, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) and Galapagos (Euronext: GLPG) announced today that they have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II developme
Read more →ABTAbbott to Present at Cowen and Company 32nd Annual Health Care Conference Abbott (NYSE: ABT) will present at the Cowen and Company 32nd Annual Health Care Conference on Wednesday, March 7, 2012. Thomas C. Freyman, executive ...
ABBOTT PARK, Ill., Feb. 23, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Cowen and Company 32nd Annual Health Care Conference on Wednesday, March 7 , 2012. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation o
Read more →ABTAbbott Announces 40th Consecutive Annual Increase in Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend from 48 cents per share to 51 cents per share....
ABBOTT PARK, Ill., Feb. 17, 2012 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend from 48 cents per share to 51 cents per share. This marks the 40th consecutive year that Abbott has increased its dividend payou
Read more →ABTStudy Shows Abbott's Tacrolimus Assay Demonstrates Consistent Organ Transplant Drug Monitoring A new study published in the journal Clinical Chemistry reported Abbott's (NYSE: ABT) ARCHITECT® Tacrolimus assay provides accurate and consistent...
ABBOTT PARK, Ill., Feb. 13, 2012 /PRNewswire/ -- A new study published in the journal Clinical Chemistry reported Abbott's (NYSE: ABT ) ARCHITECT ® Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medicat
Read more →ABTAbbott Creates New Similac SimplySmart™ Baby Bottle with Innovative Features Abbott (NYSE: ABT) introduces Similac SimplySmart, an innovative BPA-free baby bottle designed to improve the bottle feeding experience for parents...
ABBOTT PARK, Ill., Feb. 8, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) introduces Similac SimplySmart , an innovative BPA-free baby bottle designed to improve the bottle feeding experience for parents and babies through advanced features that provide comfort and convenience. This u
Read more →ABTAbbott to Present at Leerink Swann 2012 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, Feb. 15, 2012. Thomas C. Freyman, executive vice ...
ABBOTT PARK, Ill., Feb. 1, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, Feb. 15, 2012 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a presentation on the
Read more →ABTDNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases The Drugs for Neglected Diseases initiative (DNDi) and Abbott (NYSE: ABT) have signed a four-year joint research and non-exclusive licensing...
GENEVA , Jan. 30, 2012 /PRNewswire/ -- The Drugs for Neglected Diseases initiative (DND i ) and Abbott (NYSE: ABT ) have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropi
Read more →ABTAbbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011 Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2011. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Jan. 25, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter ended Dec. 31, 2011 . "Despite another challenging year for the global economy, Abbott again delivered leading performance, including strong sales and on
Read more →ABTAbbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) will begin implementing Abbott's STARLIMS® software-based...
ABBOTT PARK, Ill., Jan. 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) will begin implementing Abbott's STARLIMS® software-based laboratory information management system (LIMS) as part of the agency's initiative to en
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2011 financial results on Wednesday, Jan. 25, 2012, before the market opens. The...
ABBOTT PARK, Ill., Jan. 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2011 financial results on Wednesday, Jan. 25, 2012 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at
Read more →ABTAbbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of...
ABBOTT PARK, Ill., Dec. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit ™ drug eluting bioresorbable vascular scaffold (BVS) for the tre
Read more →ABTAbbott and University of Illinois Establish Center for Nutrition, Learning and Memory Abbott (NYSE: ABT) and the University of Illinois at Urbana-Champaign announced today they have established the first-ever multi-disciplinary...
ABBOTT PARK, Ill. and URBANA, Ill. , Dec. 19, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) and the University of Illinois at Urbana-Champaign announced today they have established the first-ever multi-disciplinary nutrition and cognition research center, which will be located on the
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2012. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Dec. 15, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2012 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on
Read more →ABTAbbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and...
ABBOTT PARK, Ill. and IRVING, Texas , Dec. 12, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inf
Read more →ABTAbbott Declares 352nd Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 48 cents per share. This marks the 352nd consecutive...
ABBOTT PARK, Ill., Dec. 9, 2011 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 48 cents per share. This marks the 352nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb.
Read more →ABTAbbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, ...
ABBOTT PARK, Ill., Dec. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) com
Read more →ABTAbbott Receives FDA Clearance for New Test to Detect Vitamin D Levels Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay...
ABBOTT PARK, Ill., Nov. 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT ® laboratory testing platform. Published d
Read more →ABTAbbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development...
DES PLAINES, Ill. , Nov. 28, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK's cancer immunother
Read more →ABTAbbott Introduces the First FDA-Approved Supplemental Blood Test for Chagas Disease Abbott (NYSE: ABT) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA...
ABBOTT PARK, Ill., Nov. 21, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA Chagas is the first FDA-approved supplemental test that detects antibodies to Trypanos
Read more →ABTAbbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011 Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test...
ORLANDO, Fla. , Nov. 15, 2011 /PRNewswire/ -- Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide
Read more →ABTNew Data Reinforce Clinical Performance of Abbott's ABSORB Bioresorbable Vascular Scaffold Abbott (NYSE: ABT) today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable ...
ABBOTT PARK, Ill., Nov. 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Five-year
Read more →ABTAbbott Reports Five-Year Data for HUMIRA® (Adalimumab) in Ankylosing Spondylitis Abbott (NYSE: ABT) today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of...
ABBOTT PARK, Ill., Nov. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA® (adalimumab) on disease activity, including spinal mobility in pa
Read more →ABTAbbott Presents HUMIRA® (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-1 study of HUMIRA® (adalimumab) in patients with active non-radiographic axial...
ABBOTT PARK, Ill., Nov. 7, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from the Phase 3 ABILITY-1 study of HUMIRA® (adalimumab) in patients with active non-radiographic axial spondyloarthritis (axSpA). AxSpA is a debilitating condition that primarily presents
Read more →ABTAbbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA®...
ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early mod
Read more →ABTAbbott Honored With Scrip Award for Leadership in Corporate Social Responsibility Scrip, a leading global pharmaceutical and biotech news organisation, honored Abbott and its philanthropic foundation, the Abbott Fund, with a 2011...
LONDON , Nov. 4, 2011 /PRNewswire/ -- Scrip , a leading global pharmaceutical and biotech news organisation, honored Abbott and its philanthropic foundation, the Abbott Fund, with a 2011 Scrip Award for Corporate Social Responsibility (CSR) at Scrip's seventh annual awards ceremo
Read more →ABTPATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition PATH, Abbott (NYSE: ABT) and the Abbott Fund today announced a partnership to address malnutrition by advancing the rice fortification market in...
MUMBAI, India and NEW DELHI , Nov. 3, 2011 /PRNewswire/ -- PATH, Abbott (NYSE: ABT ) and the Abbott Fund today announced a partnership to address malnutrition by advancing the rice fortification market in India . Currently, 200 million people suffer from hunger and malnutrition i
Read more →ABTAbbott to Present New Data for Key Vascular Products at TCT 2011 Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics...
ABBOTT PARK, Ill., Nov. 3, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, to be held Nov. 7 – 11 in San Francisco . New data will be
Read more →ABTAbbott to Present at 2011 Credit Suisse Annual Health Care Conference Abbott (NYSE: ABT) will present at the 2011 Credit Suisse Annual Health Care Conference on Thursday, Nov. 10, 2011. Thomas C. Freyman, executive vice ...
ABBOTT PARK, Ill., Nov. 2, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 2011 Credit Suisse Annual Health Care Conference on Thursday, Nov. 10, 2011 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a presentation on the
Read more →ABTAbbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of Rheumatology Annual Scientific Meeting Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year's American ...
ABBOTT PARK, Ill., Nov. 2, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5
Read more →ABTExperts Report that Abbott's New PLEX-ID Assay Offers Important Testing Capabilities for Biothreat Defense Abbott's PLEX-ID system provides reliable and rapid results for key microbial biothreat agents and should be considered as a first line analytical...
MUNICH , Nov. 2, 2011 /PRNewswire/ -- Abbott's PLEX-ID system provides reliable and rapid results for key microbial biothreat agents and should be considered as a first line analytical tool for biodefense, biosecurity and microbial forensics programs, according to research presen
Read more →ABTAbbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME™ Everolimus...
ABBOTT PARK, Ill., Nov. 1, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. With t
Read more →ABTAbbott Launches Glucerna® Hunger Smart™ Nutrition Products for People with Diabetes Responding to the growing diabetes and obesity epidemic in the United States, Abbott (NYSE: ABT) is introducing Glucerna® Hunger Smart™ nutrition...
ABBOTT PARK, Ill., Oct. 27, 2011 /PRNewswire/ -- Responding to the growing diabetes and obesity epidemic in the United States , Abbott (NYSE: ABT ) is introducing Glucerna ® Hunger Smart™ nutrition shakes and bars for people with diabetes. Diabetes affects more than 25 million A
Read more →ABTAbbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees Abbott (NYSE: ABT) today awarded $19,000 scholarships to two exceptional students – one undergraduate and one graduate – living with cystic fibrosis...
ABBOTT PARK, Ill., Oct. 25, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today awarded $19,000 scholarships to two exceptional students – one undergraduate and one graduate – living with cystic fibrosis (CF). Lauren Meiss, winner of the Thriving Undergraduate Student Scholarship, and
Read more →ABTAbbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA Abbott (NYSE: ABT) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to...
DES PLAINES, Ill. , Oct. 24, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with acute myeloid leukemia (AML),
Read more →ABTAbbott Honored With Asian CSR Award for Leadership in Science Education At the 10th Asian Forum on Corporate Responsibility in the Philippines, the global health care company Abbott and its philanthropic foundation the...
MANILA, Philippines , Oct. 24, 2011 /PRNewswire/ -- At the 10th Asian Forum on Corporate Responsibility in the Philippines , the global health care company Abbott and its philanthropic foundation the Abbott Fund were honored with an Asian CSR Award for Educational Improvement for
Read more →ABTAbbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2011 Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2011. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Oct. 19, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2011 . "Strong performance across our businesses allowed Abbott to continue to deliver superior results," said Miles D. White , chairman a
Read more →ABTAbbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals Today Abbott (NYSE: ABT) announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in ...
ABBOTT PARK, Ill., Oct. 19, 2011 /PRNewswire/ -- Today Abbott (NYSE: ABT ) announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will co
Read more →ABTAbbott's ABSORB™ Bioresorbable Vascular Scaffold Honored with Wall Street Journal Technology Innovation Award Abbott (NYSE: ABT) announced today that the investigational ABSORB™ bioresorbable vascular scaffold (BVS) has been recognized as the winner of the...
ABBOTT PARK, Ill., Oct. 17, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the investigational ABSORB™ bioresorbable vascular scaffold (BVS) has been recognized as the winner of the Medical Devices category in the 2011 Wall Street Journal Technology Innovation Awar
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2011 financial results on Wednesday, Oct. 19, 2011, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Oct. 5, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2011 financial results on Wednesday, Oct. 19, 2011 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central
Read more →ABTAbbott Enrolls First U.S. Patient in Global EXCEL Trial Comparing XIENCE to Coronary Artery Bypass Surgery Abbott (NYSE: ABT) today announced it has begun enrolling U.S. patients in the EXCEL (Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery ...
ABBOTT PARK, Ill., Oct. 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has begun enrolling U.S. patients in the EXCEL (Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial. EXCEL is
Read more →ABTAbbott Named Top Dealmaker for Fourth Consecutive Year by The Deal The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the fourth consecutive year. Abbott was recognized ...
ABBOTT PARK, Ill., Sept. 20, 2011 /PRNewswire/ -- The D e al magazine has named Abbott (NYSE: ABT ) as one of its Most Admired Corporate Dealmakers for the fourth consecutive year. Abbott was recognized by The Deal for the most effective and consistent use of acquisitions and div
Read more →ABTAbbott Earns 100 Percent Banned Substance Free Certification for all of its EAS® Sports Nutrition Products (NYSE: ABT) – Responding to the issue of illegal, unsafe products being marketed as dietary supplements, Abbott's EAS Sports Nutrition brand...
ABBOTT PARK, Ill., Sept. 20, 2011 /PRNewswire/ -- (NYSE: ABT ) – Responding to the issue of illegal, unsafe products being marketed as dietary supplements, Abbott's EAS Sports Nutrition brand announced that it has certified all EAS nutrition products as free of banned substances.
Read more →ABTAbbott Declares 351st Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 48 cents per share. This marks the 351st consecutive...
ABBOTT PARK, Ill., Sept. 15, 2011 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 48 cents per share. This marks the 351st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov
Read more →ABTAbbott Named to Working Mother Magazine's 'Best Companies' List for the Eleventh Consecutive Year Abbott (NYSE: ABT) announced today that it has been named one of the 100 Best Companies by Working Mother magazine. This is the eleventh consecutive...
ABBOTT PARK, Ill., Sept 15, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has been named one of the 100 Best Companies by Working Mother magazine. This is the eleventh consecutive year that Abbott has been included on the prestigious list, which recognizes comp
Read more →ABTAbbott Again Recognized as One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine Abbott (NYSE: ABT) today was named one of the top 20 employers in Science magazine's 2011 Top Biopharma Employers survey. The annual survey polls...
ABBOTT PARK, Ill., Sept. 15, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today was named one of the top 20 employers in Science magazine's 2011 Top Biopharma Employers survey. The annual survey polls employees at innovation-based companies and determines the best employers based on
Read more →ABTAbbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia Abbott (NYSE: ABT) today announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB™...
ABBOTT PARK, Ill., Sept. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB™ bioresorbable vascular scaffold (BVS) for the treatment of below-the-knee (BTK) cri
Read more →ABTAbbott Named to the Dow Jones Sustainability Indexes for Seventh Consecutive Year in Recognition of Leading Corporate Citizenship Performance Abbott (NYSE: ABT) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the seventh...
ABBOTT PARK, Ill., Sept. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the seventh consecutive year. The Dow Jones Sustainability Indexes (DJSI) recognize the leading c
Read more →ABTAbbott to Present at Morgan Stanley Global Healthcare Conference Abbott (NYSE: ABT) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011. John Leonard, M.D., senior vice...
ABBOTT PARK, Ill., Aug. 31, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011 . John Leonard , M.D., senior vice president, pharmaceuticals, research and development, will participate in a 30-minute
Read more →ABTAbbott Awards CFCareForward Scholarships to 40 Exceptional Graduate and Undergraduate Students Living with Cystic Fibrosis Abbott (NYSE: ABT) has awarded CFCareForward Scholarships totaling $100,000 to 40 undergraduate and graduate students living with cystic fibrosis...
ABBOTT PARK, Ill., Aug. 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) has awarded CF CareForward Scholarships totaling $100,000 to 40 undergraduate and graduate students living with cystic fibrosis (CF) for use during the 2011-2012 academic year. Distinguished undergraduate and gr
Read more →ABTAbbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test...
ABBOTT PARK, Ill., Aug. 26, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non
Read more →ABTAbbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery Abbott (NYSE: ABT) announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of...
SANTA ANA, Calif. , Aug. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD. The clear, viscous, low molecular weight dispersive OVD is i
Read more →ABTFDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis Abbott (NYSE: ABT) announced today it has received 510k clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to...
ABBOTT PARK, Ill., Aug. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received 510k clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with chronic lymphocytic leukemia (CLL
Read more →ABTAbbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market Abbott (NYSE: ABT) announced today that it will invest $230 million (USD) to build a state-of-the-art nutrition manufacturing facility in Jiaxing,...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it will invest $230 million (USD) to build a state-of-the-art nutrition manufacturing facility in Jiaxing, China . The facility represents Abbott's largest investment in China to date and wi
Read more →ABTFirst Patient in Japan Treated with Abbott's Bioresorbable Vascular Scaffold as Part of Global Clinical Trial Abbott (NYSE: ABT) announced today that the first patient in Japan has been treated with the ABSORB™ bioresorbable vascular scaffold (BVS) as part of ...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the first patient in Japan has been treated with the ABSORB™ bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND clinical trial. Abbott's BVS restores blood flow by opening a
Read more →ABTAbbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED® (leuprolide acetate for depot suspension) for the Treatment of Central Precocious Puberty (CPP) Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED ® (leuprolide acetate for depot suspension) for the treatment of
Read more →ABTAbbott's PediaSure® Brand Aims to Help Moms With Picky Eaters Take Back the Table By Building Lifelong Healthy Eating Habits (NYSE: ABT) -- Providing proper nutrition is one of the most important things moms can do to help kids grow and develop. However, a recent survey by...
ABBOTT PARK, Ill., Aug. 11, 2011 /PRNewswire/ -- (NYSE: ABT ) -- Providing proper nutrition is one of the most important things moms can do to help kids grow and develop. However, a recent survey by Abbott, the makers of PediaSure nutritional shakes, reveals that getting kids to
Read more →ABTAbbott Introduces Vector-borne Pathogen Test to Detect Microorganisms Carried by Ticks and Other Insects Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to...
ABBOTT PARK, Ill., Aug. 10, 2011 /PRNewswire/ -- Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anapl
Read more →ABTAbbott Receives U.S. FDA Approval for RX Herculink Elite® Renal Stent System for Treatment of Renal Artery Disease Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System...
ABBOTT PARK, Ill., Aug. 10, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplyin
Read more →ABTData Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels Data presented this week at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that ...
ATLANTA , July 28, 2011 /PRNewswire/ -- Data presented this week at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial. According to published data from the Third
Read more →ABTAbbott's HIV Combo Test Detects Infections Earlier, Provides Valuable Information to Help Prevent Further HIV Transmission and May Save Treatment Costs Hospital and public health laboratories across the country are now detecting early-stage HIV infections much sooner than previous tests since the...
ATLANTA , July 27, 2011 /PRNewswire/ -- Hospital and public health laboratories across the country are now detecting early-stage HIV infections much sooner than previous tests since the launch of Abbott's ARCHITECT ® HIV Ag/Ab Combo assay, a combination antigen-antibody test, in
Read more →ABTAbbott to Feature Acute HIV Diagnostic, Metabolic Function Tests and Lab Informatics at American Association for Clinical Chemistry Annual Meeting Abbott (NYSE: ABT) announced its schedule of key workshops and scientific presentations at the American Association for Clinical Chemistry (AACC)...
ABBOTT PARK, Ill., July 21, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced its schedule of key workshops and scientific presentations at the American Association for Clinical Chemistry (AACC) annual meeting, July 24-28 in Atlanta . The company will sponsor four scientific ind
Read more →ABTAbbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2011. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., July 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the second quarter ended June 30, 2011 . "Abbott is well-positioned for a strong second half of the year as we remain on track for double-digit EPS growth in 2011," said Mi
Read more →ABTAbbott Hosts Conference Call for Second-Quarter Earnings Abbott (NYSE: ABT) will announce its second-quarter 2011 financial results on Wednesday, July 20, 2011, before the market opens. The announcement...
ABBOTT PARK, Ill., June 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its second-quarter 2011 financial results on Wednesday, July 20, 2011 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABTNew Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic...
IRVING, Texas and ABBOTT PARK, Ill., June 24, 2011 /PRNewswire/ -- New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for
Read more →ABTInformation Notice on Stolen Abbott Diabetes Care Blood Glucose Monitoring Products Abbott Diabetes Care is working with the U.S. Food and Drug Administration, Office of Criminal Investigations, the Federal Bureau of Investigation...
ALAMEDA, Calif. , June 24, 2011 /PRNewswire/ --– Abbott Diabetes Care is working with the U.S. Food and Drug Administration, Office of Criminal Investigations, the Federal Bureau of Investigation and other law enforcement officials to recover one tractor-trailer shipment of blood
Read more →ABTAbbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of...
ABBOTT PARK, Ill. and DREIEICH, Germany , June 21, 2011 /PRNewswire/ -- Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Pha
Read more →ABTAbbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot® (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron...
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot ® (leuprolide acetate for depot suspension), a medication used for the pallia
Read more →ABTReata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes Reata Pharmaceuticals, Inc. and Abbott announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of...
IRVING, Texas and ABBOTT PARK, Ill., June 16, 2011 /PRNewswire/ -- Reata Pharmaceuticals , Inc. and Abbott announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of
Read more →ABTAbbott Receives FDA Approval for CREON® (Pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase)...
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cys
Read more →ABTNew National Survey Results Reveal Majority of Men Find It Easier to Care for Their Car Than for Their Personal Health Almost 70 percent of men find it easier to care for their cars than for their personal health, according to findings from a new survey of 501 men...
NEW YORK , June 13, 2011 /PRNewswire/ -- Almost 70 percent of men find it easier to care for their cars than for their personal health, according to findings from a new survey of 501 men ages 45-65. The survey was commissioned by Men's Health Network and Abbott (NYSE: ABT ). In a
Read more →ABTAbbott Declares 350th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 48 cents per share. This marks the company's 350th...
ABBOTT PARK, Ill., June 10, 2011 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 48 cents per share. This marks the company's 350th consecutive quarterly dividend to be paid since 1924. In February, Abbott increased its
Read more →ABTAbbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease nterim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced...
ABBOTT PARK, Ill., June 9, 2011 /PRNewswire/ --Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCI
Read more →ABTAbbott Statement on Interim Study Results of AIM-HIGH The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), today disclosed results from an interim...
ABBOTT PARK, Ill., May 26, 2011 /PRNewswire/ -- The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), today disclosed results from an interim analysis of the AIM-HIGH clinical trial. AIM-HIGH was designed to test whether rai
Read more →ABTAbbott to Present at Goldman Sachs 32nd Annual Global Healthcare Conference Abbott (NYSE: ABT) will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011. Thomas C. Freyman,...
ABBOTT PARK, Ill., May 25, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a presentation
Read more →ABTAbbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the XIENCE nano™ Everolimus Eluting Coronary...
ABBOTT PARK, Ill., May 24, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the XIENCE nano™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels. XIENCE
Read more →ABTAbbott Completes Submission of New Molecular Test Intended for Non-small-cell Lung Cancer Therapy Selection Abbott (NYSE: ABT) today announced it filed premarket approval applications to the U.S. Food and Drug Administration and the Japanese Ministry of...
ABBOTT PARK, Ill., May 23, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it filed premarket approval applications to the U.S. Food and Drug Administration and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect ab
Read more →ABTAbbott Statement on the FDA Advisory Committee Recommendations on Fenofibric Acid The U.S. Food and Drug Administration (FDA) today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD...
ABBOTT PARK, Ill., May 19, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix® in the U
Read more →ABTAbbott Receives FDA Approval for Molecular Test for Hepatitis C Abbott (NYSE: ABT) announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase...
ABBOTT PARK, Ill., May 18, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTi m e PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leadin
Read more →ABTStudy Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower...
BERLIN , May 18, 2011 /PRNewswire/ -- Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with s
Read more →ABTAbbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to...
ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT ) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW)
Read more →ABTAbbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Receives CE Mark Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its new FreeStyle InsuLinx Blood Glucose Monitoring...
WIESBADEN, Germany , May 10, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that it has received CE Mark (Conformite Europeenne) for its new FreeStyle InsuLinx Blood Glucose Monitoring System,(1,2) the first blood glucose monitoring device from Abbott that includes a me
Read more →ABTAbbott Receives FDA Approval to Expand Use of the RX ACCULINK® Carotid Stent System to Patients at Standard Surgical Risk Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment...
ABBOTT PARK, Ill., May 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events
Read more →ABTAbbott to Present at Bank of America Merrill Lynch 2011 Health Care Conference Abbott (NYSE: ABT) will present at the Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, 2011. Thomas C. Freyman,...
ABBOTT PARK, Ill., May 3, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, 2011 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presen
Read more →ABTAbbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with Low Testosterone Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear,...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with
Read more →ABTAbbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting Healthy performance across Abbott's diverse businesses and emerging markets expansion drove strong and consistent growth in 2010, Chairman and Chief...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Healthy performance across Abbott's diverse businesses and emerging markets expansion drove strong and consistent growth in 2010, Chairman and Chief Executive Officer Miles D. White told shareholders today at the company's annual
Read more →ABTAbbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2011. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., April 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the first quarter ended March 31, 2011 . "Stronger-than-expected sales helped us deliver 12 percent ongoing earnings-per-share growth in the first quarter," said Miles Whi
Read more →ABTAbbott Chairman and CEO Miles D. White Elected to the American Academy of Arts & Sciences Abbott (NYSE: ABT) today announced that Miles D. White, chairman of the board and chief executive officer, has been elected to the American Academy...
ABBOTT PARK, Ill., April 19, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced that Miles D. White , chairman of the board and chief executive officer, has been elected to the American Academy of Arts and Sciences. Selected from among the world's most accomplished leaders
Read more →ABTNew Fully Automated Vitamin D Assay Submitted for FDA Clearance According to a recent report from the U.S. Centers for Disease Control and Prevention, a third of Americans have vitamin D levels that are either...
ABBOTT PARK, Ill., April 15, 2011 /PRNewswire/ -- According to a recent report from the U.S. Centers for Disease Control and Prevention, a third of Americans have vitamin D levels that are either inadequate or deficient. While many people know that vitamin D is necessary to help
Read more →ABTData From Landmark Clinical Trial of Abbott's MitraClip® System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment Abbott (NYSE: ABT) today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with...
NEW ORLEANS , April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous c
Read more →ABTAbbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease...
ABBOTT PARK, Ill., and WATERTOWN, Mass. , April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (
Read more →ABTAnalysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's...
NEW ORLEANS , April 3, 2011 /PRNewswire/ -- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT ) market-leading XIENCE V ® Everolimus Eluting Coronary Stent System. As part of
Read more →ABTAbbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results Abbott (NYSE: ABT) today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the...
NEW ORLEANS , April 3, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold (BVS) for the treatment of corona
Read more →ABTAbbott Introduces Hepatitis B Sequencing Test in Europe Abbott Molecular announced today that it has received CE Marking (Conformite Europeene) to market the Abbott HBV Sequencing test in the European...
The CE-Marked Abbott HBV Sequencing test identifies the DNA sequence of the HBV polymerase gene including all clinically relevant HBV drug resistant mutations. The test is not intended for screening blood donors, plasma or tissue donors for HBV, or to be used as a diagnostic test
Read more →ABTAbbott Hosts Conference Call for First-Quarter Earnings Abbott (NYSE: ABT) will announce its first-quarter 2011 financial results on Wednesday, April 20, 2011, before the market opens. The announcement...
ABBOTT PARK, Ill., March 31, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its first-quarter 2011 financial results on Wednesday, April 20, 2011 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Cent
Read more →ABTAbbott Announces Launch of Catheter-Based MitraClip® System in Australia for Mitral Regurgitation, the Most Common Heart Valve Condition Abbott (NYSE: ABT) today announced the launch of the company's catheter-based MitraClip® system for the treatment of mitral regurgitation (MR) in...
ABBOTT PARK, Ill., March 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the launch of the company's catheter-based MitraClip ® system for the treatment of mitral regurgitation (MR) in Australia . The MitraClip device, which has received Therapeutic Goods Administrat
Read more →ABTFDA Clears Abbott's i-STAT® 1 Wireless Point of Care Testing System Abbott announced today it has received clearance from the U.S. Food and Drug Administration to begin marketing the i-STAT® 1 Wireless handheld, a new ...
PRINCETON, N.J. , March 29, 2011 /PRNewswire/ -- Abbott announced today it has received clearance from the U.S. Food and Drug Administration to begin marketing the i-STAT® 1 Wireless handheld, a new wireless version of the i-STAT® point of care testing system that is widely used
Read more →ABTAbbott Introduces Micro-Implantation Cataract Suite Abbott (NYSE: ABT) announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes...
ABBOTT PARK, Ill., March 28, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes and safety. The Micro-Implantation Cataract Suite, featured at the American Socie
Read more →ABTAbbott to Present Data on Novel Vascular Technologies and XIENCE V® at ACC 2011 Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the American College of Cardiology's (ACC) 60th Annual...
ABBOTT PARK, Ill., March 28, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced the company's schedule of key data presentations at the American College of Cardiology's (ACC) 60th Annual Scientific Session and i2 Summit 2011, to be held April 2 – 5 in New Orleans . Highligh
Read more →ABTAbbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from ...
WIESBADEN, Germany , March 21, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagno
Read more →ABTAbbott Supports Relief Efforts in Japan Abbott (NYSE: ABT), through its philanthropic foundation the Abbott Fund, is providing $3 million (245 million yen) to support immediate relief...
ABBOTT PARK, Ill., March 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ), through its philanthropic foundation the Abbott Fund, is providing $3 million ( 245 million yen ) to support immediate relief efforts in response to the devastating earthquake and tsunami in Japan . The Abbott
Read more →ABTPositive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in...
ABBOTT PARK, Ill., March 4, 2011 /PRNewswire/ -- Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in the Journal of the American Society of Nephrology. The published study results sug
Read more →ABTAbbott to Present at Barclays Capital 2011 Global Healthcare Conference Abbott (NYSE: ABT) will present at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., March 1, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentat
Read more →ABTAbbott to Present at Cowen and Company 31st Annual Health Care Conference Abbott (NYSE: ABT) will present at the Cowen and Company 31st Annual Health Care Conference on Tuesday, March 8, 2011. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., Feb. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the Cowen and Company 31st Annual Health Care Conference on Tuesday, March 8, 2011 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a presentation on
Read more →ABTAbbott Announces Increase in Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend 9 percent to 48 cents per share. This marks the...
ABBOTT PARK, Ill., Feb. 18, 2011 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT ) today increased the company's quarterly common dividend 9 percent to 48 cents per share. This marks the 39th consecutive year that Abbott has increased its dividend payout and the 349t
Read more →ABTAbbott to Present at RBC Capital Markets' Healthcare Conference Abbott (NYSE: ABT) will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Feb. 15, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the
Read more →ABTAbbott Introduces Biothreat Assay for PLEX-ID™ System Abbott (NYSE: ABT) announced today that it has introduced the PLEX-ID™ Biothreat Assay, which is designed to detect and distinguish 17 different...
WASHINGTON , Feb. 7, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has introduced the PLEX-ID™ Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens. This assay enables rapid and accurate detection of potentially dangerou
Read more →ABTAbbott's Ibis Technology Identified Fatal Disease Organism in Afghanistan Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data...
WASHINGTON , Feb. 7, 2011 /PRNewswire/ -- Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the unique power of the company's Ibis technology to identify and further characterize
Read more →ABTAbbott's TREK® Coronary Balloon System Now Available in the United States and Japan Abbott (NYSE: ABT) today announced it has received regulatory clearance in the United States and approval in Japan for its TREK® and MINI-TREK™...
ABBOTT PARK, Ill., Jan. 31, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced it has received regulatory clearance in the United States and approval in Japan for its TREK ® and MINI-TREK™ Coronary Dilatation Catheters for the treatment of coronary artery disease. The TREK
Read more →ABTAbbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011 Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2010. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Jan. 26, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the fourth quarter ended Dec. 31, 2010 . "Despite a very challenging environment, 2010 was another productive year for Abbott, resulting in strong financial performance," s
Read more →ABTFDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory...
"After a thorough review of the scientific evidence, we are pleased that the advisory committee concluded that less-invasive carotid artery stenting is as safe and effective as surgery for patients at standard surgical risk," said Charles A. Simonton , M.D., FACC, FSCAI, division
Read more →ABTAbbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease Abbott (NYSE: ABT) announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for ...
ABBOTT PARK, Ill., Jan. 10, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flo
Read more →ABTPartners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti Partners In Health (PIH) and Abbott (NYSE: ABT) and its philanthropic foundation, the Abbott Fund, today announced a partnership to empower Haitians...
BOSTON and ABBOTT PARK, Ill., Jan. 7, 2011 /PRNewswire/ -- Partners In Health (PIH) and Abbott (NYSE: ABT ) and its philanthropic foundation, the Abbott Fund, today announced a partnership to empower Haitians to create local solutions to the longstanding problem of severe malnutr
Read more →ABTAbbott Hosts Conference Call for Fourth-Quarter and Full-Year 2010 Earnings Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2010 financial results on Wednesday, Jan. 26, 2011, before the market opens. The...
ABBOTT PARK, Ill., Jan. 3, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ) will announce its fourth-quarter and full-year 2010 financial results on Wednesday, Jan. 26, 2011 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at
Read more →ABTAbbott to Present at J.P. Morgan Healthcare Conference Abbott (NYSE: ABT) will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2011. Thomas C. Freyman, executive vice...
ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2011 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal present
Read more →ABTAbbott and AstraZeneca End License Agreement for the Development of CERTRIAD™ Abbott (NYSE: ABT) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD™...
There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, incl
Read more →ABTAbbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico Abbott Diabetes Care today announced that it has initiated a recall of 359 lots (approximately 359 million strips) of Precision Xtra®, Precision...
The affected test strips may give falsely low blood glucose results, which can lead users to try to raise their blood glucose when it is unnecessary and to fail to treat elevated blood glucose due to a falsely low reading. The problem appears to be related to longer than expected
Read more →ABTEpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets EpiTherapeutics and Abbott (NYSE: ABT) today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors ...
ABBOTT PARK, Ill. and COPENHAGEN, Denmark , Dec. 20, 2010 /PRNewswire-FirstCall/ -- EpiTherapeutics and Abbott (NYSE: ABT ) today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Read more →ABTAbbott Declares 348th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 44 cents per share. This marks the 348th consecutive...
ABBOTT PARK, Ill., Dec. 10, 2010 /PRNewswire-FirstCall/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 44 cents per share. This marks the 348th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is pa
Read more →ABTAbbott Again Recognized for Leadership in Workplace Diversity and Inclusion Abbott (NYSE: ABT) announced today that it has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. The...
ABBOTT PARK, Ill., Nov. 23, 2010 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. The survey reviewed the diversity programs, policies and performance of all companies
Read more →ABTAbbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease Abbott (NYSE: ABT) today announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor...
ABBOTT PARK, Ill., Nov. 22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progressio
Read more →ABTReata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational...
IRVING, Texas and ABBOTT PARK, Ill., Nov. 20, 2010 /PRNewswire-FirstCall/ -- Reata Pharmaceuticals and Abbott (NYSE: ABT ) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce
Read more →ABTAbbott Named One of America's Most Generous Companies, Sets Company Records for Employee Giving Abbott (NYSE: ABT) has been recognized by The Chronicle of Philanthropy as one of the most generous companies in the U.S., ranking No. 5 out of 162...
ABBOTT PARK, Ill., Nov. 16, 2010 /PRNewswire/ -- Abbott (NYSE: ABT ) has been recognized by The Chronicle of Philanthropy as one of the most generous companies in the U.S., ranking No. 5 out of 162 of the largest U.S. companies that participated in the magazine's survey of 2009 g
Read more →ABTAbbott Awards Scholarships to Students Living with Cystic Fibrosis to Help Them Pursue Their Dreams Abbott today awarded the 2010 Thriving Student Achiever Scholarship to Jason Egbert, a student with cystic fibrosis who demonstrates exceptional...
ABBOTT PARK, Ill., Nov. 11, 2010 /PRNewswire/ -- Abbott today awarded the 2010 Thriving Student Achiever Scholarship to Jason Egbert , a student with cystic fibrosis who demonstrates exceptional academic achievement, community service, creative and artistic talent and passion for
Read more →ABTAbbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa Abbott (NYSE: ABT) and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in...
ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Sa
Read more →ABTAbbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA Today, Abbott (NYSE: ABT) presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and...
ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Today, Abbott (NYSE: ABT ) presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the Ameri
Read more →ABTAbbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance Abbott (NYSE: ABT) was once again included on both the Dow Jones Sustainability World Index and North America Index, following the reassessment of...
ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire/ -- Abbott (NYSE: ABT ) was once again included on both the Dow Jones Sustainability World Index and North America Index, following the reassessment of 2010 scores announced by Dow Jones Indexes and SAM. This is the sixth consecutive ye
Read more →ABTAbbott Wins Two Scrip Awards Recognizing Excellence in Pharmaceutical and Biotech Industries Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott (NYSE: ABT) with two 2010 Scrip Awards for its business...
ABBOTT PARK, Ill., Nov. 5, 2010 /PRNewswire/ -- Scrip , a leading global pharmaceutical and biotech news organization, honored Abbott (NYSE: ABT ) with two 2010 Scrip Awards for its business excellence and strong management. "We are honored to receive these two prestigious award
Read more →ABTARCHITECT HIV Ag/Ab Combo Test Wins Prestigious Chicago Innovation Award Abbott today announced it has received a 2010 Chicago Innovation Award for its ARCHITECT HIV Ag/Ab Combo assay, the first test approved in the United ...
ABBOTT PARK, Ill., Nov. 3, 2010 /PRNewswire/ -- Abbott today announced it has received a 2010 Chicago Innovation Award for its ARCHITECT HIV Ag/Ab Combo assay, the first test approved in the United States that can simultaneously detect both HIV antigens and antibodies. The HIV A
Read more →ABTAbbott to Present at 2010 Credit Suisse Annual Health Care Conference Abbott (NYSE: ABT) will present at the 2010 Credit Suisse Annual Health Care Conference on Thursday, Nov. 11, 2010. Thomas C. Freyman, executive vice ...
ABBOTT PARK, Ill., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) will present at the 2010 Credit Suisse Annual Health Care Conference on Thursday, Nov. 11, 2010 . Thomas C. Freyman , executive vice president, finance and chief financial officer, will make a presentat
Read more →ABTAbbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease...
ABBOTT PARK, Ill. and WATERTOWN, Mass. , Nov. 1, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepa
Read more →ABTAbbott Again Recognized for Environmental Initiatives in Illinois Abbott (NYSE: ABT) announced today that it has received the annual Illinois Continuous Improvement Award for environmental excellence. It is the...
ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has received the annual Illinois Continuous Improvement Award for environmental excellence. It is the ninth time Abbott has been honored for its efforts to safeguard the environment and integra
Read more →ABTAbbott's New ZonePerfect® Cookie Dough Nutrition Bars: A Nutritious Twist for Cookie Dough Lovers Abbott makes nutritious snacking a lot tastier for cookie lovers today with the introduction of ZonePerfect Cookie Dough Bars, the first-ever full...
To view the multimedia assets associated with this release, click: http://multivu.prnewswire.com/mnr/abbott/46839/ From Monica Hysell , division vice president and general manager of Global Performance Nutrition, Abbott Nutrition: About ZonePerfect ® The ZonePerfect brand prov
Read more →ABTAbbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti Abbott (NYSE: ABT) and its philanthropic foundation the Abbott Fund are providing the following updates on relief efforts in Haiti: Abbott Supports...
ABBOTT PARK, Ill., Oct. 27 /PRNewswire/ -- Abbott (NYSE: ABT ) and its philanthropic foundation the Abbott Fund are providing the following updates on relief efforts in Haiti : Abbott Supports Relief Efforts for Cholera Outbreak Abbott is providing $180,000 in support to help a
Read more →ABTAbbott Reports Strong Third Quarter Results; Confirms Double-Digit Ongoing Earnings Outlook for 2010 Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2010. Diluted earnings per share, excluding specified...
ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2010 . "Abbott delivered strong performance in the quarter as we confirmed our double-digit growth outlook for the full year," said Mi
Read more →ABTAbbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874) In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated...
ABBOTT PARK, Ill., Oct. 11 /PRNewswire-FirstCall/ -- In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achiev
Read more →ABTAbbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S. Abbott (NYSE: ABT) will voluntarily withdraw Meridia® (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration...
ABBOTT PARK, Ill., Oct. 8 /PRNewswire/ -- Abbott (NYSE: ABT ) will voluntarily withdraw Meridia® (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA). The FDA's request is based primarily on the results of the SCOUT (Sibutramine Cardio
Read more →ABTAbbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine Abbott (NYSE: ABT) today was named one of the top 20 employers in Science magazine's 2010 Top Biopharma Employers survey. The annual survey seeks to...
ABBOTT PARK, Ill., Oct. 7 /PRNewswire/ -- Abbott (NYSE: ABT ) today was named one of the top 20 employers in Science magazine's 2010 Top Biopharma Employers survey. The annual survey seeks to identify the companies with the best reputations as employers. According to the survey,
Read more →ABTAbbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation...
ABBOTT PARK, Ill., Sept. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact
Read more →ABTAbbott Hosts Conference Call for Third-Quarter Earnings Abbott (NYSE: ABT) will announce its third-quarter 2010 financial results on Wednesday, Oct. 20, 2010, before the market opens. The announcement will ...
ABBOTT PARK, Ill., Sept. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) will announce its third-quarter 2010 financial results on Wednesday, Oct. 20, 2010 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. C
Read more →ABTAbbott's XIENCE V® Shows Outstanding Two-Year Clinical Results Versus TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Trial Late-breaking data from the SPIRIT IV trial, one of the largest randomized clinical trials between two drug eluting stents, continued to demonstrate...
ABBOTT PARK, Ill., Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data from the SPIRIT IV trial, one of the largest randomized clinical trials between two drug eluting stents, continued to demonstrate outstanding clinical results of Abbott's (NYSE: ABT ) market-leading XIENCE V
Read more →ABTAbbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize...
ABBOTT PARK, Ill. and IRVING, Texas , Sept. 23 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late P
Read more →ABTAbbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott's (NYSE: ABT)...
ABBOTT PARK, Ill., Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott's (NYSE: ABT ) market-leading XIENCE V® Everolimus Eluting Coronary Stent System and the TAXUS
Read more →ABTAbbott Voluntariamente Recoge del Mercado Ciertas Unidades De Fórmula Infantil Marca Similac® Que No Cumplen Con Sus Estándares De Calidad Abbott proactivamente ha comenzado a recoger voluntariamente del mercado ciertas unidades de fórmula infantil en polvo de la marca Similac en Estados ...
ABBOTT PARK , Illinois , 22 de septiembre /PRNewswire-HISPANIC PR WIRE/ -- Abbott proactivamente ha comenzado a recoger voluntariamente del mercado ciertas unidades de fórmula infantil en polvo de la marca Similac en Estados Unidos, Puerto Rico , Guam y algunos países en el Carib
Read more →ABTAbbott's Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results Abbott (NYSE: ABT) today announced positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial. At nine...
ABBOTT PARK, Ill., Sept. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial. At nine months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong re
Read more →ABTThe Deal Names Abbott Top Dealmaker for Third Consecutive Year The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the third consecutive year. The Deal honored...
ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ -- The D e al magazine has named Abbott (NYSE: ABT ) as one of its Most Admired Corporate Dealmakers for the third consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective a
Read more →ABTAbbott Introduces Sports Nutrition Performance Beverage - EAS Peak™ With New P3™ Technology Abbott today announced EAS Peak™, a novel sports nutrition performance beverage. EAS Peak is the only performance beverage with P3™ technology, which ...
ABBOTT PARK, Ill., Sept. 20 /PRNewswire/ -- Abbott today announced EAS Peak™, a novel sports nutrition performance beverage. EAS Peak is the only performance beverage with P3 ™ technology, which sustains energy, increases workout capacity and protects muscles from breakdown. To
Read more →ABTAbbott Declares 347th Consecutive Quarterly Dividend The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 44 cents per share. This marks the 347th consecutive...
ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ -- The board of directors of Abbott (NYSE: ABT ) today declared a quarterly common dividend of 44 cents per share. This marks the 347th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable
Read more →ABTAbbott Launches New Ensure® Shakes with Focus on Helping Baby Boomers Regain Muscle and Strength Responding to the growing needs of America's aging baby boomer population, the global health care company Abbott today introduced two new nutrition...
ABBOTT PARK, Ill., Sept. 16 /PRNewswire/ -- Responding to the growing needs of America's aging baby boomer population, the global health care company Abbott today introduced two new nutrition shakes – Ensure ® Muscle Health and Ensure Clinical Strength. To view the multimedia as
Read more →ABTAbbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010 Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual...
ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D
Read more →ABTAbbott Statement on the FDA Advisory Committee Recommendation on Sibutramine The U.S. Food and Drug Administration (FDA) today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT...
ABBOTT PARK, Ill., Sept. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT (Sibutramine Cardiovascular OUTcome Trial) and the weight loss medication sibutrami
Read more →ABTAbbott Honored for Workplace Leadership for the Tenth Consecutive Year by Working Mother Magazine Abbott (NYSE: ABT) announced today that it has been named one of the 100 Best Companies by Working Mother magazine. This was the tenth consecutive...
ABBOTT PARK, Ill., Sept. 14 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has been named one of the 100 Best Companies by Working Mother magazine. This was the tenth consecutive year that Abbott has been included on the prestigious list, which recognizes companies f
Read more →ABTAbbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance Abbott (NYSE: ABT) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the sixth...
ABBOTT PARK, Ill., Sept. 9 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) announced today that it was included on both the Dow Jones Sustainability World Index and North America Index for the sixth consecutive year. The Dow Jones Sustainability Indexes (DJSI) recognize the leading
Read more →ABTAbbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India Abbott (NYSE: ABT) has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian...
ABBOTT PARK, Ill., Sept. 8 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging mark
Read more →ABTAbbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment Abbott (NYSE: ABT) announced today it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTime HBV assay...
DES PLAINES, Ill. , Sept. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) announced today it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTi m e HBV assay for measuring viral load or the amount of hepatitis B virus (HBV) in a pat
Read more →ABTAbbott to Present at Morgan Stanley Global Healthcare Unplugged Conference Abbott (NYSE: ABT) will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 13, 2010. Thomas C. Freyman, executive...
ABBOTT PARK, Ill., Aug. 30 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 13, 2010 . Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentatio
Read more →ABTAbbott Launches New Psoriasisanswers.com Web site August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million...
ABBOTT PARK, Ill., Aug. 12 /PRNewswire-FirstCall/ -- August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what'
Read more →Competitive Position
How ABT ranks across every disease it competes inCompetitive Position is a premium feature
See how ABT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial